Identification of low-penetrance alleles, genetic modifiers and mutation analysis in familial breast cancer cases by Catucci, Irene
Open Research Online
The Open University’s repository of research publications
and other research outputs
Identification of low-penetrance alleles, genetic
modifiers and mutation analysis in familial breastcancer cases
Thesis
How to cite:
Catucci, Irene (2013). Identification of low-penetrance alleles, genetic modifiers and mutation analysis in familial
breast cancer cases. PhD thesis The Open University.
For guidance on citations see FAQs.
c© 2013 The Author
Version: Version of Record
Copyright and Moral Rights for the articles on this site are retained by the individual authors and/or other copyright
owners. For more information on Open Research Online’s data policy on reuse of materials please consult the policies
page.
oro.open.ac.uk
Irene Catucci 
Degree in Biotechnology 
Identification of low-penetrance alleles, genetic modifiers 
and mutation analysis in familial breast cancer cases 
Thesis presented to The Open University of London 
for the Degree of Doctor of Philosophy 
Discipline: Life and Biomolecular Sciences 
Date of Submission: 28 June 2013 
DA, E:. 0\- (\ I.A:)f'I R.b; 2. 5 0 c. n~ e (;: j(7.. :2 0' :;: 
Affiliated Research Centre: Fondazione IRCCS "Istituto Nazionale dei Tumori" 
TABLE OF CONTENTS 
ABSTRACT 
CHAPTER 1. INTRODUCTION 
1.1 Genetic risk for breast cancer 
1.2 Breast cancer high-penetrance genes 
1.2.1 BRCA I and BRCA2 genes 
1.2.2 Other high-penetrance genes 
1.3 Breast cancer moderate-penetrance genes 
1.3.1 ATM, CHEK2 and BRIP I genes 
1.3.2 Fanconi Anemia and breast cancer susceptibility 
1.3.3 The P ALB2/ FANCN gene 
1.3.4 The SLX41FANCP gene 
1.4 Low-penetrance alleles 
1.4.1 SNPs in microRNA as low-penetrance alleles 
1.5 Genetic risk modifiers in BRCA genes mutation carriers 
Table of contents 
4 
6 
6 
7 
7 
14 
15 
15 
16 
20 
22 
24 
26 
29 
1.5.1 The rs3834129 in the CASP8 promoter region as candidate 35 
genetic risk modifier in BRCA genes mutation carriers 
CHAPTER 2. AIM OF THE STUDY 
CHAPTER 3. MATERIALS AND METHODS 
3.1 Study population 
3.1.1 Genetic counseling and eligibility to BRCAI and BRCA2 
genetic test 
1 
38 
39 
39 
39 
3.2 
3.3 
3.4 
3.5 
3.6 
3.7 
3.8 
3.1.2 Recruiting and inclusion criteria in our study of individuals 
affected with breast cancer or at-risk for breast cancer 
3.1.3 Recruiting of blood donors 
Association studies 
DNA samples preparation 
Mutation screenings 
3.4.1 PCRs conditions 
3.4.2 Mutations detection by sequencing 
Genotyping analyses 
111 silico analyses 
3.6.1 Software for prediction of the missense mutations effect 
3.6.2 Software for prediction of non-canonical splicing 
Investigation of the PALB2 c.48G>A splicing mutation 
3.7.1 B-lymphocytes immortalization 
3.7.2 RNA extraction and cDNA synthesis 
3.7.3 Amplification ofcDNA and transcript analysis 
Statistical analyses 
CHAPTER 4. RESULTS 
4.1 
4.2 
PALB21FANCNmutation analysis 
4.1.1 Mutation screening in a series of Italian BRCAX cases 
4.1.2 Investigation of the c.72delG and the c.l 027C> T recurrent 
mutations 
4.1.3 P ALB2 mutation analysis in breast and pancreatic cancer 
families 
Sequencing analysis of SLX41FANCP gene 
2 
Table of contents 
40 
41 
42 
43 
43 
43 
44 
47 
48 
48 
49 
49 
49 
50 
51 
52 
53 
53 
53 
61 
62 
69 
4.3 
4.4 
Investigation of miR-27a rs895819 polymorphism as candidate 
low-penetrance allele 
Analysis of the CASP8 rs3834129 as risk modifier in BRCA gene 
mutation carriers 
CHAPTER 5. DISCUSSION 
REFERENCES 
LIST OF FIGURES 
LIST OF TABLES 
PUBLISHED MATERIALS FROM THIS THESIS 
3 
Table of contents 
74 
76 
80 
92 
112 
113 
115 
Abstract 
ABSTRACT 
To date, germline mutations in known high-penetrance genes, mainly BRCAI and 
BRCA2, and in moderate- and low-penetrance genes are responsible for approximately 30-
35% of breast cancer familial clustering, leaving the majority of them unexplained. In 
addition, the variability of the risk conferred by BRCAI and BRCA2 mutations suggests the 
presence of genetic modifiers of this risk. Therefore, the identification and characterization 
of as many as possible of genetic factors is crucial for risk prediction in members of breast 
cancer families. 
In this context, the aim of this thesis was firstly to investigate the role of the two 
Fanconi Anemia (FA) genes PALB2 and SLX4 as breast cancer predisposing loci. In the 
P ALB2 screening, I observed a frequency of deleterious mutation of 2.1 % in familial cases 
recruited in cancer centers in Milan. Interestingly, I also identified the recurrent mutation 
c.I027C>T, detected with IO-fold increased frequency in cases from Bergamo with respect 
to those ascertained in Milan, suggesting a founder effect. On the contrary, the SLX4 
analysis failed to identify any clearly deleterious mutation, excluding a major role of this 
gene in breast cancer susceptibility in the Italian population. In addition, I genotyped the 
candidate low-risk rs895819 polymorphism, located in the gene coding for miR-27a, to 
evaluate its role in reducing breast cancer risk, previously reported in the German 
population. No such an association was observed in our sample set. Finally, I investigated 
the role of the CASP8 rs3834129 insldel polymorphism as a genetic modifier in Italian 
BRCA 1 and BRCA2 mutation carries and I observed an association of this SNP with 
increased breast cancer risk only in individuals carrying BRCA 1 mutations. 
4 
Abstract 
In conclusion, our investigation contributed to assess the role of candidate 
predisposing loci and genetic modifiers of breast cancer risk, providing further knowledge 
on the susceptibility to this disease. 
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CHAPTER 1 
INTRODUCTION 
1.1 Genetic risk for breast cancer 
Chapter I -Introduction 
Breast cancer is the second most common type of cancer and the fifth most 
common cause of cancer death in world population. In particular, in Italy about 45,000 
novel breast cancer cases are diagnosed every year and breast cancer affects one in eight 
women during their lifetime. It represents about 29% of all female cancer and the first 
cause of cancer death in Italian women (AIRTUM Working Group, 2011). 
Ten to 15% of all breast cancer cases can be considered familial since occurring in 
families where relatives of the index case are affected with the disease. It has been 
suggested that family history for breast cancer is one of the strongest risk factor. In fact, it 
has been observed that breast cancer risk among first-degree relatives of breast cancer 
patients is two to four-fold increased with respect to the general population (reviewed in 
Stratton and Rahman, 2008). This risk depends on the number of affected relatives, their 
age at diagnosis and their relationship proximity to the proband (Bradbury and Olopade, 
2007; Mavaddat et aI., 2010). 
Recently, the understanding of breast cancer genetic predisposition was largely 
improved and novel breast cancer susceptibility loci have been identified. To date, breast 
cancer cases can be accounted by germline mutations that can be classified in three 
different groups according to the increase of relative risk (RR») that they confer. Mutations 
in high-penetrance genes are very rare, being detected with a cumulative frequency of no 
I Relative risk is the risk of an event (or of developing a disease) relative to exposure. In particular, it 
represents the ratio of the probability of the event occurring in the exposed group versus the non-exposed 
group 
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more than 0.1-0.5%, and they increase the risk of more than 10 to 20-fold, accounting for 
no more the 3-5% of all breast cancer cases. Moderate-penetrance mutations are also rare, 
being detected with a cumulative frequency of 0.5-1 %, but the increase of risk conferred is 
from two to three-fold. Finally, a large number of low-penetrance alleles have been 
identified. These are found with an individual frequency of more than 5% and each confers 
a RR ranging from approximately 1.05 to 1.3. Currently known high-penetrance genes are 
responsible for about 15-20% of breast cancer familial clustering whereas identified 
moderate-penetrance genes account for about 2% (reviewed in Mavaddat et aI., 2010 and 
in LaIloo and Evans, 2012); in addition, it has been estimated that low-penetrance alleles 
are responsible for an additional 28% of familial risk of which 14% can be explained by 
currently known loci (Michailidou et aI., 2013) (Figure 1.1). Since only about 30-35% of 
familial breast cancer clustering can be explained by the above mentioned genes, the large 
majority of the high-risk breast cancer cases are molecularly unexplained. 
1.2 Breast cancer high-penetrance genes 
1.2.1 BHCA 1 and BHCA2 Kcncs 
The two major genes involved in breast cancer susceptibility are the tumor 
suppressor genes BRCAI and BRCA2, identified in the early 1990s. 
In 1990, genetic linkage analysis, performed in families with multiple cases of early 
onset breast cancer, resulted in the localization of BRCAI on chromosome 17q12-21 (Hall 
et aI., 1990). Subsequently, an international collaborative study confirmed this data, and 
BRCAI was cloned in 1994 (Miki et aI., 1994). This gene is composed of 23 exons, of 
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which one is not coding, and extends for approximately 100 kb of the genomic DNA. The 
exon 11 of BRCAI is unusually large, representing about 60% of the entire coding region. 
0.1% 1% 
Common low-ri.k variant. 
30% 
Risk allele frequency 
50% 
f rom Varghese and Easton, Curr Opin Genet Dev. 2010 
Figure 1.1. Breast cancer genetic susceptibility loci. In the y·axis, the relative risk 
(RR) is represented. In the x-axis, the frequency of each allele is indicated. High 
risk variants, reported in the red area, have low frequency (0.1-0.5%) and confer a 
strong increase in breast cancer risk (> I 0 fold). Moderate risk variants, reported in 
the light-red area, are also rare (0.5·1 %), but increase breast cancer risk of no more 
than two to three folds. Low risk alleles, reported in the yellow area, are common « 
5%) but each confers a small increase of breast cancer risk (1-1.5 fold) . Variants 
with low frequencies and very small risk increase are difficult or impossible to find , 
whereas common variants that confer a high breast cancer ri sk do not exist. 
BRCAI encodes a protein of 1,863 amino acids with a very weak sequence conservation 
among species, except for highly conserved functional domains located at the terminal 
regions. In particular, the N-terminus region contains a RING domain, with E3 ubiquitin 
ligase activity, that binds the BRCAl-associated RING domain protein (BARDl) gene, 
and a nuclear localization sequence (NLS). The C-terminus region contains a coiled-coil 
domain that associates with the BRCA2 partner and localizer (P ALB2) gene, and a BRCT 
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domain, responsible for the activation of several transcription factors (reviewed in Roy et 
aI., 2012). BRCAI is involved in several cellular mechanisms including DNA double-
strand break repair, homologous recombination, cell cycle checkpoint control, 
transcriptional regulation and ubiquitination (Ahmed et aI., 2009; Foulkes, 2008). 
Since in early studies only 45% of all families with multiple cases of breast cancer 
were associated with BRCA 1 mutations, the presence of an additional breast cancer 
susceptibility locus was proposed and confirmed by subsequent analyses (reviewed in 
Ahmed et aI., 2009). The BRCA2 gene was mapped to chromosome 13q 12-q 13 in 1994 
(Wooster et aI., 1994), and cloned the following year (Wooster et aI., 1995). This gene 
consists of 26 coding exons, it extends for approximately 70 kb of the genomic DNA and 
encodes a very large protein of 3,418 amino acids. BRCA2 contains a PALB2 binding 
domain at the N-terminus of the protein, eight BRC repeats from amino acid residues 1009 
to 2083 that form the binding site of the DNA recombination repair protein RAD51, and a 
NLS domain in the C-terminus. BRCA2 is involved in DNA repair processes and 
maintenance of chromosome stability, being responsible for the double strand DNA breaks 
recognition, and participating in the homologous recombination repair (reviewed in Roy et 
aI.,2012). 
Gcrmline deleterious mutations III BRCA 1 and BRCA2 are associated with 
increased breast cancer risk and have high penetrance. It was estimated that these 
mutations increase the risk by approximately 10 to 20-fold. This means that carriers of 
BRCAI and BRCA2 mutations have risk of developing breast cancer of 30-60% by the age 
of 60, compared with 3% observed in the general population (reviewed in Stratton and 
Rahman, 2008). It has been also reported that BRCA genes mutations confer a risk of 
developing other types of cancer. In particular, BRCAI and BRCA2 mutation carriers have 
a cumulative ovarian cancer risk of 39% and 11%, respectively (Milne and Antoniou, 
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2011) whereas mutations in BRCA2 are also responsible for increased risk of developing 
pancreatic and prostate cancer (Foulkes, 2008). 
A large amount of BRCA 1 and BRCA2 mutations have been identified. The 
majority of these mutations are very rare, with a cumulative frequency of approximately 
0.2-0.4% in the general population and are mostly found in single families only (reviewed 
in Turnbull and Rahman, 2008 and in Lalloo and Evans, 2012). However, this frequency 
varies depending on the tightness of the inclusion criteria in each study, the method of 
mutation analysis and also the screened population (reviewed in Roy et aI., 2012). 
While a large amount of different BRCA 1 and BRCA2 mutations are detected in the 
majority of the screened populations, specific ethnic groups are characterized by few 
mutations with higher frequency, due to a 'founder' effect. The 'founder' concept was 
introduced to explain the loss of genetic variation that occurs when a new population was 
founded by a very small number of individuals, deriving from a larger group. This 
phenomenon can be caused by geographical isolation or by a dramatic decrease of the 
original population (reviewed in Fackenthal and Olopade, 2007). 
One of the more interesting example of founder mutations IS found in the 
Ashkenazi Jews that originates from Eastern and Central Europe (Germany, Poland, 
Lithuania, Ukraine and Russia). In this population, the BRCA 1 mutations 185delAG2 and 
5382insC have been found with a frequency of 0.8-1 % and 0.1-0.4%, and the BRCA2 
mutation 6174dclT with a frequency of 1-1.5%. These three mutations are responsible for 
about 6.7-11.7% of all breast cancer cases and about 59% of high-risk cases (Table 1.1; 
reviewed in Fackenthal and Olopade, 2007 and in Feria et aI., 2007). 
2 Throughout the text, BRCA I and BRCA2 mutation are reported according to the Breast Cancer Information 
Core (BIC, http://research.nhgri.nih.govlbic/) nomenclature. 
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Additional founder mutations have been detected in other European populations (Table 
1.1). In Icelanders, the BRCA2 mutation 999de15 has been detected with a frequency of 
8.5% and the BRCA 1 mutation G5193A has been found in 1 % of breast cancer cases. In 
Norway, four main founder mutations have been detected in BRCA1, of which three, 
1675de1A, 816de1GT, 3347de1AG, originated from southwestern and the fourth, 1135insA, 
from the southeast. They represent about 68% of all BRCA 1 mutations found in the 
country. In Finland, 11 recurrent mutations have been identified and four of them, 
IVSll+3A>G in BRCAl and IVS23+1G>A, C7708T and T8555G in BRCA2 are exclusive 
to the Finnish population. In Sweden, the BRCA 1 3171 ins5 accounts for 70% of the DRCA 
gene mutations. In The Netherlands, the BRCA 1 2804delAA accounts for about 24% of all 
mutations in BRCA 1 and BRCA2 and probably originated more than 200 years ago. Two 
additional founder mutations, BRCAJ IVS12-1643del3835 and BRCA2 5579insA, were 
found in the southwest of the country. In France, the BRCAJ founder mutations 3600deJll 
and G 171 OX represent 37% and 15% of all mutations found in high-risk breast cancer 
cases, respectively. In addition, several founder mutations, originating from France, were 
found in French-Canadians of Quebec. Among these, the most common are BRCA J 
C4446T, BRCA2 8765delAG and 3398deIAAAAG. (Table 1.2; reviewed in Fackcnthal 
and Olopade, 2007 and in FerIa et aI., 2007). 
In Italy, there are only few mutations that result recurrent in specific geographical 
areas of the country. In particular, the BRCAl 5083deJl9 mutation, was found in four 
pro bands from families that originated from Calabria (Daudi et aI., 2001); in Sardinia, the 
BRCA2 8765delAG mutation was detected with a frequency of 1.7% (Pisano et aI., 2000); 
BRCA 1 V 1688del was reported as recurrent in families from Northeast Italy (Ma\acrida et 
aI., 2008); finally four distinct BRCAI mutations, 1499insA, 3347de1AG, 3404delA and 
5181 del3, have been shown to account for about 73% of familial breast and/or ovarian 
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cancers originating from Central-Eastern Tuscany (Table 1.1) (Caligo et a1.. 1996; Papi et 
a1.,2009). 
Table 1.1. BRCAI and BRCA2 founder mutations identified in 
European countries 
Population 
Ashkenazi Jews 
Icelandics 
Norwegians 
Finnish 
Swedish 
Dutch 
French 
Italians (Calabria) 
Italians (Sardinia) 
Italians (Tuscany) 
BRCAI Mutations 
I 85deIAG"·b 
5382insCb 
1675dclAd 
816dclGTd 
3347delAGd 
1135insAd 
IVS II + 3A>Ge 
3171 ins5f.g 
2804dclAAh 
IVS 12.1643dcI3835h 
3600dclll i 
GI710X i 
5083dcll~ 
1499insA1•m 
3347dclAGm 
3404dclAm 
5181dc13m 
Italians (Northeast Italy) V 1688dcl" 
BRCA2 Mutations 
6174delTb 
999del5c 
IVS23+IG>Ae 
C7708T" 
T8555Ge 
5579insAh 
8765delAGk 
·Struewing et aI., 1995; bRoa et aI., 1996; cThorlacius et aL, 1996; 
dM011er et aI., 2007; eSarantaus et aI., 2000; fBergman et aI., 200 I; 
gBergman et aI., 2005; hZeegers et aI., 2004; iMuller et aI., 2004; .iBaudi 
et aI., 200 I; kPisano et aI., 2000; 'Cal igo et aI., 1996; mPapi et aI., 2009; 
"Malacrida et aI., 2008. 
In non-European countries, founder mutations were identified in American-
Hispanic breast cancer cases (BReAl 2552delC and S995X), in Columbian-Hispanics 
(BRCA 1 3450delCAAG and A 1708E, BRCA2 3034delACAA), in Afro-Americans 
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(BRCAl 943insl0, 1832del5 and 5296deI4), in South-Africans (BRCAl E881X), in the 
Chinese population (BRCAl 1081de1G) and in other Asian countries, such as Japan 
(BRCAl Q934X and K63X, BRCA2 5802delAATT), Malaysia (BRCAl 2846insA), 
Philippines (BRCAl 5454de1C, BRCA2 4265deiCT and 4859delA) and Pakistan (BRCAl 
S1503X and R1835X) (Table 1.2) (reviewed in FerIa et aI., 2007). 
Table 1.2. BRCA I and BRCA2 founder mutations identified in non-
European countries 
Population 
French-Canadians 
Amcrican-Ilispanics 
Columbian-Hispanics 
A fro-Americans 
South-A fricans 
Chineses 
Japaneses 
Malaysians 
Filipinos 
Pakistanis 
RRCA I Mutations RRCA2 Mutations 
C4446T1 ,b,c 8765delAOa,b,c 
3398deIAAAA08.b.c 
2552delCd 
S995Xd 
3450delCAAOe 3034dclACAAe 
AI708Ee 
943insiOf 
1832del5 f 
5296del4f 
E881Xg 
1081deiGh 
Q934Xij 5802delAA TTij 
K63Xij 
2846insAk 
5454de1C' 4265de1CT' 
4859de1A' 
SI503Xm 
RI835Xm 
"Tonin et aI., 1999; ~onin et aI., 200 I; cOros et aI., 2006; dWeitzel et 
aI., 2005; eTorres et aI., 2007; fOlopade et al. 2003; ~Reeves et aI., 2004; 
. k hKhoo et aI., 2002; 'Ikeda et aI., 200 I; JSekine et aI., 200 I; Lee et aI., 
2003; 'De Leon Matsuda et aI., 2002; mRashid et aI., 2006. 
To date, a very large number of BRCAl and BRCA2 variants have been identified, 
including disease-causing, neutral and unclassified variants. Disease-causing mutations 
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include nonsense mutations, frameshifts caused by small insertions and/or deletions, and 
splice-site mutations leading to the formation of a truncated protein. In addition to point 
mutations, large genomic rearrangements, including large deletions (whole exon) and 
insertions/duplications, have been also detected. In high-risk cases, these have been found 
in approximately 2%-12% and 2%-5% of BRCAI and BRCA2 mutation carriers, 
respectively (reviewed in Fackenthal and Olopade, 2007). Also, a small number of unique 
missense variants both in BRCAI and BRCA2 have been classified as deleterious. These 
are especially located in the functional domains of the two proteins. In addition to 
deleterious mutations, common variants have been detected and classified as neutral or 
with no clinical significance. IIowever, there is a large number of missense mutations, 
intronic variants and in-frame deletions or insertions with an uncertain clinical relevance. 
These variants of unknown significance (VUS) represent a major problem in the 
counseling and clinical management of at risk individuals, since it is unclear how these 
variants can alter the protein function. Multi-factorial probability based models and 
functional assays can be used to clarify the role of variants not yet classified, improving 
breast cancer risk assessment in families that carry these mutations (Lindor et aI., 2012; 
Couch et aI., 2008). 
1.2.2 Other high-penetrance genes 
Another small fraction of familial breast cancer cases can be accounted by germline 
mutations in other high-penetrance genes, responsible for hereditary syndromes that 
include breast cancer as phenotype. These genes include TP53, causing the Li-Fraumeni 
syndrome; LKBlISTKll, causing the Peutz-Jeghers syndrome and PTEN, causing the 
Cowden syndrome. All these genes are involved in multiple pathways that regulate cell 
cycle, transcription and cell polarity. Mutations in these genes are very rare and account for 
14 
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less than 1 % of all familial breast cancer cases, increasing breast cancer risk by more than 
ten-fold (Turnbull and Rahman, 2008). 
1.3 Breast cancer moderate-penetrance genes 
Moderate-penetrance genes were considered of more interest in the last decade, when 
it became clear that mutations in high-risk genes could explain only about 20% of all 
familial breast cancer cases and linkage analyses failed to identify novel high-risk genes, 
although their existence cannot be completely excluded (Ahmed et aI., 2009). Moderate 
penetrance genes have been firstly identified through the approach of candidate genes, 
based on the investigation of genes involved in DRCA1 and DRCA2 pathways. It has been 
reported that mutations inATM, CHEK2, BRIPI and PALB2 are associated with increased 
breast cancer risk. These mutations are less rare than BRCAJ and BRCA2 mutations, being 
detected with a cumulative frequency of approximately 1 %, and increase breast cancer risk 
of no more than two to three folds. Carriers of moderate penetrance variants have 6-10% 
risk of developing breast cancer by age 60, compared with 3% in the general population 
(reviewed in Stratton and Rahman, 2008). 
1.3.1 ATM, CllEK2 and BRIPI genes 
The gene ATM encodes a protein kinase with a crucial role in response to DNA 
double-strand breaks. In particular, A TM promotes the activation of a signaling cascade 
that causes the phosphorylation of multiple proteins, including DRCA 1 and p53. 
llomozygous mutations in this gene are responsible for the Ataxia Telangiectasia, an 
autosomal recessive disease characterized by predisposition to cancer in childhood, 
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particularly lymphoid cancer, and an increased breast cancer risk. The role of ATlvl in 
breast cancer susceptibility was suggested in 2006, when mutations in A TAl were found in 
12/443 familial breast cancer cases, negative for mutations in BRCAI and BRCA2, and in 
2/521 controls, with a relative risk of 2.3 7 (Renwick et aI., 2006). 
CHEK2 was the first moderate risk breast cancer gene identified, in 2002. This gene 
encodes a cell cycle checkpoint protein kinase responsible for the phosphorylation of p53 
and BRCA I, and it is involved in the response to DNA damage. Among all reported 
variants, the c.I100de1C is the most common CIIEK2 mutation. It was found with a 
frequency of 0.2-1 % in the European population and in about 4.2% of breast cancer 
families, with a relative risk of 2.34. IIowever, this mutation frequency is highly variable 
among different populations (reviewed in Lalloo and Evans, 2012) and extremely low in 
Italy (0.11 %; Caligo et aI., 2004). 
In 2006, it was showed that BRIP 1, which encodes a BRCA I-interacting helicase 
involved in DNA repair, was a moderate breast cancer risk gene. In a case-control study, 
BRIP1 gerrnline mutations were found in 9/1212 familial breast cancer cases and 1/2081 
controls (Seal et aI., 2006). 
1.3.2 Fanconi Anemia and breast cancer susceptibility 
In the last decade, a strong connection between breast cancer susceptibility and the 
Fanconi Anemia (FA) disease has been suggested. In 2002, it has been showed that the FA 
gene FANCD1, responsible for FA subtype Dl, and BRCA2 are the same genes (Howlett et 
aI., 2002). Subsequently, it has been also reported that mutations in other FA genes, 
including FANCNIPALB2, FANCJIBRIP1 and FANCOlRAD51C, have a frequency of 
approximately 0.5-1 % in familial breast and ovarian cancer cases (Tischkowitz and Xia, 
2010; lIo11estelle et aI., 2010; Meindl et aI., 2010). These data contributed to consider FA 
genes as interesting candidates in breast cancer susceptibility. 
16 
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The Fanconi Anemia is an autosomal recessive hereditary disorder characterized by 
congenital defects, progressive bone marrow failure and cancer predisposition. FA is 
caused by biallelic mutations in one of the 15 FA or FA-like genes, that are FANCA, 
FANCB, FANC~ FANCDl, FANCD2, FA NCE, FANC~ FANCG, FANC~ FANC~ 
FANCL, FANCM, FANCN, FANCO and FANCP. In particular, about 85% of FA cases are 
accounted by mutations in FANCA, FANCC and FANCG; about 10% are due to mutations 
in FANCDl, FANCD2, FANCE, FANCF and FANCL, and the remaining 5% by mutations 
in FANCB, responsible for the X-linked FA disease, FANC!, FANCJ, FANC}.,!, FANCN, 
FANCO and FANCP. 
Recent studies suggested that all FA proteins are involved in a common pathway, the 
Fanconi Anemia pathway, required for DNA damage response and DNA repair 
mechanisms. Among all of the FA proteins, FANCA, FANCD, FANCC, FANCE, FANCF, 
F ANCG, F ANCL and F ANCM are assembled in a nuclear complex named FA core 
complex. The role of this complex is the mono-ubiquitination of two other FA proteins, 
FANCI and FANCD2, forming the ID complex. The activation of the ID complex leads to 
the recruitment of the downstream proteins of the FA pathway, that are FANCD1, FANC}, 
FANCN, FANCO and FANCP, and the promotion of the DNA repair. 
Specifically, when a DNA damage is recognized, the activation of the FA pathway 
promotes the assembly of the FA core complex proteins and other associated proteins, such 
as FAAP24, FAAPIOO and the recently identified FANCM-associated proteins, MIIFI and 
MIIF2. Generally, F ANCA, F ANCD, F ANCC, F ANCE, F ANCF, F ANCG and F ANCL 
are constitutively associated, forming a stable sub-complex, whereas the association of 
FANCM to the complex occurs only after the activation of the pathway. This binding is 
mediated by the associated proteins FAAP24, FAAPlOO, MIIFI and MHF2. The formation 
of this sub-complex is required for recognizing of stalled replication forks, the recruitment 
17 
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of the core complex and its binding with chromatin. It was also suggested that the mono-
ubiquitination activity of the core complex is mediated by FANCL. This protein contains a 
ring finger domain for the E3 ubiquitin ligase activity required for the mono-ubiquitination 
of the ID complex, mediated by the UBE2T enzyme. This event results in the translocation 
of the complex to the chromatin, where it forms DNA repair foci. The correct modification 
of F ANCD2 and F ANCI in the ID complex is also mediated by ataxia telangiectasia and 
Rad3-relatcd kinase ATR, responsible for the phosphorylation of F ANCD2 and F ANCI 
and the formation of the ID complex heterodimer. This process is reversible: the 
deubiquitination is mediated by the USP I ubiquitin hydrolase that presumably deactivates 
the ID complex at the end of the repair process. 
At the level of the DNA repair foci, the ID complex interacts with the downstream FA 
proteins FANCDI, FANCN, FANCJ, FANCO and FANCP, and other proteins involved in 
DNA repair, promoting homologous recombination repair. In particular, FANCDI or 
FANCO are cofactor of the recombinase protein RAD5t; F ANCN interacts with 
F ANCD 1, promoting its nuclear localization and its stabilization and FANCJ is an helicase 
interacting with BRCA 1, also involved in DNA damage response and homologous 
recombination (Figure 1.2; Kitao and Takata, 2011; Su and Huang, 20 11; Cybulski and 
I Iowlett, 2011). 
Vcry recently, in addition to mutations reported in FANCNIPALB2, FANCJIBRIPJ 
and FANCOlRAD5JC, mutations in other FA genes have been reported in breast cancer 
cases. As a result of exome sequencing analyses, the protein truncating mutation 
c.651 652del was identified in the X-ray repair cross completing gene-2 (XRCC2), a 
paralog gene of RAD51C, in an Australian breast cancer patient (Park et al., 2012). 
Subsequent analyses revealed the presence of other carriers of XRCC2 pathogenic 
mutations, both in cases and in controls. Ilowever, the role of XRCC2 mutations in breast 
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cancer susceptibility remains controversial. A recent screening of a large series of familial 
breast cancer cases and controls did not confirm an involvement of XRCC2 mutations in 
increasing the risk in familial breast cancer cases from The Netherlands, USA, Spain and 
Italy (Hilbers et aI., 2012). In 2012, mutations in FANCA and FANCC were also reported 
in familial breast cancer cases. In particular, the p.Thr561Met, the p.Cys625Ser and the 
p.Serl088Phe missense variants were found in FANCA and predicted to be deleterious by 
protein prediction programs (Litim et aI., 2013), and three truncating mutations, c.535C>T 
(p.Arg179X), c.553C>T (p.Arg185X) and c.67deIG, were detected in FANCC, suggesting 
a role in breast cancer susceptibility (Thompson et aI. , 2012) . 
.-
10 
Modified/rom Kitao and Takata. Int J Hematol. 2011 
Figure 1.2. A schematic model of the Fanconi Anemia (FA) pathway. The activation of the FA 
pathway promotes the assembly ofFANCM with the associated proteins MHFI, MHF2, FAAP24 
and FAAPIOO. Subsequently, the binding of this sub-complex with FANCA, FANCS, FANCC, 
FANCE FANCF FANCG and FANCL results in the formation of the FA core complex and its 
binding' to the ~hromatin. After the phosphorylation mediated by ATR, the ID complex, 
composed by FANCD2 and F ANCI, is mono-ubiquitinated by the E3 ligase activity, mediated by 
the core complex protein FANCL. This mechanism leads to the association of the 10 complex 
with the chromatin and the recruiting of FA downstream proteins (FANCD1, FANCJ, FANCN, 
FAN CO and FANCP) promoted by the associated protein FAN\, All of these events promote the 
DNA repair. 
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1.3.3 The PALB21FANCN gene 
The gene P ALB2 (Partner and Localizer of BRCA2) was identified by searching novel 
components of endogenous BRCA2-containing complexes. This gene is located on 
chromosome 16p 12.2 and consists of 13 exons. It encodes a protein of 1,186 amino acids, 
with no clearly functional domains, a coiled-coil motif at the N-terminus and a series of 
WD40 repeats at C-terminus of the protein. The major function of P ALB2 is the 
stabilization of BRCA2 and the promotion of its nuclear localization. The PALB2 binding 
site on BRCA2 is localized on the extreme N-terminus of the protein and interacts with the 
C-terminus of P ALB2, in the WD40 repeats region. This interaction is essential for 
BRCA2 role in homologous recombination. In particular, it has been proposed that P ALB2 
is able to recruit BRCA2 in the site of the DNA damage, promoting the assembly with 
RAD51 and the activation of the homologous recombination mechanisms (Oliver et aI., 
2009; Tischkowitz and Xia, 2010). Recent studies indicated that PALB2 can also interact 
with BRCAl. Specifically, a coiled-coil motif in the N-terminus of PALB2 directly binds 
the BRCT domain of BRCA 1, physically linking BRCA 1 and BRCA2. It has been also 
proposed that BRCAI is responsible for the recruiting ofPALB2 in the DNA damage site. 
causing the subsequent recruiting of BRCA2 (Zhang et aI.. 2009). 
In 2007, it was reported that biallelie mutations in PALB21FANCN are responsible for 
the FA disease (Reid et aI., 2007), whereas monoallelic mutations are involved in breast 
cancer susceptibility. P ALB2 germline truncating mutations were identified in 10/923 
English familial breast cancer cases, with a frequency of 1.1 % and it has been estimated 
that these mutations increase breast cancer risk by approximately two-fold (Rahman et aI., 
2007). Subsequently, PALB2 truncating mutations were also reported in 1195 Spanish 
(Garcia et aI., 2009), 8/976 German (Hellebrand et aI., 2010; Bogdanova et aI., 2011), 
19/1512 Australian (Southey et aI., 2010; Wong et aI., 2011; Teo et aI., 2013-a), 2/227 
Italian (Papi et aI., 2009; Balia et aI., 2010) and 5/1,124 Danish familial breast cancer cases 
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(Tischkowitz et aI., 2012). P ALB2 mutations were also found in 34/995 cases with 
unselected ancestry (Tischkowitz et aI., 2007; Casadei et aI., 2011) and in 3/360 Chinese 
breast cancer cases with early onset of disease (Cao et aI., 2008). Among the above 
mentioned studies, mutation frequency varied from 0.2% to 3.3%. In addition, founder 
mutations have been identified in different populations. In 2007, the c.1592delT mutation 
was identified in 31113 Finnish familial breast cancer cases and 6/2,501 controls, with a 
frcquency of 2.7% and 0.2%, respectively (Erkko et aI., 2007). Subsequently, the 
c.2323C>T mutation (p.Gln775X) was reported in 4/564 (0.7%) French-Canadian breast 
cancer cases with early onset of disease (Ghadirian et aI., 2009), and the c.509 _510de1GA 
mutation was detected in 4/648 (0.6%) Polish familial breast cancer cases and in 111,310 
(0.08%) unrelated controls (Dansonka-Mieszkowska et aI., 2010). Very recently, the 
c.3113G>A (p.Trpl038X) mutation was found in 5/1,403 (0.4%) Australian cases and in 
01764 controls from a population-based study (Southey et aI., 2010), and in 8/871 (0.9%) 
high-risk familial cases (Teo et aI., 2013-b). 
In 2009, the PALB2 pathogenic mutation c.l72_175de1TTGT was identified in a 
pancreatic cancer patient using exomic sequencing analysis (Jones et aI., 2009). Following 
this observation the genomic region of the gene was sequenced in 96 familial pancreatic 
cancer cases. In this analysis, three different truncating mutations were found, for a 
frequency of 3.1 %. Interestingly, among the four PALB2 positive families, three presented 
cases of breast cancer in their pedigrees. Two subsequent studies reported PALB2 
truncating mutations in four other pancreatic cancer families, with a frequency of less than 
1% and 3.7%, respectively, and in each of these families, cases of breast cancer were 
reported (Tischkowitz et aI., 2009; Slater et aI., 2010). Thus, of the eight pancreatic cancer 
families positive for PALB2 mutations, reported in the above mentioned studies, seven had 
one or more cases of breast cancer in their pedigrees. More recently, PALB2 was also 
screened in breast cancer cases with personal or family history of pancreatic cancer 
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(Hofstatter et aI., 2011; Stadler et aI., 2011). In the first analysis, it was reported that 2/94 
cases carried a P ALB2 pathogenic mutation, for a frequency of 2.1 %, whereas no P ALB2 
mutation was identified in the second study. All of these findings indicate a possibly co-
occurrence of breast and pancreatic cancer in P ALB2 mutation positive families. 
1.3.4 The SLX41FANCP gene 
SLX4 encodes a 1,834 amino acids multidomain scaffold protein involved in DNA 
repair. In particular, it has been proposed that SLX4 interacts with three different 
endonucJeases, SLX1, ERCC4/XPF-ERCCI and MUS81-EMEl, promoting their 
enzymatic activity in the processing of DNA repair intermediates and in the repair 
mechanism (Fekairi et aI., 2009; Munoz et aI., 2009; Svendsen et aI., 2009). In addition, it 
has been shown that SLX4 directly interacts with the telomere-binding protein TRF2 and 
its partner TERF2IP/RAPI, and with the mismatch repair heterodimer MSH2-MSII3 
(Cybulski and Howlett, 2011). 
In early 2011, two different studies proposed an involvement of SLX4 in the 
development of the Fanconi Anemia. Firstly, Stoepker and colleagues analyzed an 
individual with a Fanconi Anemia diagnosis but with no mutations in known Fanconi 
Anemia genes, proposing a possible involvement of the SLX4 gene (Stoepker et aI., 2011). 
Sequence analysis revealed the presence of a homozygous truncating mutation, c.268deIA, 
in the first ex on of the gene, resulting in the formation of a premature stop at codon 126. 
Additional evidences of the role of SLX4 in the disease were obtained by sequencing a 
second Fanconi Anemia family, in which three siblings carried two SLX4 mutations, the 
c.1093deIC, inherited from their father, and the splicing site mutation c.1163+ 3dupT, 
inherited from their mother. Subsequently, Kim and colleagues identified two novel 
Fanconi Anemia individuals with unassigned Fanconi Anemia complementation group and 
carrying SLX4 pathogenic mutations (Kim ct aI., 2011). In particular, they detected one 
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individual carrying two heterozygous deleterious mutations, c.514de1C and 
c.2013+225_3147delinsCC, and a second individual carrying the homozygous mutation 
c.lI63+2T>A. This evidence supports a role of the gene SLX4 in Fanconi Anemia 
development, and indicates the SLX41FANCP gene as responsible for the new FA subtype-
P. Since germline mutations in some of the other FA genes, such as BRCA2, PALB2 and 
BRIP 1, are associated with an increased breast cancer risk, SLX4 may be considered a good 
candidate as a breast cancer predisposing gene. 
To date, four different studies focused on the involvement of SLX4 in breast cancer 
susceptibility have been performed and only two truncating mutations have been found. In 
2011, 52 German and Byelorussian and 94 Spanish familial breast cancer cases were 
screened for the entire SLX4 coding region (Landwehr et aI., 2011; Fernandez-Rodriguez et 
aI., 2012). Although a large number of variants were found in both of these analyses, none 
of them resulted as a clearly pathogenic mutation. Subsequently, the screening of a large 
cohort of 729 familial breast cancer cases from The Netherland, Canada and Belgium 
identified a splicing site mutation, c.2013+2T>A, that causes the disruption of the splice 
donor site, loss of the reading frame and the introduction of a premature codon stop 
(Bakker et aI., 2013). More recently, a Spanish study screened 486 familial breast cancer 
cases and identified the nonsense mutation p.Glu 1517X and an additional missense 
mutation, the p.Arg372Trp, that was predicted to be pathogenic by in silica analysis (de 
Garibay et aI., 2012). In conclusion, two carriers of SLX4 clearly deleterious mutations 
were found in a total of 1,361 familial breast cancer cases, for a very low frequency of 
0.15%. 
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1.4 Low-penetrance alleles 
In the early 2000, a hypothesis began to emerge the that a percentage of familial breast 
cancer cases was due to a large number of low-penetrance alleles, each conferring a very 
small increased or decreased breast cancer risk, and possibly acting simultaneously, under 
a polygenic model. In fact, germline mutations in high- and moderate-penetrance genes 
explain only approximately 20-25% of all familial breast cancer cases (reviewed in 
Varghese and Easton, 2010). 
Association studies are the most important instrument for detection of low-pcnctrance 
alleles. In these studies, frequencies of genetic variants are measured and compared in 
cases versus controls, to evaluate their association with a specific phenotype. Early 
association studies were based on the analysis of a limited number of variants, mainly 
single nucleotide polymorphisms (SNPs), located in genes of interest for breast cancer. 
This method is known as the candidate gene approach and requires an a priori knowledge 
of the biological functions of the candidate gene (Ahmed et aI., 2009; Mavaddat et aI., 
2010; Varghese and Easton, 2010). With this approach, the CASP8 variant D30211 
(rs 1045485) was investigated and it was reported as associated with breast cancer risk, 
although it is possible that other variants in linkage disequilibrium are those actually 
causative (Cox et aI., 2007). In addition to the CASP8 rs1045485, other variants were 
reported as associated with increased risk but none of these associations was confirmed 
(Breast Cancer Association Consortium, 2006), probably because of the limited sample 
size of each single study that did not allow enough statistical power. To overcome single 
study limitations, consortia or multi-group collaborations have been established. These 
consortia collect a very large number of cases and controls and provide a higher statistical 
power to detect small increased or decreased breast cancer risk. 
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The identification of common genetic variations tagging genomic regions and the 
developing of high-throughput platforms has led to the advent of a novel strategy for 
detection of low-risk alleles, the genome wide association studies (GWASs), that allow the 
simultaneous genotyping of hundreds of thousands of SNPs throughout the genome. This 
strategy is based on the selection of subsets of SNPs to detect most common variations in 
the genome in a given population, taking advantage of the correlation among flanking 
genetic variants in linkage disequilibrium (reviewed in Mavaddat et al., 2010). This is an 
agnostic approach not based on prior knowledge of functions of a gene or its involvement 
in a particular pathway. The initial GWASs identified SNPs in 12 breast cancer 
susceptibility loci (Table 1.3). Some of these variants were located in known genes, such 
as FGFR2, TOX3, MAP 3KI, that play a role in breast cancer development or in cells 
proliferation and apoptosis or in cancer progression and metastasis. Other variants were 
located in regions, such as the 8q24 and the 2q35, that do not contain any gene (reviewed 
in Varghese and Easton, 2010). 
Very recently, a large-scale genotyping were performed on 10,052 breast cancer cases 
and 12,575 controls of European origins in the Breast Cancer Association Consortium 
(BCAC). as part of a collaborative project involving four different consortia (COGS). In 
this analysis, 41 novel SNPs associated with breast cancer risk were identified, both in 
genes and in desert gene regions, largely increasing the number of susceptibility loci 
known to date (Michailidou et aI., 2013). It was estimated that these newly associated loci 
account for approximately 5% of the familial breast cancer risk, and individually 
conferring a small risk increase, with the higher odds ratio (OR) of 1.26. 
The profiling of the current set of known susceptibility loci, under the assumption that 
their effects combine multiplicatively, may allow the identification of the 5% of female 
individuals with a 2.3-fold increased breast cancer risk and the 1 % with a 3-fold increased 
risk with respect to the average population. 
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Table 1.3. Low-penetrance breast cancer susceptibility loci identified in the initial GWASs 
Locus Gene SNP 
Per allele 
P-value Reference 
OR 
I P 11.2 NOTCH2/FCGRIB rsl1249433 l.16 7 x 10-10 Thomas et aJ., 2009 
2q3S none rs13387042 1.20 I x 10-13 Stacey et at, 2007 
3p24 NEKlOISLC4A7 rs4973768 LlI 4 x 10-23 Ahmed et aJ., 2009 
Sql1 MAP3KI rs889312 l.13 7 x 10-20 Easton et at, 2007 
Spl2 MRPS30 rsl0941S79 Ll9 3 x 10-11 Stacey et at, 2008 
6q2S.l ESRl rs2046210 1.29 2 x 10-15 Zheng et at, 2009 
8q24 none rs1328161S 1.08 S x 10-12 Easton et aJ., 2007 
IOq26 FGFR2 rs2981582 1.26 2 x 10-76 
Easton et at, 2007; 
Hunter et at, 2007 
Ilp15 LSPl rs3817198 1.07 3 x 10-9 Easton et at, 2007 
14q24.l RAD5lLl rs999737 1.06 2 x 10-7 Thomas et aJ., 2009 
16ql2 TOX3 rs3803662 1.20 I x 10-36 
Easton et at, 2007; 
Stacey et at, 2007 
17q23.2 COXlI rs6S049S0 1.0S 1 x 10-8 Ahmed et at, 2009 
OR, odds ratio 
1.4.1 SNPs in rnicroRNA as low-penetrance alleles 
MicroRNAs (miRNAs) are a class of small non-coding RNAs of about 22 nucleotides, 
involved in the regulation of gene expression through a specific binding with the mRNA. 
Usually, miRNAs are transcribed by RNA polymerase II as long primary transcripts (pri-
miR), processed and cleaved in the nucleus (pre-miR), and exported to the cytoplasm. 
Here, an additional enzymatic cleavage leads to the formation of the mature miRNA 
(Figure 1.3; reviewed in Ryan et al., 2010). 
The activity of mature miRNA is due to the recognition of a 6-7 nucleotide target 
sequence located at the 3' -untraslated region (UTR) of the mRNA. The mRNA-miRNA 
binding results in the inhibition of translation and/or degradation of target mRNA 
(reviewed in Le Quesne and Caldas, 2010). 
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It has been suggested that deregulation of miRNAs is involved in etiology, progression 
and prognosis of different types of cancer. In addition, it has been observed that SNPs 
located in miRNA genes can affect miRNA function by modulating the transcription of the 
primary transcript, pri-miRNA and pre-miRNA processing and maturation, or miRNA-
mRNA interaction. SNPs in miRNA have been investigated in case-control studies and an 
association of these SNPs with increased or decreased risk has been reported in different 
types of cancer (reviewed in Ryan et aI., 2010). 
Mature miRNA 
Translational repression 
Target mRNA cleavage 
from Ryan e/ al .. Na/ Rev Cancer. 2010 
Figure 1.3. MicroRNA maturation processes. RNA polymerase II (Pol 
II) produces a long transcript of about 500-3000 nucleotides, known as 
pri-miRNA. This molecule is subsequently cropped by the ribonuclease 
DROSHA, forming a 60-100 nuc1eotides molecule, named pre-miRNA. 
This double strand structure is exported from the nucleus to the 
cytoplasm by RAN GTPase and exportin 5 (XP05). Within the 
cytoplasm, the pre-miRNA is cleaved by the enzyme D1CERI , forming a 
mature miRNA of about 20 nucleotides. The mature miRNA is selected 
by an argonaute protein (AG02) and incorporated, with other associated 
proteins, in the RNA-inducing silencing complex (R1SC). The R1SC 
complex, containing the mature miRNA, is then competent to target 
mRNA. 
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To date, different SNPs located in miRNAs have been investigated as associated with 
breast cancer risk. Shen et al. reported the association ofrs2910164, located in miR-146a, 
with increased risk of developing breast cancer in Chinese breast cancer cases with early 
age at onset (Shen et al., 2008). However, this association was not confirmed by 
subsequent studies in Caucasian (Catucci et al., 2010) and in Chinese (Hu et al., 2009) 
populations, and in different meta-analyses (Gao et al., 2011; Tian et al., 2010; Xu et al., 
2011; Lian et al., 2012; Wang et al., 2012). 
In 2009, rs 11614913, located in miR-196a2, was reported as associated with increased 
breast cancer risk in Chinese breast cancer cases by Hu et al. (Hu et al., 2009), with an OR 
= 1.23 (95% confidence interval [CI] 1.02-1.48, P = 0.032). Subsequently, different meta-
analyses confirmed this association in breast cancer and also in other types of cancer (Tian 
et al., 2010; Gao et al., 2011; Wang et al., 2012; Qiu et al., 2011), whereas these data were 
not confirmed in Italian breast cancer cases (Catucci et al., 2010). 
A case-control study performed in Antwerp, Belgium, reported a strong association of 
rs12975333, located in miR-125a, with breast cancer risk (Li et al., 2009). In this study, the 
rare minor allele [T] was detected in 6172 (8.3%) breast cancer cases and in none of 869 
Caucasian controls, including 289 recruited in the Antwerp area and 587 collected in the 
USA. However, a large multicenter study, performed in 2011, failed to confirm this 
association in German, Italian, Spanish and Australian breast cancer cases (Peterlongo et 
al.,2011). 
In 2009, the miR-27a SNP rs895819 was investigated in a series of 1,217 German 
familial breast cancer cases and 1,422 unrelated German controls (Yang et al., 2009). This 
analysis showed an association of the minor allele [G] with reduced breast cancer risk, 
with a OR = 0.88 (95% CI 0.78-0.99, P = 0.0287). Additional analyses indicated also that 
the protective effect was limited to cases with age at diagnosis <50 years (OR = 0.83, 95% 
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CI 0.70-0.98, P = 0.0314), whereas a stronger effect was observed in bilateral breast cancer 
cases (OR = 0.70, 95% CI 0.52-0.95, P = 0.238). 
1.5 Genetic risk modifiers in BRCA genes mutation carriers 
To date, it has been estimated that the cumulative average risk to develop breast 
cancer by the age of 70 in BRCA gene mutation carriers is about 65% in BRCAl and 45% 
in BRCA2 mutation carriers (reviewed in Milne and Antoniou, 2011). However, it has been 
also observed that the risk conferred by a specific BRCAl or BRCA2 mutation may be 
variable among carriers from different families and also from the same family where the 
mutation segregates. Such evidence suggests the presence of additional factors, including 
genetic modifiers, that could modulate the risk conferred by BRCAl and BRCA2 mutations 
in these families. 
In this context, as reported for the detection of the low-risk alleles, two main different 
approaches, the candidate gene strategy and the OW ASs, were used to identify genetic risk 
modifiers. With the gene candidate approach, several common SNPs were screened as 
plausible modifiers as they are located in genes possibly acting as risk factors for the 
disease and in genes involved in BRCAl and BRCA2 pathway, or functionally interacting 
with them. Although these studies reported several positive associations between candidate 
SNPs and increased breast cancer risk, the large part of these associations failed to be 
confirmed by replication studies (reviewed in Chenevix-Trench et aI., 2007). As an 
example of the investigation of modifiers in candidate genes, Rebbeck and colleagues 
analyzed two CAO repeat length polymorphisms located in the androgen receptor (AR) 
gene and in the nuclear receptor coactivator 3 (NCOA3, also referred to as AIBl) gene, 
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encoding a hormone receptor and a receptor interacting protein, respectively. They 
suggested an association between the alleles containing more than 28 repeats and increased 
breast cancer risk (Rebbeck et aI., 1999; Rebbeck et aI., 2001), but this association failed to 
be confirmed in subsequent studies (reviewed in Chenevix-Trench et aI., 2007). An 
interesting exception was represented by the RAD5JC/135G>C polymorphism 
(rsI801320). Wang and colleagues reported the association of the minor allele [C] with 
increased breast cancer risk in BRCA2 mutation carriers (Wang et aI., 2001). Subsequently, 
this association was confirmed in two additional studies (Levy-Lahad et aI., 2001; Kadouri 
et aI., 2004). The apparent difficulty of reproducing results obtained in the original studies 
was probably due to the limitations of the candidate gene approach and the small sample 
size of each single study, that often does not allow enough statistical power. As described 
for low-penetrance alleles, these issues were overcome by establishing larger studies and 
consortia. 
The Consortium of Investigators of Modifiers of BRCAJ and BRCA2 (CIMBA) was 
established in 2005 to provide sufficient sample size, combining DNAs and data from 
several studies. As concerned the gene candidate approach, the RAD5J C/135G>C SNP 
was re-genotyped in more than 8,500 female BRCAJ and BRCA2 mutation carriers from 19 
different studies. This analysis indicated that carriers of two copies of the [C] allele had 
three-fold increased risk of developing breast cancer (hazard ratio [HR] = 3.18), 
confirming the previous data (Antoniou et aI., 2007). In a following study, the 
CASP8/D302H polymorphism was investigated by CIMBA because of the reported 
association with reduced breast cancer risk in the general population (Frank et aI., 2006). 
CIMBA analysis showed a significant association of the minor allele with reduced breast 
cancer risk, as reported in the general population, but only in BRCAJ mutation carriers, 
with a HR = 0.85 (Engel et aI., 2010). 
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Recently, the investigation of novel candidate breast cancer risk modifiers has been 
focused on low-penetrance alleles that were found to be strongly associated with risk by 
OW ASs. These common variants were screened as risk modifiers in a large series of 
BRCA 1 and BRCA2 mutation carriers collected by the CIMBA. 
In the first two studies, a total of six variants were genotyped. Of them, five, 
rs2981522 in FGFR2, rs3803662 in TOX3ITNRC9, rs889312 in MAP3KI, rs3817198 in 
LSP 1 and rs13387042 in the 2q35 region, were associated with increased risk in BRCA2 
mutation carriers whereas only two, rs3803662 in the TOX31TNRC9 gene and rs13387042 
in the 2q35 region, were associated with increased risk in BRCAI mutation carriers. No 
association was found for rs13281615 in the 8q24 region. (Antoniou et al., 2008; Antoniou 
et al., 2009). The estimated relative risk conferred by these variants in BRCAI and BRCA2 
mutation carriers was comparable to that observed in the general population. 
In additional studies, novel low-penetrance alleles were tested as genetic modifiers. 
This genotyping showed an association of two SNPs, rs2046210 and rs9397435 both 
located in the 6q25 region, with increased risk in BRCA 1 mutation carriers and another 
four variants, rs4973768 in the NEKJO/SLC4A7 gene, rs10941679 in the 5p12 region, 
rs9397435 in the 6q25.1 region and rs 11249433 in the 1 p 11.2 region, associated with 
increased risk in BRCA2 mutation carriers (Antoniou et al., 2010; Antoniou et al., 2011). 
These findings strongly suggest that common variants that are associated with breast 
cancer risk in the general population may also act as genetic risk modifiers in BRCA 
mutation carriers. The differential association, observed between BRCAJ and BRCA2 
mutation carriers, of the risk conferred by these genetic modifiers probably reflects the 
distinct biology features of BRCAI- and BRCA2-related tumors, related to estrogen 
receptor (ER) status (reviewed in Antoniou and Chenevix-Trench, 2010). 
Very recently, two GWASs were performed in BRCAJ and BRCA2 mutation carriers, 
confirming the association with a few previously identified loci and identifying novel 
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genetic modifiers in both genes. In BRCAI mutation carriers, two known SNPs located in 
the LSP 1 and RAD5I LI genes were found to be associated with increased risk and one 
novel locus was also detected. This is located at 1 q32 and contains the oncogene MDM4 
(Couch et aI., 2013). In BRCA2 mutation carriers, rs4733664, located in the 8q24 region, 
rs 16917302 and rs 17221319, located in the ZNF356 gene, rs311499, located in the 20q 13 
region and the rs27633, located in the 12pll region, were found associated with increased 
breast cancer risk (Gaudet et aI., 2013). All these identified breast cancer risk genetic 
modifiers are reported in Tables 1.4 and 1.5. 
Table 1.4. SNPs associated with breast cancer risk modification in BRCA I mutation carriers 
Gene/Region SNP IIR (95% el) P Reference 
CASf'S rsl045485 0.85 (0.76-0.97) 0.028 Engel et aI., 2010 
TOX3ITNRC9 rs3803662 1.11 (1.03-1.19) 0.004 Antoniou et aI., 2008 
2q35 rsl3387042 1.14 (1.04-1.25)" 0.005 Antoniou et aI., 2009 
6q25.1 rs2046210 1.17 (1.11-1.23) 4.5xlO-9 Antoniou et aI., 2011 
6q25.1 rs9397435 1.28 (1.18-1040) 1.3 x 10-8 Antoniou et aI., 20 II 
LSf'J rs3817198 1.09 (1.04-1.14) 9.4xI0-4 Couch et aI., 2013 
RAD51 Ll rs999737 0.94 (0.89-0.99) 0.035 Couch et aI., 2013 
Ig32 rs2290854 1.14 (1.09-1.20) 2.7xlO-8 Couch et aI., 2013 
IIR hazard ratio, allR under a dominant model 
Likewise in the general population, it is estimated that each of the identified risk 
modifiers conferred a very small increase of breast cancer risk in BRCAI and BRCA2 
mutation carriers, with IIRs $ 1.32. The larger increase is conferred by rs2981522 in the 
FGFR2 gene in carriers of BRCA2 mutation. Nevertheless, different studies suggested that 
the combined effect of these alleles accounts for a larger risk increase, depending on the 
number of risk alleles carried, under a multiplicative model (reviewed in Milne and 
Antoniou, 2011). For example, Antoniou and colleagues estimated the breast cancer risk 
for BRCA2 mutation carriers combining the genotype distribution of seven different SNPs 
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(Antoniou et aI., 2010). The risk of developing breast cancer by age 50 for the 5% of the 
mutation carriers at lower risk was predicted to be 10-13%, whereas this risk is 29-47% for 
the 5% of the mutation carriers at higher risk (Figure 1.4). 
Table 1.5. SNPs associated with breast cancer risk modification in BRCA2 mutation carriers 
Gene/Region SNP HR(95% CI) P Reference 
RAD51C rsl801320 3.IS (1.39-7.27) 0.0007 Antoniou et aI., 2007 
FGFR2 rs2981522 1.32 (1.20- 1.45) 2x10·8 Antoniou et aI., 2008 
FGFR2 rs2420946 1.27 (1.19, 1.34) 2x10·14 Gaudet et aI., 2013 
TOXJITNRC9 rs3S03662 1.15 (1.03-1.27) 0.009 Antoniou et aI., 2008 
MAPJKI rsS89312 1.12 (1.02-1.24) 0.02 Antoniou et aI., 2008 
LSPI rs3817198 1.16 (1.07-1.25) 0.0003 Antoniou et aI., 2009 
2q35 rs I 33S7042 1.18 (1.04-1.33)" 0.008 Antoniou et aI., 2009 
N£K IOlSLC4A 7 rs4973768 1.10 (1.03-1.18) 0.0064 Antoniou et aI., 20 I 0 
5pl2 rsl0941679 1.15 (1.04-1.27)" 0.0083 Antoniou et aI., 20 I 0 
6q25.1 rs9397435 1.14 (1.01-1.28) 0.031 Antoniou et aI., 20 I I 
Ipl1.2 rsl1249433 1.09 (1.02-1.17) 0.015 Anton iou et aI., 20 II 
MAPJKI rsl6886113 1.24(1.11,1.38) lxlO-4 Gaudet et aI., 2013 
Sq24 rs4733664 1.10 (1.04, 1.17) 1.7xlO·3 Gaudet et aI., 2013 
ZNFJ65 rs I 691 7302 0.88 (0.80, 0.98) 0.01 Gaudet et aI., 2013 
ZNFJ65 rsl7221319 1.09 (1.02, I. I 5) 6xlO·3 Gaudet et aI., 2013 
20ql3 rsl3039229 0.90 (0.84, 0.97) 5x 10.3 Gaudet et aI., 2013 
12pll rs27633 1.14 (1.07, 1.21) 4xI0·$ Gaudet et aI., 2013 
IIR hazard ratio, "I IR under a dominant model 
While the impact of the SNP profiles in the assessment of breast cancer risk in the 
general population is at present very limited, because of the very small risk increase 
conferred, in ORCA mutation carriers this profiling may be of clinical relevance. In fact, 
the combined relative risk of several alleles results in much larger differences, compared to 
the general population, in the absolute lifetime risk of developing breast cancer, since 
ORCA mutation carriers are individuals with already high risk of the disease (reviewed in 
Milne and Antoniou, 2011 ~ Figure 1.5). 
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Figure 1.4. Breast cancer age-specific cumulative risk for BRCA2 
mutation carriers. This risk has been estimated by combining the 
genotype distribution of the following SNPs: rs2981582 in FGFR2, 
rs3 803662 in TOX3ITNRC9, rs889312 in MAP3KI, rs3817198 in LSPI , 
rs l3387042 in the 2q35 region, rs4973768 in NEKIOISLC4A7 and 
rs I 0941679 in the 5p 12 region. 
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Figure 1.5. Comparison of predicted age-specific cumulative breast cancer risks in the 
general population (on the left) and in BRCA2 mutation carriers (on the right). This predicted 
risk is based on the combined genotypes of 18 different SNPs associated with breast cancer 
risk in the general population. The figure estimates that the absolute lifetime ri sk of 
developing breast cancer in the general population varies from 5.7% to 19%, whereas this 
risk in BRCA2 mutation carriers varies from 47% to 89%. 
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1.5.1 The rs3834129 in the CASP8 promoter region as candidate genetic risk 
modifier in BRCA genes mutation carriers 
The CASP8 gene encodes a protein of the cysteine-aspartic acid protease (caspase) 
family. Caspases playa crucial role in apoptosis, a process of programmed cell death 
essential for controlling cell proliferation and cancer development. In particular, CASP8 is 
an apical caspase involved in the apoptosis activation mediated by death receptors and 
their ligands, cooperating with CASPIO and CFLAR (110 and Howkins, 2005). Because of 
the crucial role of these proteins, it has been suggested that mutations in their genes may be 
associated with breast cancer susceptibility. 
The initial report observed the association of the CASP8/D302H (rs I 045485) with a 
reduced breast cancer risk (OR = 0.83; 95% CI 0.74-0.94 for heterozygotes and OR = 0.58; 
95% CI 0.39-0.88 for homozygotes) (MacPherson et al., 2004). This association was 
confirmed by two additional studies (Cox et al., 2007; Sergentanis et al., 2010). 
Subsequently, an additional SNP in the CASP8 gene was studied as a susceptibility 
allele. Sun and colleagues investigated rs3834I29, a common six-nucleotide (AGTAAG) 
insertion/deletion, located at position -652 in the promoter region of the gene (-652 6N 
ins/del) (Figure 1.6). Firstly, they observed that the deletion of these six nucleotides 
destroys the binding site for the transcriptional activator SpI, decreasing the gene 
transcription. Furthermore, they performed a case-control analysis and found a significant 
association of the del allele with a reduced risk of developing breast cancer, with an OR of 
0.65 (95% CI 0.54-0.78) for heterozygotes and 0.50 (95% CI 0.34-0.74) for homozygotes, 
in Chinese unselected cases (Sun et al., 2007). However, this association was not 
confirmed in three different studies performed in unselected Caucasian breast cancer cases 
(Frank et aI., 2008; Cybulski et aI., 2008; Haiman et aI., 2008). 
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rs3934129 
AGTAAGI-
____ ~ _____ I~ ________ ~C=:J_~_T~l~r::J_SP_l~C::J_F_·~ ~r=: ____ L~ __ S~_~' _____ AGT 
~52 Transcrtption start (Exon 3) (Spl?) 
Modified/rom Sun el al., Nal Genel. 2007 
Figure 1.6. Structure of the CASP8 promoter region. The green boxes indicate the binding 
sites for the transcription factors STATI, Spl , NF-kB and ETS. The six-nucleotides 
insertion/deletion polymorphism (rs3834 129) is located at position -652 from the translation 
initiation site. 
Italian familial breast cancer cases negative for mutation in BRCAl and BRCA2 were 
also genotyped for this SNP and, although this analysis failed to confirm the association of 
rs3834129 with breast cancer risk, a case-only analysis suggested a significant association 
of the del/del genotype with increased age at diagnosis (De Vecchi et al., 2009). Recently, 
two different meta-analyses were also performed. The first one, based on the five 
previously described studies, showed a borderline association of the del allele with a 
reduced breast cancer risk, with an OR = 0.94 (95% CI 0.884-1.008), suggesting that, in 
each of the above mentioned studies, sample size was inadequate (Sergentanis and 
Economopoulos, 2009). In the second meta-analysis, four of the five above mentioned 
studies were included to test the association of rs3834129 and breast cancer risk. Here, it 
has been confirmed the protective effect of the del allele, with an OR of 0.95 (95% CI 
0.83-1.08) for heterozygotes and 0.82 (95% CI 0.70-0.95) for homozygotes (Yin et al., 
2010). 
As mentioned above, recent studies have indicated that common low-risk alleles are 
also responsible for risk variability in BRCAI and BRCA2 mutation carriers (Antoniou et 
al., 2008; Antoniou et al., 2009; Antoniou et a1. , 2010; Antoniou et a1., 2011). Among them 
the CASP8 D302H variant was reported, reducing breast cancer risk in BRCA J mutation 
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carriers (HR = 0.85) (Engel et aI., 2010). These findings suggest that also other CASP8 
gene variants, specifically the -652 6N ins/del, might be responsible for breast cancer risk 
variation in BRCAI and BRCA2 mutation carriers. 
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AIM OF THE STUDY 
Chapter 2 - A im of the study 
The major aIm of this thesis was to investigate candidate moderate- and low-
penetrance genes and alleles and genetic risk modifiers associated with breast cancer 
susceptibility in familial cases. This project can be considered as a part of a wider study 
aimed at the identification of as many as possible of these genetic factors to allow a more 
accurate prediction of the individual breast cancer risk both in the general population and 
in breast cancer families. In the first part of this thesis, I investigated the role of the two FA 
genes PALB2 and SLX4 as candidate moderate-penetrance loci, in affected individuals 
negative for mutations in BRCAl and BRCA2. A mutation screening of the entire coding 
region and splice sites of these genes were performed in a large series of familial breast 
cancer cases to verify the association of mutations of PALB2 and SLX4 with increased 
breast cancer risk. 
In the second part of this thesis, a case-control study was performed in a large series of 
familial breast cancer cases to investigate the role ofrs895819, located in the gene coding 
for miR-27a, as a low-penetrance allele. In particular, I wanted to verify the association of 
this SNP with reduced breast cancer risk, previously reported in the German population. 
Finally, the rs3834129 SNP located in the promoter region of the CASP8 gene, was 
investigated as a genetic risk modifier in a large series of affected and unaffected 
individuals carrying a BRCAl or BRCA2 mutation. 
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CHAPTER 3 
MATERIALS AND METHODS 
3.1 Study population 
3.1.1 Genetic counseling and eligibility to BRCAI and BRCA2 genetic test 
Individuals affected with breast cancer or at-risk for breast cancer because of their 
family history underwent genetic counseling in the cancer genetic clinics of different 
centers, collaborating with our research group. The majority of individuals were recruited 
through the Medical Genetic Unit of the "Fondazione IRCCS Istituto Nazionale dei 
Tumori" (INT) and the Division of Cancer Prevention and Genetics of the "Istituto 
Europeo di Oncologia" (lEO), in Milan. Additional individuals were recruited through the 
Unit of Medical Oncology of Azienda Ospedaliera Ospedali Riuniti of Bergamo and the 
cancer genetic clinics of other six centers participating in the "Consorzio degli Studi 
Italiani suI Tumore Ereditario alla Mammella" (CONSIT TEAM; Consortium of Italian 
Studies on Hereditary Breast Cancer) including: Universita degli Studi in Turin, Centro 
Riferimento Oncologico in Aviano, Universita "La Sapienza" and Istituto Nazionale 
Tumori "Regina Elena" in Rome, Universita degli Studi in Florence and "Istituto 
Nazionale per la Ricerca suI Cancro" in Genoa; these individuals were interviewed 
following the specific protocol of each center, to collect a detailed family history of cancer 
or other disease, and to reconstruct detailed pedigrees. When possible, the diagnoses of 
reported cancers were verified by medical records. 
Individuals recruited at INT and lEO were considered eligible for mutation screening 
in BRCAI and BRCA2 when fulfilling the following criteria, based on tumor type, age at 
onset and family history of cancer: 
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• Female individuals affected with breast cancer <36 years, or breast cancer and 
ovarian cancer at any age, or male patients affected with breast cancer at any 
age, independently of family history; 
• Members of families with three or more first degree relatives (or second degree, 
if in paternal lineage ) affected with breast cancer or ovarian cancer at any age; 
• Members of families with two first degree relatives (or second degree, if in 
paternal lineage ) with the following features: 
-both affected with breast cancer <50 years, 
-one affected with breast cancer <50 years and the other with either bilateral 
breast cancer, or ovarian cancer, or male breast cancer at any age 
-both affected with ovarian cancer at any age. 
In the other collaborating centers, individuals were recruited following very similar 
criteria. Family history information and pedigrees were subsequently communicated to the 
diagnostic and research laboratories. For all eligible individuals, the BRCAI and BRCA2 
genetic tests were performed. Individuals from INT, lEO and Azienda Ospedaliera 
Ospedali Riuniti of Bergamo were screened in the diagnostic laboratory located at the 
Fondazione Istituto FIRC di Oncologia Molecolare, in Milan (IFOM). 
3.1.2 Recruitment and inclusion criteria to research studies of individuals 
affected with breast cancer or at-risk for breast cancer 
For the recruitment of individuals who underwent a BRCA gene test into the studies 
here described an informed consent for the use of their biological samples for research 
purpose was required. Blood samples of these individuals, including index cases, and their 
relatives, were sent to our laboratory. In the present project, the following two groups of 
individuals were included: 
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• FemaJe individuals with disease causing mutations in BRCAl or BRCA2, with or 
without a diagnosis of cancer (BRCA mutation carriers); 
• FemaJe individuals negative for disease causing mutations in BRCAl and BRCA2, 
with a personal history of breast cancer as the first diagnosed (BRCAX cases). 
The entire recruitment process is described in Figure 3.1. 
Cousent to the usc 
of biological 
sampl for research 
purpose 
Yes (- 99%)· 
DNA extraction 
from blood 
swnple 
I BRCAI and 
BRCA] 
mutation 
camers 
(lOS)·· 
Figure 3.1. The entire process of recruitment and selection of individuals affected with breast cancer or 
at-risk of breast cancer included in the present studies. 
*Based on individuals recruited at the Medical Genetic Unit oflNT from 2009 to 2012 . 
.. Based on individuals recruited from all collaborating centers in 2012. BRCA I and BRCA2 mutation 
positive individuals include all ascertained carriers of examined families. As for BRCAX cases, only the 
family probands were considered. 
3.1.3 Recruiting of blood donors 
Normal controls were female blood donors consecutively recruited through the 
Immunohematology and Transfusion Medicine Unit of INT and the Associazione 
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Volontari Italiani Sangue (AVIS) agencies, in Milan and Bergamo. All individuals signed 
an inform consent to the use of their biological samples for research purpose. 
3.2 Association studies 
Association studies (or case-controls studies) are analyses that allow evaluation of the 
association of a specific variant with a particular phenotype. These analyses are performed 
measuring the frequencies of candidate genetic variants in two different groups represented 
by individuals affected with a disease (cases) and individuals unaffected (controls) (Mann 
et aI., 2003). Statistically significant differences in the frequencies measured in cases 
versus controls indicate the association with the disease. In addition, the odds rati03 (OR) 
calculation allows to define the role of the associated variant in increasing or decreasing 
the risk of developing the disease. In particular, an OR> 1 indicates that the variant is a 
risk factor, whereas an OR < 1 indicates that the variant act as a protective factor for the 
disease (Turnbull and Rahman, 2008). However, one of the major limitations of these 
studies is the sample size. In fact, underpowered studies did not allow enough statistical 
power to demonstrate the association of a genetic variant with the disease. This limitation 
is even more evident for variants with very low frequencies (Turnbull and Rahman, 2008). 
The establishment of national and international consortia became indispensable for 
collecting a large number of cases and controls, hundreds of thousands of samples, to 
ensure higher level of statistical significance. 
3 The odds ratio represents the measure of the association between the exposure to a risk factor and the 
disease in association studies. 
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3.3 DNA samples preparation 
Blood samples were obtained from the diagnostic laboratory, after mutation screening 
in BRCAl and BRCA2 genes. DNA was extracted from peripheral blood, using the Gentra 
Puregene Blood Kit (QIAGEN), according to manufacturer's protocol. After DNA 
extraction, samples were quantified by Thermo Scientific NanoDropTM 1000 (NanoDrop), 
diluted at a final concentration of 25 ng/J..lI in the DNA Hydration Solution, included in the 
commercial kit, and distributed in 96-well plates. 
3.4 Mutation screenings 
3.4.1 PCRs conditions 
DNA amplification was performed using the polymerase chain reaction (PCR), for the 
entire coding region and intronlexon junctions of the PALB2 and SLX4 genes. For the 
CASP8 gene, only the promoter region including rs3834129 was amplified. Each PCR was 
performed in a total volume of 15 J..lI, containing 30 ng of genomic DNA, IX PCR Buffer, 
2.5 mM MgCh, 0.2 mM of each dNTP, 0.5 J..lM of each primer, 0.75 units of @Taq 
(EuroClone). Amplification was carried out as follow: 32 PCR cycles consisting of a 
denaturation step at 94°C for 30 seconds, an annealing step at different temperature for 
each fragment for 30 seconds and an extension step at 72°C for 30 seconds, followed by a 
final extension step at 72°C for 5 minutes. The CASP8 region containing rs3834129 was 
amplified using primers specifically designed. The amplification of PALB2 fragments was 
performed using primers described by Reid et al. (Reid et aI., 2007). SLX4 fragments were 
amplified using primers described by Stoepker et al. (Stoepker et aI., 2011), with the 
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exception of primers for exons 5, 8, 12B-F, 13 and 15 that were redesigned. The 
amplification of SLX4 exon 8 was optimized using 5% DMSO. Primer sequences and PCR 
conditions are described in Tables 3.1, 3.2 and 3.3. All PCR products were checked by 
electrophoresis on 1.5% agarose gels. 
3.4.2 Mutation detection by sequencing 
Mutation screening of the PALE2 and SLX4 genes and the genotyping of rs3834129 
were performed at the DNA Sequencing Unit of the Technological Service at IFOM, using 
single strand sequence analysis. 
PCR fragments were sequenced usmg the chain termination sequencing (Sanger 
sequencing) method on ABI 3730xl or ABI 3500dx sequence analyzers (Life 
Technologies). Sequencing results were analyzed using the DNA Sequence Analysis 
Software Sequencher 5.0 (GeneCode Corporation). Identified truncating mutations were 
confirmed by double strand DNA sequencing. 
Table 3.1. CASP8 primer sequences and PCR conditions 
Primer Name Primer Sequence 
CASP8F TCCCCGCTGTT AACA TTTTG 
CASP8R CTGCATCCAGGAGCTAAGT 
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Table 3.2. PALB2 primer sequences and PCR conditions 
peR Annealing 
Primer Name Primer Sequence Fragment temperature 
{b~) eq 
IF GGATTTAATTGGCCGGAGTT 309 59 
IR GACACAAAGCCAGGCCTAAA 
2-3F ACCTTTCCACTTGCCCAGTA 400 59 
2-3R GGGAAAAAGAACAATAGCCAAA 
4AF GCCTGAATGAAATGTCACTGATT 495 59 
4AR GCAAAAATCCTGCTAGATCACC 
4BF CCCTAGTGGTGAGCAAAAGC 387 59 
4BR TCAAGGTGCTGACTACTACCG 
4CF ACCAACTGCCCAACCAGA 357 59 
4CR TGGTTTTCATTTGCTGGTAAG 
4DF AAGTAAAAGTGGCCAACTGC 388 58 
4DR TTTTTTCTTGACATCCAAATGACTC 
4EF GCAGAAAAACATTCTTGCACA 589 65 
4ER AAGGAAGTGCCAGGCAAATA 
5AF GATTGTCTGTTTTGTTGGGTTT 395 59 
5AR GGTCCTCTTCTAAGTCCTCCATT 
5BF AAAGAGGGAAGCTGTATTTTTCC 398 58 
5BR CTGCCTGAACTCTCGAATTG 
5CF CACCTGCTTTCCCCATCTTA 389 59 
5CR GGCATTTCATTCCTTCAGAGA 
6F AGTGGGTAATGCAGGCAGA 213 59 
6R TGACTGAATTCTTTTCAGTTCATT 
7F TGCTTTGCATAAAACAGCACT 293 62 
7R TGGTAAGCTGCCCATCTACA 
8F TGGAAAATCTGGATTAAACAAAAA 221 58 
8R TGCACTTAAAACCAGCTGACA 
9F ATTAAAAGGTTACTCCTCACATCAC 287 64 
9R CCCAACTTTCTCTGAAACCTGT 
IOF CCTAGAGACTGCTTTAGTGCAAA 250 58 
lOR TTCACAACAACCCTGTAAAATTAG 
IIF TTTTCTGAATACTGGTTTGTTGGA 244 58 
llR CGGGGAAGGTTTGTTCATTA 
12F TGCCAGATCTTTATTTTTCCTGA 281 59 
12R TGTGTTTGCACAGTGCCTTT 
13F TGGTTTTGGGAACATGGTTT 400 58 
13R TTAAGTGTCATTCAGATATTCTCCTTT 
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Table 3.3. SLX4 Erimer seguences and PCR conditions 
peR Annealing 
Primer Name Primer Sequence Fragment temperature 
{bl!} {0C} 
S2F TGTTTAACCACAGGCCCAAT 707 60 
S2R GCCCTTTCCAGGAAGTTTTC 
S3F ACCAACAAGCAACCAGTCCT 524 62 
S3R ATCCAGTGAAGTGGCAAAGG 
S4F TTCCCGGAGTGCTGATTAGT 500 62 
S4R ACAACAAAGCTGAGGTGCTG 
S5F GACCCACATTTGCTCCAATC 387 62 
S5R GGTGTGAACTACTGCGTCCA 
S6F AACTTCTGGCCTGGAATTGA 518 59 
S6R ATACCGGGGGTTTCTTCTTG 
S7F CCAGAAGCAGGTTTGTGTGA 534 59 
S7R CCTTCCTGGACTTTCCATCA 
S8F GTAGTTTTAGGTCCAGCCGTGCATA 494 64 S8R AAAAATGAAAGCGCCCAGAGG 
S9F TCTCTTACCTCCCTGGTGGA 440 62 
S9R CTCACGGATGTCAGGATGTG 
SIOF GGGTCACTCAGAGGTTGAGG 444 62 
SIOR GCAGGAAGTGAGGGAGAGTG 
SII F AGGCTGCAGTAAGCCATGAT 492 65,5 
SIIR CTGGTCATGGACTTGGGATT 
SI2AF TGTTTCTGGCAAGGAGTGTG 548 62 
SI2AR CTCCACCTTGTCCCACTGTT 
SI2BF TACTCAGCGAAAGCTTCTCCA 587 62 
SI2BR ACGACCCACTTGTGTGATGAG 
SI2CF GAACAAAGTGGCGCTGTCA 556 62 
SI2CR GCTCACAGGACCTAGGGCTAA 
SI2DF TCTTACTGGACTCGGATGAGGA 547 62 
SI2DR CCGTCAGAAGTTCCTGGAGAG 
SI2EF AAACAGGGAAGGGAACGAAGT 540 62 
SI2ER GGGGTGGTGTCCAGGAGT 
SI2FF AATTCCAATTGACGACTGCTG 505 62 
SI2FR AAGTGTCATGCCTCAGGTCAG 
S13F ACCACTGTTGCTTTCATGGAG 353 62 
SI3R ACCAGACCCAGAGACCACAC 
SI4F ATAGGGAACGTGGAGTGTGG 588 62 
SI4R GACGGGGGTTTTTGAAGATT 
SI5F CATGGGACCCGTAGACACC 522 62 
SI5R CAGGTCCTCCCTGCAAATG 
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3.5 Genotyping analyses 
Genotyping analyses were performed at the Real-Time PCR Unit of the Technological 
Service at IFOM. 
The rs895819 SNP, located in the miR-27a gene region, was genotyped using a pre-
designed TaqMan SNP Genotyping Assay (Life Technologies). The genotyping of the two 
recurrent PALE2 mutations, c.72delG and c.1027C>T, was performed using two custom 
TaqMan SNP Genotyping Assays (Table 3.4 and Table 3.5). Primers design was provided 
by the manufacturer. 
Table 3.4. TaqMan assay information of the PALB2 c.72deIG mutation 
Primer Name 
72deIG] 
72deIG_R 
Reporter Name 
72deIG_V 
72delG M 
Primer Sequence 
TGGTGTTTTTCTTCTTCCAGTTAAAGGA 
GCGGGCTAGTGTCTTGCT 
Reporter Sequence 
TTCCCTTTTCAAGAATG 
A TTCCCTTTT -AAGAA TG 
Reporter Dye 
VIC 
FAM 
Table 3.5. TagMan assay information of the PALB2 c.t027C>T mutation 
Primer Name Primer Sequence 
t027CTJ AACTCACCTACAATAACTTACCAGCAAA 
I027CT_R CAAGAGTGTCACTGGGAGATTTTAAAGA 
Reporter Name Reporter Sequence Reporter Dye 
I027CT_V TTCTTTTAAGTTTTGGTTTTC VIC 
I027CT M TTCTTTTAAGTTTTAGTTTTC FAM 
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For all the genotyping tests, the reactions were performed in a total volume of 8J.ll, 
containing 20 ng of genomic DNA, using the ABI 7500 Fast Real Time PCR System (Life 
Technologies). Amplification was carried out as follow: an initial hold step at 95°C for 20 
seconds, followed by 40 PCR cycles consisting of a denaturation step at 95°C for 3 
seconds and an annealing/extension step at 60°C for 30 seconds and by a final post-PCR 
read step at 60°C for 1 minute. In each of the 96-well plates, three duplicate samples, one 
non-DNA blank control and one positive control sample were included. Genotypes for all 
duplicates and positive controls were completely concordant. 
3.6 In silico analyses 
3.6.1 Software for prediction of the missense mutations effect 
For the protein prediction analysis, the following software were used: 
• PolyPhen-2 (Polymorphism Phenotyping v2; http://genetics.bwh.harvard.eduJpph2D 
predicts the results of an amino acid substitution based of the comparison between the 
wild-type and the mutant allele, using physical and evolutionary comparative 
characteristics (Adzhubei et aI., 2010); 
• SIFT (Sorts Intolerant From Tolerant; http://sift.icvLorgD predicts the consequences 
of an amino acid substitution based on the amino acid conservation, assuming that 
functionally important positions should be conserved in an alignment of the protein family, 
whereas unimportant positions should appear diverse in an alignment (Kumar et aI., 2009); 
• SNPs&GO (http://snps.biofold.org/snps-and-go/snps-and-go.html) predicts the results 
of an amino acid substitution collecting data from protein sequence, protein sequence 
profile, and protein function (Calabrese et aI., 2009). 
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3.6.2 Software for prediction of non-canonical splicing 
Analyses of candidate splicing aberrations were performed using the following 
prediction software: 
• Berkeley Drosophila Genome Project . (BDGP; 
http://www.fruitfly.org/seg tools/splice.html; Reese et aI., 1997); 
• NetGene2 (http://www.cbs.dtu.dk/serviceslNetGene2/; Brunak et aI., 1991; 
Hebsgaard et aI., 1996); 
• Splice View (http://zeus2.itb.cnr.it/-webgene/wwwspliceview ex.html; Rogozin et 
aI., 1997); 
• MaxEntScan (http://genes.mit.edu/burgelab/maxentIXmaxentscan scoreseg.html; 
Yeo et aI., 2004); 
• SplicePredictor (http://deepc2.psi.iastate.edu/cgi-binlsp.cgi; Brendel et aI., 2004); 
• GeneSplicer (http://www.cbcb.umd.edu/software/GeneSplicer/gene spl.shtml; 
Pertea et aI., 2001); 
• Automated Splice Site and Exon Definition Analyses (ASSEDA) 
(http://splice.uwo.cal; Mucaki et aI., 2013). 
3.7 Investigation of the PALB2 c.48G>A splicing mutation 
3.7.1 "-lymphocytes immortalization 
The lymphoblastoid cell line carrying the PALR2 c.48G>A mutation was obtained by 
transformation of peripheral B-lymphocytes obtained from a carrier of the variant using 
Epstein-Barr virus (EBV) infection, according to the following protocols. This was kindly 
made available by the Dr. Mara Colombo of INT. 
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I. Collection of B-lymphocytes from peripheral blood sample. Lymphocytes were isolated 
from whole blood sample by gradient centrifugation with Ficoll-Paque (Amersham 
Pharmacia Biotech AB). Briefly, blood sample was diluted 1:2 in RPMI 1640 medium 
(Biowhittaker Europe), stratified on equal volume of Ficoll-Paque and centrifuged at 1800 
rpm for 25 minutes. After the centrifugation, B-lymphocytes were recovered, washed twice 
with RPMI 1640 medium and centrifuged at 1800 rpm for 10 minutes. 
II. Preparation of the viral solution. The viral stock was obtained from the B95-8 cell line. 
These cells were expanded in RPMI 1640 medium supplemented with 10% Fetal Bovine 
Serum (FBS, EuroClone) and 1 % penicillin/streptomycin, at 37°C, 5% CO2. After cells 
became confluent, the recovered supernatant was centrifuged at 1500 rpm for 5 minutes 
and filtered with 0,22~m filter (Millipore). 
III. Immortalization with EBV. B-lymphocytes were resuspended with 1.5ml of RPMI 
1640 medium, 15% FBS, 4% Glutamine and 1 % penicillin/streptomycin, supplemented 
with 1.5ml of the viral solution and 2/-lg of CSA (Ciclosporin A, Sandimmun Sandoz-
Wander PHARMA S.A.) and cultured at 37°C, 5% C02. For the complete transformation, 
one month was required. 
IV. Cell culture conditions. Lymphoblastoid cell line was cultured using RPMI 1640, 15% 
FBS, 1 % penicillin/streptomycin, 25mM Hepes, until their use for RNA extraction. 
3.7.2 RNA extraction and eDNA synthesis 
RNA extraction was performed using the NucleoSpin RNA II Kit (Macherey-Nagel), 
according to the manufacturer's protocol. After the RNA extraction, a eDNA synthesis 
with random primers was performed, using the ImProm-II Reverse Transcription System 
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(Promega). About 140 ng of RNA and 1 III of random primers were combined in a initial 
pre-mix with a final volume of 5 Ill, heated at 70°C for 5 minutes and chilled on ice for 5 
minutes. Subsequently, the reverse transcription mix was prepared in a total reaction 
volume of 15 Ill, containing 4 III of ImProm-II Buffer IX, 3 mM MgCh, 0.5 mM of each 
dNTP, 0.5 units of Recombinant RNasin Ribonuclease Inhibitor and 1 JlI of ImProm-II 
Reverse Transcriptase. Reverse transcription was carried out as follow: 25°C for 5 minutes, 
40°C for 1 hour and 70°C for 15 minutes. 
3.7.3 Amplification of cDNA and transcript analysis 
The amplification of the cDNA obtained from the above described reverse 
transcription was performed in a total reaction volume of 15 ,.d, containing IX PCR 
Buffer, 2.5 mM MgCh, 0.2 mM of each dNTP, 0.5 IlM of each primer, 0.75 units of @Taq 
(EuroClone) and 2 III of non-diluted cDNA. Amplification was carried out as follow: 32 
PCR cycles, including a denaturation step at 94°C for 30 seconds, an annealing step at 
58°C for 30 seconds and an extension step at 72°C for 45 seconds, followed by a final 
extension step at 72°C for 5 minutes. Primers for amplification are reported in Table 3.6. 
The amplification was checked by electrophoresis on 1.5% agarose gels. The transcripts 
found with this amplification were analyzed by direct sequencing, as described in 
paragraph 3.4.2. 
Table 3.6. PALEl PCR primer and conditions for c.48G>A variant characterization 
PCR Annealing 
Primer Name Primer Sequence Fragment temperature 
(bp) (OC) 
FW GCTGCTCTTTTCGTTCTGTC 223 58 
RV GGTGAGAGATCCTGCTGAGAC 
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3.8 Statistical analyses 
Statistical analyses were perfonned by the Unit of Medical Statistics and Biometry of 
INT by Dr. Paolo Verderio and his collaborators. Comparison of frequencies in cases and 
controls was perfonned by resorting to a logistic regression model both in univariate and 
multivariate fashion (Hosmer and Lemeshow, 1989). In this model, fitted by method of 
maximum likelihood, each regression coefficients is the logarithmic of the OR. Under the 
null hypothesis (absence of association between cancer and alleles), OR is expected to be 
1.00. A final parsimonious model was obtained using appropriate selection procedures. 
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4.1 PALB21FANCNmutation analysis 
4.1.1 Mutation screening in a series of Italian BRCAX cases 
Chapter 4 - Results 
Mutation screening of all coding exons and flanking intronic sequences of the P ALB2 
gene was performed in a series of 575 Italian BRCAX cases collected in cancer centers in 
Milan. In addition, gene fragments where a deleterious mutation was found were also 
tested in 784 controls recruited in Milan. In this analysis, a total of 34 variants were found. 
Eight of these were previously reported as common (allelic frequency > 1%) with 
comparable distribution in cases and controls and, therefore, considered as neutral 
polymorphisms (Table 4.1) (Rahman et aI., 2007; Erkko et aI., 2007; Garcia et aI., 2008). 
Table 4.1. Frequencies of common PALE2 polymorphisms in 575 BRCAX cases and 784 controls 
Mutation Annotation 
Cases (%,) Controls (%) 
Protein change 
status 
nor het hom nor het hom 
c.-47G>A na rs8053 188 554 (96.3) 21 (3.7) 0(0.0) 744 (94.9) 39 (5.0) I (0.1) 
c.212-58A>C na none" 519 (90.3) 54 (9.4) 2 (0.3) nd nd nd 
c.IOIOT>C p.Leu337Scr rs45494092 568 (98.8) 7 (1.2) 0(0.0) 776 (99.0) 8 (1.0) 0(0.0) 
c.1676A>G p.Gln559Arg rs45494092 449 (78.1) 121 (21.0) 5 (0.9) 613 (78.2) 164 (20.9) 7 (0.9) 
c.2014G>C p.Glu672Gln rs45532440 528 (9\.8) 46 (8.0) I (0.2) 699 (89.2) 79 (10.1) 6 (0.8) 
c.2794G>A p.Val932Mct rs45624036 563 (98.0) 12 (2.0) 0(0.0) 773 (98.6) 11 (1.4) 0(0.0) 
c.2993G>A p.Gly998Glu rs4555 1636 527 (91.7) 48 (8.3) 0(0.0) nd nd nd 
c.3300T>G E·ThrIIOOThr rs45516100 522 (90.8) 51 (8.9) 2 (0.3) nd nd nd 
na not applicable, nor normal, het heterozygote, hom homozygote, nd not done 
"reported in Erkko et aI., 2007; Garcia et aI., 2008; Tischkowitz et aI., 2009; Sluiter et aI., 2009; Dansonka-
Mieszkowska et aI., 20 I 0; Silvestri et aI., 20 I 0; Catucci et aI., 2012. 
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In addition, we detected 26 rare or unique variants. Of these, eight, none of which 
previously reported, introduced a premature protein termination codon (Table 4.2). Two of 
these mutations, c.72deIG (p.Arg26fs) and c.1027C>T (p.Gln343X), were recurrent being 
detected in two and three cases, respectively. None of the truncating mutations were found 
in controls. 
Table 4.2. PALB2 truncating mutations found in 575 BRCAX cases 
Protcin Families Exon Mutation 
change Class with 
mutation 
2 c.72deIG p.Arg26fs frameshift 2 
4 c.1027C>T p.Gln343X nonsense 3 
4 c.1037 _1041 delAAGAA p.Leu346fs frameshift 
4 c.1108C>T p.Gln370X nonsense 1 
5 c.2074C>T p.Gln692X nonsense 1 
5 c.2167_2168deIAT p.Met723fs frameshift 
8 c.2787 _2788de1T A p.Tyr929X frameshift 
13 c.3497de1G p.Glyl166fs frameshift 
Of the remaining 18 rare or unique variants (11 previously reported and seven novel) 
seven were synonymous, seven were missense and four were intronic (Table 4.3). In silica 
analyses were performed to identify potential splicing mutations, using the bioinformatics 
tools described in paragraph 3.6.2. The c.48G>A (p.LysI6Lys) synonymous mutation, 
located at the last base of exon one, was predicted to affect the canonical mRNA splicing 
by causing the loss of the physiological donor splice site by all five bioinformatics tools 
that correctly detected the natural site (Figure 4.1). To verify this prediction, we performed 
a reverse transcriptase (RT)-PCR analysis in which we amplified a cDNA fragment 
spanning exons 112 junction from a Iymphoblastoid cell line (LCL) of the c.48G>A 
mutation carrier. An aberrant transcript not present in control cDNA was observed (Figure 
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4.2A). Sequencing of this transcript showed the loss of 17 nucleotides at the 3' end of the 
exon 1 (Figure 4.2B). These results indicate that the c.48G>A mutation abolishes the 
canonical donor splice site and activates an alternative site within exon I, causing the loss 
of the reading frame and the formation of a premature termination codon at the amino acid 
residue 36. In addition, we observed that this transcript was absent in LCLs from seven 
individuals affected with breast cancer, but negative for the investigated mutation (data not 
shown). Furthermore, two additional synonymous mutations, c.2379C>T (p.Gly793Gly) 
and c.2418G>T (p.Pr0806Pro), were predicted to affect mRNA splicing. In particular, 
these mutations were predicted to cause the activation of a cryptic donor and a cryptic 
acceptor splice site, respectively by five of the seven bioinformatics tools considered. No 
LCLs of carriers of either mutations were available to verify these outputs. All the 
remaining variants were predicted not to affect normal mRNA splicing by the majority of 
bioinformatics analyses. 
In silico analyses were also performed to investigate all of the missense mutations 
found, using three different software packages (Polyphen2, SIFT and SNPs&GO) 
predicting the effect of mutations on the protein structure and functioning. In this analysis, 
two mutations, c.2792T>G (p.Leu93 1 Arg) and c.2816G>T (p.Leu939Trp), were predicted 
to be damaging by all these tools. 
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Table 4.3. Frequencies ofrare or unique non-truncating PALB2 variants in cases and controls 
Protein Cases Controls Found Polyphen2/SIFTI Mutation 
change Class Annotation (n=575) (n=784) previous SNPs&GO 
studies predictions· 
c.13C>T p.Pro5Ser missense none 2 0 Yes' BITIN 
c.48G>A p.Lysl6Lys synonymous none I 0 No na 
c.243G>A p.Lys8lLys synonymous none 2 nd No na 
c.292A>G p.lle98Val missense none I nd No BITIN 
c.IOOIA>G p.Tyr334Cys missense rs200620434 I I Yesb-e BITIN 
c.1194G>A p'va1398Val synonymous rs61755173 I 0 Yesb.f,g-j na 
c.1572A>G p.Ser524Ser synonymous rs45472400 3 3 Yesb,f.8-k na 
c.1684+42_1684+43insTGA na intronic none 4 7 Yesd .•. h na 
c.2091C>G p.Gly697Gly synonymous none 0 No na 
c.2379C>T p.Gly793Gly synonymous none nd No oa 
c.2418G>T p.Pro806Pro synonymous none 1 nd Yes' na 
c.2587-38G>C na intronic rsI80177119 5 nd No na 
c.2587-25A>G na intronic none 1 nd No na 
c.2590C>T p.Pr0864Ser missense rs45568339 5 nd Yesb-d.f-j,I-o PrDlT1N 
c.2792T>G p.Leu93lArg missense none 1 0 No PoD/APFID 
c.2816T>G p.Leu939Trp missense rs45478192 2 2 Yes··d.r-hJ.m PoD/APFID 
c.2996+ 17T>C na intronic rs180177128 2 nd Yesl na 
c.3428T>A p.LeuI143His missense rs62625284 2 I Yesb,c,e PoD/APFIN 
·8 benign, PrD probably damaging, PoD possibly damaging, U unclassified (PolyPhen-2); T tolerated, APF affecting protein 
function (SIFT); N neutral, D disease, U unclassified (SNP&GO); na not available; nd not done. ·Casadei et ai., 2011; bUellebrand et 
ai., 20 II; cBalia ct ai., 20 I 0; dTischkowitz et ai., 2012; ·Catucci et ai., 2012; fRahman et ai., 2007; SOarcia et ai., 2008; hTischkowitz 
et ai., 2009; iBlanco ct aI., 20 II; illofstatter et al.. 20 II; kBogdanova et aI., 20 I 0; Ipapi et aI., 2009; mSauty de Chalon et aI., 2009; 
"Zheng ct aI., 2012; "Teo et ai., 2013. The variants predicted by in silica analyses to be deleterious, including the c.48G>A verified in 
vitro, arc shown in bold. 
In summary, we found nine PALE2 mutations classifiable as pathogenic, including 
eight truncating and one splicing variant (Figure 4.3) and 12 carriers of these mutations, for 
a frequency of 2.1 %. None of these mutations were detected in 784 tested controls. 
Families in which the index case carried a PALE2 truncating mutation are showed in Table 
4.4 and in Figure 4.4. 
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Figure 4.1. Sioinformatics analyses of the PALB2 c.48G>A splicing mutation. In silica 
analyses were performed using the indicated tools. In the A, S, D and E panels, the 
canonical splicing site (indicated by the red arrow) is detected only in the wild-type 
sequence (wt) and not in the mutated sequence (mut). In the C panel , there is a substantial 
decrease of the site recognition score in the mutated compared to the wild type sequence. 
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Figure 4.2. haracterization of the mRNA transcripts caused by the PALB2 c.48G>A mutation. (A) 
RT-PCR results : M, molecular marker (<I>X-174 Hael"); lane I, no template; lane 2, genomic DNA 
u ed as negative control of the RT-PCR; lane 3, cDNA from a PALB2 wild-type LCL used as a 
normal control of the RT-P R lane 4, cDNA from the LCL carrying the heterozygous PALB2 
c.48 >A mutation . The size of the full-length (FL) and aberrant (Ex 1_ 17bp dcl) transcripts are 
indicated. The additional band due to the improper annealing of the two transcripts is indicated by 
the asterisk. (8) equencing results : the mutated cDNA (upper panel) shows two overlapping 
sequence one corresponding to the full-length transcript (the unique fi-agment presents in the 
normal control c NA, lower panel) and one to the aberrant transcript due to the skipping of 17nt 
( T AG A AAGGAAAAG) at the 3 ' -end of exon I. 
Relative f the index ca e were available for mutation testing in four of the families 
with a PALB2 pathogenic mutation (family D, F, Hand K; Figure 4.4). In particular, we 
te ted a paternal aunt affected with breast cancer at age 45, in family D; a sister affected 
with bilateral brea t cancer at age 39 and 44, in family F; a sister and a maternal cousin 
affected with breast cancer at age 41 and 30, respectively, in family H; all of these 
individual carried the same mutation found in the index case. In addition, three nieces of 
the proband were available for testing in family K, of whom only two were affected with 
breast cancer. None of them carried the PALB2 mutation, but they were carriers of the 
BR 'A 1 2335 2336delAA mutation inherited from the other family branch. 
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Table 4.4. Characteristics of families with PALB2 truncating mutations 
Index case Relatives Family Mutation affected with 
status breast cancer'" 
A c.ll08C>T Br,36 none 
B c.1 03 7_1041 delAAGAA Br,47 2 
C c.72deIG Br,56 3 
0 c.2167 2168delA T Br,26 2 
E c.I027C>T Br,37 2 
F c.3497de1G Br,39 4 
G c.I027C>T Br bi!, 33 4 
H c.I027C>T Br bi!42 5 
I c.72deIG Br,46 2 
J c.2074C>T Br,31 none 
K c.2787 2788delT A Brbil,41 10 
L c.48G>A Br,41 6 
tindex case excluded 
Br breast cancer, Br bi! bilateral breast cancer 
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c.I027C>T (p. Gln343X) 
c.3497de1G (p.GlyI166fs) 
Figure 4.3. Electropherograms of the sequences where a PALB2 pathogenic 
mutation was found . For each mutation, the mutated (mul) and the wild-type 
(WI) sequence are showed. 
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4.1.2 Investigation of the c.72delG and the c.l027C>T recurrent mutations 
In the PALE2 screening, the c.72delG and the c.l027C>T recurrent mutations were 
identified. To better investigate the frequency of these two variants, we further genotyped 
an additional 332 BRCAX cases and 176 controls recruited in Milan, using a TaqMan SNP 
Genotyping Assay. No other carriers of these two mutations were found. Interestingly, we 
also observed that, among the three carriers of the c.1027C>T mutation, two individuals 
were from families that self-reported as being originally from the province of Bergamo, in 
Northern Italy. To explore the possibility that the c.1027C>T is more frequent in this area, 
we genotyped 112 BRCAX cases recruited at the Ospedali Riuniti of Bergamo and 477 
controls recruited through the AVIS of Bergamo. Interestingly, we found that 5/112 cases 
and 2/477 controls carried the c.1027C>T mutation, for a frequency of 4.5% and 0.4%, 
respectively (Table 4.5). Pedigrees of BRCAX families collected in Bergamo in which the 
index case carried the c.1027C>T mutation are showed in Figure 4.5. Only in family 0, 
three relatives of the proband were available for mutation testing: the father, affected with 
breast cancer at 86, was a non-carrier, while two unaffected sisters carried the c.1 027C>T 
mutation. 
Table 4.5. Number of carriers of I 027C>T mutation in BRCAX and controls 
recruited in Milan and Bergamo 
Group 
BRCAX from Milan 
Controls from Milan 
BRCAX from Bergamo 
Controls from Bergamo 
Carriers/total samples 
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3/907 
0/960 
5/112 
2/477 
Carriers % 
0.3 
0.0 
4.5 
0.4 
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To verify the statistical power of the study, the null hypothesis of an equal mutation 
rate in cases and controls was assessed by resorting to Fisher's exact test with a Type I 
error probability of 0.05. This made possible to reject the null hypothesis with a probability 
(power) of 0.824. 
4.1.3 PA LB] mutation analysis in breast and pancreatic cancer families 
Although the families included in the screening for PALB2 mutations were selected 
based on family history of breast cancer, several other cancers types were diagnosed in the 
relatives of the proband, including pancreatic cancers. Following the analysis of the 
pedigrees of the 575 screened families, we identified 39 families with both breast and 
pancreatic cancer cases, including three in which the index case carried a P ALB2 
truncating mutation (family C, F and G; Figure 4.4), for a frequency of7.7% (3/39), higher 
than that observed in the overall group. This observation suggested that breast cancer 
families with cases of pancreatic cancer could be enriched in PALB2 mutations. To verify 
this hypothesis, we screened for PALB2 mutations an additional 23 BRCAX index cases, 
selected from families in which at least one case of pancreatic cancer was reported in first-
or second-degree relatives, independently of the breast cancer family branch. No other 
truncating mutation was found, for an overall frequency in the two combined groups of 
breast and pancreatic cancer families of 4.8% (3/62; Figure 4.6). 
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Br bil, 42, " 
c.27S7 _27S8deITA 
• BRCAI posilive 
Bl-233S_2336de1AA (Ier 741) 
Figure 4.4. Pedigrees of the 12 families in which the index case carried a PALB2 truncating mutation. Index 
cases are indicated by arrow and PALB2 mutations are described. Cancer type and age at diagnosis are 
reported, when known. Br breast cancer, Br hil bilateral breast cancer, Ch choledoch cancer, CR colorectal 
cancer, Ep epidermoid cancer, GC granulosa cell cancer, Ki kidney cancer, La larynx cancer, Le leukemia, 
LH Hodgkin's lymphoma, Li liver cancer, Lu lung cancer, Ov ovarian cancer, Os osteosarcoma, Pa 
pancreatic cancer, Pr prostate cancer, Sf stomach cancer, Vt uterine cancer, VC vocal cords cancer. 
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Figure 4.5. Pedigrees of the five families recruited at the Ospedali Riuniti of Bergamo, in which the index 
case carried the c.1 027C>T PALB2 mutation. Index cases are indicated by arrow. Cancer type and age at 
diagnosis are reported when known . Br breast cancer, Br bil bilateral breast cancer, La larynx cancer, LH 
Hodgkin ' s lymphoma, Li liver cancer, Lu lung cancer, SI stomach cancer, In intestinal cancer, Pa pancreatic 
cancer, Pr prostate cancer. 
Figure 4.6. Venn diagram representing the distribution of 
PALB2 truncating mutations in breast and 
breast/pancreatic cancer families recruited in this study. 
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4.2 Sequencing analysis of SLX41FANCP gene 
A series of 526 BRCAX cases were screened for mutations in SLX41FANCP gene by 
sequencing of coding exons and flanking intronic sequences. In this analysis, a total of 81 
different variants were detected, but no one could be considered as a clear pathogenic 
mutation (Table 4.6). Of these variants, 35 were previously annotated in public databases 
including dbSNP (Sherry et aI., 2001), 1000 Genomes (Altshuler et aI., 2010) and Exome 
Variant Server (http://evs.gs.washington.edu/EVSD with a carrier frequency ?: 1 % in 
Caucasians and thus considered as likely neutral polymorphisms. We used the above 
mentioned frequency as threshold value because it was estimated that the overall allelic 
frequency of variants of each highlmoderate-penetrance gene does not exceed 0.5% 
(reviewed in Mavaddat et aI., 2010). Among the 46 remaining variants, 29 were missense, 
14 were silent, two were intronic and one was a 3-nucleotide in-frame deletion causing the 
loss of a single conserved amino acid (p.Ile 119 5del). All 46 variants were analyzed in 
silica to investigate their potential impact on mRNA splicing, using the following four 
programs: Berkeley Drosophila Genome Project (BDGP), NetGene2, SplicePredictor and 
GeneSplicer (Table 4.7). In this analysis, three programs predicted the c.833G>A to create 
a new donor splice site, whereas two of them predicted the c.5155T>A to abolish the 
physiological acceptor site of exon 15. Both predictions were confirmed using an 
additional software (MaxEntScan). The 29 missense mutations were also analyzed using 
three different protein prediction programs: PolyPhen-2, SIFT and SNP&GO (Table 4.7). 
Of all the tested variants, the c.5155T>A (p.Ser1719Tyr) was classified as a variant with 
pathogenic effect by all three programs. 
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To evaluate the statistical power of this study, we estimated that in our sample size of 
526 BRCAX cases, we had a probability of detecting SLX4 truncating mutations of 0.6%, 
that corresponds to the upper limit of the 95% confidence interval of the event probability 
in which no events (no carriers of truncating SLX4 mutations) have been observed. 
70 
Chapter 4 - Results 
Table 4.6. Frequencies of SLX4 variants in BRCAX cases 
Mutation type/considered Number of Amino acid Nor/Het/Hom Nucleotide change 
change as a neutral Annotation status genotypes (allelic polymorphism· frequency) 
c.60G>A p.Leu20Leu silent/no not annotated 525/1/0 (0.001) 
c.90C>T p.Ser30Ser silent/yes rsll8089506 511115/0 (0.014) 
c.244A>G p.Asn82Asp missense/no not annotated 525/1/0 (0.001) 
c.247G>A p.Gly83Ser missense/no not annotated 525/1/0 (0.001) 
c.299C>A p.ThrlOOAsn missense/no not annotated 525/1/0 (0.001) 
c.421 G>T p.Glyl4lTrp missense/no not annotated 524/2/0 (0.002) 
c.452C>T p.Prol5lLeu missense/no not annotated 525/110 (0.001) 
c.553G>A p.Asp 1 85Asn missense/no not annotatcd 525/1/0 (0.001) 
c.555C>T p.Asp I 85Asp silent/yes rs74640850 484/42/0 (0.040) 
c.590T>C p.Val197Ala missense/no not annotated 523/3/0 (0.003) 
c.610C>T p.Arg204Cys misscnse/yes rs79842542 484/42/0 (0.040) 
c.678C>T p.His226His silcnt/yes rs28516461 498/27/1 (0.028) 
c.707C>T p.Ala236Val missense/no not annotated 525/1/0 (0.001) 
c.7\OG>A p.Arg237Gln missense/no not annotated 52115/0 (0.005) 
c.734C>T p.Pro245Leu missense/no not annotated 524/2/0 (0.002) 
c.742G>A p.Glu248Lys missense/no not annotated 525/1/0 (0.001) 
c.753G>A p.Ala25IAla silcnt/yes rs8061528 329/172/25 (0.211) 
c.761-32T>G none intronic/yes rsll8098382 514/12/0 (0.011) 
c.833G>A p.Arg278Gln missense/no not annotated 525/110 (0.001) 
c.999C>T p.Ile333J1e silcnt/yes rs7198338 525/1/0 (0.00 I) 
c.1065G>A p.Gln355Gln silcnt/no not annotated 525/110 (0.001) 
c.1152A>G p.Pro384Pro silcnt/yes rsl1251 \042 484/4111 (0.041) 
c.1153C>A p.Pro385Thr missense/yes rs1l5694169 520/6/0 (0.006) 
c.1156A>G p.Met386Val missense/yes rsl13490934 484/4111 (0.041) 
c.1163+\OC>T none intronic/yes rs80116508 484/4111 (0.041) 
c.II64-75C>G none intronic/yes rs59622 164 484/42/0 (0.040) 
c.1164-66T>A none intronic/no not annotated 524/2/0 (0.002) 
c.\366+llT>C none intronic/yes rs76350200 477/48/1 (0.048) 
c.\371T>G p.Asn457Lys missense/yes rs743 19927 488/38/0 (0.036) 
c.164IG>A p.Thr547Thr silent/no not annotated 525/110 (0.001) 
c.1755C>T p.Pr0585Pro silent/yes rsl14016359 520/6/0 (0.006) 
c.1755C>A p.Pr0585Pro silcnt/no not annotated 525/110 (0.001) 
c.1803G>A p.Ser60lSer silcnt/no not annotated 520/6/0 (0.006) 
c.1832C>A p.Ala611 Asp missense/no not annotated 525/1/0 (0.00 I) 
c.1846G>A p.Val616Met missense/no not annotated 525/1/0 (0.00 I) 
c.1896G>C p.Gly632G1y silent/no not annotated 525/1/0 (0.001) 
c.1898G>A p.Gly633Asp missense/yes rs\056085 525/1/0 (0.001) 
c.191IG>A p.Ser637Scr silent/no not annotated 525/1/0 (0.001) 
c.2006G>A p.Arg669Asp missense/no not annotatcd 525/1/0 (0.00 I) 
c.2012T>C p.Leu671 Scr missense/yes rs77985244 482/44/0 (0.042) 
c.2013+23G>A none intronic/yes rsl12226642 483/43/0 (0.041) 
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c.2160+50C>T none intronic/yes rs75762935 484/42/0 (0.040) 
c.2235C>T p.Thr745Thr silent/no rs75184268 524/2/0 (0.002) 
e.2359G>A p.Glu787Lys missense/no not annotated 518/8/0 (0.008) 
c.2597A>C p.Gln866Pro missense/no not annotated 525/1/0 (0.001) 
c.2854G>A p.Ala952Thr missense/yes rs59939128 482/44/0 (0.042) 
c.2855C>T p.Ala952Val missense/yes rs78637028 484/42/0 (0.040) 
c.2924C>T p.Pro975Leu missense/yes rs114472821 5191710 (0.007) 
c.2975G>A p.Gly992Glu missenselno not annotatcd 525/1/0 (0.001) 
c.3062G>A p.Arg 102IHis missenselno not annotated 525/1/0 (0.00 I) 
c.3109T>C p.Leul037Leu silent/no rs58735 123 525/1/0 (0.001) 
c.3162G>A p.SerlO54Ser silent/yes rs764889 I 7 500/25/1 (0.026) 
c.3I 89C>T p.Glyl063Gly silent/no not annotated 511/12/3 (0.017) 
c.3308G>A p.Argl103His missense/no not annotated 525/1/0 (0.001) 
c.3316G>A p.Valll06Met missense/no not annotated 525/1/0 (0.001) 
c.3365C>T p.Prol122Leu missense/yes rs714181 462/63/1 (0.062) 
c.3420A>G p.Lys 1140Lys silent/no not annotated 525/1/0 (0.001) 
c.3583 _3585dc1A IT p.lle I I 95dcl in frame del/no not annotated 525/1/0 (0.001) 
c.3662C>T p.Alal22lVal missense/yes rs3827530 491/3510 (0.033) 
c.3783G>A p.Prol26lPro silent/yes rs77699867 520/6/0 (0.006) 
c.3812C>T p.Scrl27lPhe missense/yes rs38 10813 474/52/0 (0.049) 
c.3849C>G p.Ala 1283Ala silent/no not annotated 525/1/0 (0.00 I) 
c.3963G>A p.Prol32lPro silent/yes rs116781836 516/1 % (0.010) 
c.4068G>A p.Pro I 356Pro silent/no rsl15491049 5251110 (0.001) 
c.4338C>T p. Thr 1446Ser missenselno rs777 I 8962 525/1/0 (0.001) 
c.4500T>C p.Asn 1500Asn silent/yes rs3810812 135/246/145 (0.51) 
c.4563T>C p.Pro 1521 Pro silent/no not annotated 525/1/0 (0.001) 
c.4580C>T p.Pro I 527Leu missenselno not annotated 525/1/0 (0.001) 
c.458IG>A p.Pro I 527Pro silent/yes rs78635099 517/9/0 (0.009) 
c.4597G>T p.Alal533Ser missense/no not annotated 525/1/0 (0.001) 
c.4600G>A p.Gly 1534Scr missense/no rs78770603 525/1/0 (0.00 I) 
c.4648C>T p.Arg I 550Trp missense/yes rs77021998 525/1/0 (0.001) 
e.4739+24G>T none intronic/yes rsl2933120 371/143/12 (0.159) 
c.4865A>G p.Gln I 622Arg missenselno not annotated 525/1/0 (0.00 I) 
c.5040G>C p.Arg 1680Ser missenselno not annotated 525/1/0 (0.001) 
e.5146T>A p.Serl716Thr missense/yes rs75 I 82789 525/1/0 (0.001) 
c.S 154-28C>T none intronic/no not annotated 525/1/0 (0.00 I) 
c.SIS5T>A p.Serl719Tyr missense/no not annotated 525/1/0 (0.00 I) 
c.5183T>G p.Phe 1728Cys missense/no not annotated 525/1/0 (0.001) 
c.550IA>G p.Asn 1834Ser missense/yes rs 111738042 522/4/0 (0.004) 
e.5505+8A>G none intronic/yes rs3751839 476/50/0 (0.048) 
·annotated in dbSNP, 1000 Genomes and Exome Variant Server with carrier frequency ~ I % in Caucasians. 
Nor common homozygotes, Het heterozygotes, Hom rare homozygotes. 
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Table 4.7. In silica analyses of SLX4 variants in BRCAX cases 
Amino acid Protein prediction Nucleotide change 
change Predicted effect on mRNA transcript' Polyphen SNP& 
2 SIFT GO 
c.60G>A p.Leu20Leu none not done 
c.244A>G p.Asn82Asp none B T N 
c.247G>A p.Gly83Ser none B T N 
c.299C>A p.ThrlOOAsn none B T N 
c.42IG>T p.Glyl4lTrp none PrD APF N 
c.452C>T p.Prol5lLeu none PoD APF N 
c.553G>A p.Asp 185Asn none B T N 
c.590T>C p.Va1197Ala none B T N 
c.707C>T p.AIa236Val none PoD T N 
c.710G>A p.Arg237Gln none B T N 
c.734C>T p.Pro245Leu none B T N 
c.742G>A p.Glu248Lys none PrD T N 
c.833G>A p.Arg278Gln creation of a new donor splice site B T N 
c.1065G>A p.Gln355Gln none not done 
c.1164-66T>A none none not done 
c.164IG>A p.Thr547Thr none not done 
c.1755C>A p.Pro585Pro none not done 
c.1803G>A p.Ser60lSer none not done 
c.1832C>A p.Ala61lAsp none PrD T N 
c.1846G>A p.Val616Mct none PoD APF N 
c.1896G>C p.Gly632Gly none not done 
c.191IG>A p.Ser637Scr none not done 
c.2006G>A p.Arg669Asp none B T N 
c.2235C>T p.Thr745Thr none not done 
c.2359G>A p.Glu787Lys none PoD APF N 
c.2597A>C p.Gln866Pro none PoD APF N 
c.2975G>A p.Gly992Glu none PoD T N 
c.3062G>A p.Arg 10211lis none PoD T N 
c.3109T>C p.Leu 1 03 7Leu none not done 
c.3189C>T p.Glyl063Gly none not done 
c.3308G>A p.Argll03His none PoD T D 
c.3316G>A p.Vall106Mct none B T N 
c.3420A>G p.Lysl140Lys none not done 
c.3583_3585dcIATT p.llc 1195dcl none not done 
c.3849C>G p.Alal283Ala none not done 
c.4068G>A p.Pro 1 356Pro none not done 
c.4338C>T p.Thrl446Ser none PrD T N 
c.4563T>C p.Pro 1521 Pro none not done 
c.4580C>T p.Pro 1 527Leu none B T N 
c.4597G>T p.Alal533Ser none B APF N 
c.4600G>A p.Gly 1534Ser none B T N 
c,4865A>G p.Gln I 622Arg nonc B T N 
c.5040G>C p.Arg 1680Scr none B T D 
c.5154-28C>T none none not done 
c.5155T>A p.Serl719Tyr abolishment of the natural acceptor splice site PrD APF D 
c.5183T>G p.Phe I 728Cys none B T D 
• Based on the outputs of the majority of utilized bioinformatics programs. 
Nor common homozygotes, Het heterozygotes, Hom rare homozygotes; B benign, PrD probably damaging, PoD 
possibly damaging, U unclassified (PolyPhen-2); T tolerated, APF affecting protein function (SIFT); N neutral, D 
disease, U unclassified (SNP&GO). 
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4.3 Investigation of miR-27a rs895819 polymorphism as candidate low-
penetrance allele 
A series of 1,027 BRCAX cases and 1,593 controls were screened for the miR-27a 
rs895819 polymorphism, using a TaqMan SNP Genotyping Assay. Two samples were 
excluded because the genotyping failed. Thus, a total of 1,025 BRCAX cases and 1,593 
controls were tested. Genotypes and allelic frequencies were analyzed applying a logistic 
regression model (Hosmer and Lemeshow, 1989). As performed by Yang and colleagues 
(Yang et aI., 2009), we investigated the association between rs895819 and breast cancer 
risk in the entire case group, in cases with age at diagnosis >50 years and in cases with 
bilateral breast cancer. None of these analyses was statistically significant (Table 4.8). An 
additional analysis to investigate the association with bilaterality was performed in cases 
only, testing 144 bilateral and 881 unilateral breast cancer cases. Here, we found that the 
[G] allele was marginally significant associated with an increased risk of bilateral breast 
cancer versus unilateral breast cancer, with an OR of 1.33 (95 %CI 1.01-1.74, P = 0.041) 
(Table 4.9). 
Based on the size of the examined sample set and the observed frequency of the minor 
allele [G] in cases and controls, we were able to reject the null hypothesis that this odds 
ratio equals 1 with probability (power) of 0.183 and a Type I error probability of 0.05. 
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Table 4.8. Genotype frequencies ofmiR-27a in 1,025 breast cancer cases and 1,593 controls 
Genotype Cases (%)a Controls (%)b OR 95% CI P-value 
All cases 
AA 547 (53.37) 803 (50.41) 1.00 
AO 388 (37.85) 633 (39.74) 0.90 0.76-1.06 0.214 
GO 90 (8.78) 157 (9.86) 0.84 0.63-1.1 I 0.223 
[0] vs [A] 0.91 0.80-1.02 0.114 
Ptrend=0.123 
Age at diagnosis ~ 50 years 
AA 126 (55.51) 268 (52.34) 1.00 
AO 88 (38.77) 197 (38.48) 0.96 0.68-1.33 0.778 
GO 13 (5.73) 47 (9.18) 0.58 0.30-1.12 0.104 
[G] vs [A] 0.84 0.65-1.09 0.188 
Ptrend=0.196 
Age at diagnosis < 50 years 
AA 421 (52.76) 535 (49.49) 1.00 
AO 300 (37.59) 436 (40.43) 0.86 0.71-1.05 0.144 
GO 77 (9.65) 110 (10.18) 0.88 0.64-1.22 0447 
[G] vs [A] 0.91 0.78-1.05 0.178 
Ptrend=0.191 
Bilateral breast cancer cases 
AA 68 (47.22) 843 (51.62) 1.00 
AO 59 (40.97) 633 (38.76) 1.11 0.77-1.59 0.582 
GO 17 (11.81) 157 (9.61) 1.29 0.74-2.26 0.367 
[0] vs [A] 1.13 0.88-1.47 0.338 
Ptrend=0.350 
OR, odds ratio adjusted for age; CI ,confidence interval 
• Median age 41, range: 18-80 years 
b Median age 43, range: 18-71 years 
Table 4.9. Analyses of genotype frequencies ofmiR-27a in 144 bilateral and 881 unilateral breast 
cancer cases 
Genotype Bilateral (%t,b Unilateral (%)C OR 95% CI 
AA 68 (47.22) 479 (54.37) 1.00 
AO 59 (40.97) 329 (37.34) 1.25 0.85-1.83 
GO 17 (11.81) 73 (8.29) 1.81 1.01-3.28 
[0] vs [A] 1.33 1.01-1.74 
OR, odds ratio adjusted for age; CI, confidence interval 
• Median age 45, range: 26-74 years 
b Median time interval between first and contralateral cancer 6, range: 0-32 years 
C Median age 41, range: 18-80 years 
75 
P-value 
0.250 
0.049 
0.041 
Ptrend=0.045 
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4.4 Analysis of the CASP8 rs3834129 as risk modifier in BRCA genes 
mutation carriers 
A series of 1,241 Italian BRCAI and BRCA2 mutation carriers were recruited for this 
analysis by different collaborating centers (CONSIT TEAM, Consortium of Italian Studies 
on Hereditary Breast Cancer; Table 4.10) and screened by direct sequencing. We excluded 
18 samples in which the genotyping analysis failed, 13 women who self-reported as "non-
Caucasian" and three women who carried both BRCAI and BRCA2 mutations. Overall, 
1,207 carriers, of which 508 unaffected and 699 affected with breast cancer, remained 
included. Of these cases, 740 carried a BRCAI mutation and 467 carried a BRCA2 
mutation. 
Table 4.10. List of centers participating to CONSIT TEAM with numbers of BRCAI and BRCA2 mutation 
carriers contributed 
BRCAI BRCA2 Total of 
Centre mutation mutation carriers 
carriers carriers (%) 
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano 349 152 501 (40.4) 
Universita degli Studi, Torino 100 69 169 (13.6) 
Istituto Europeo di Oncologia, Milano 95 73 168 (13.5) 
Centro Riferimento Oncologico, Aviano 52 66 118 (9.5) 
Universita degJi Studi "La Sapienza", Roma 61 44 105 (8.5) 
Universita degli Studi, Firenze 59 30 89 (7.2) 
Istituto Nazionale per la Ricerca sui Cancro, Genova 37 24 61 (4.9) 
Istituto Nazionale Tumori "Regina Elena", Roma 14 16 30 (2.4) 
All 767 474 1,241 (100) 
In this analysis, there was evidence for association of the del allele ofrs3834128 with 
increased breast cancer risk, under the dominant model, with a HR of 1.35 (95 % CI 1.04-
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1.76, P = 0.023) for BRCAJ and BRCA2 mutation carriers combined and 1.52 (95 % CI 
1.14-2.02, P = 0.004) for BRCA J mutation carriers only (Table 4.11). Oppositely, the 
analysis failed to suggest any association in BRCA2 mutation carriers. 
Table 4.11. Genotype frequencies of rs3834129 by BRCA mutation and disease status, and 
corresponding hazard ratios estimated in the overall group of BRCA mutation carriers 
BRCA Genotype Unaffected Affected group (%) (%) HR 95%CI P-value 
nor/nor 177 (34.8) 208 (29.8) 1.00 
BRCA! and nor/del 224 (44.1) 346 (49.5) 1.40 1.06-1.85 0.018 
BRCA2 del/del 107 (21. I) 145 (20.7) 1.26 0.90-1.77 0.176 (N=1,207) del vs nor (per allele) 1.15 0.96-1.38 0.121 
Dominant (del) 1.35 1.04-1.76 0.023 
nor/nor 125 (35.5) 105 (27.1) 1.00 
BRCA! nor/del 152 (43.2) 193 (49.7) 1.56 1.16-2.13 0.003 
(N = 740) del/del 75(21.3) 90 (23.2) 1.42 1.00-2.03 0.052 
del vs nor (per allele) 1.23 1.02-1.49 0.033 
Dominant (del) 1.52 1.14-2.02 0.004 
nor/nor 52 (33.3) 103 (33. I) 1.00 
BRCA2 nor/del 72 (46.2) 153 (49.2) 1.09 0.66-1.78 0.746 
(N = 467) del/del 32 (20.5) 55 (17.7) 0.80 0.42-1.55 0.516 
del vs nor (per allele) 0.92 0.66-1.29 0.619 
Dominant (del) 1.00 0.62-1.60 0.988 
JlR hazard ratio, C! confidence interval, nor/nor common homozygotes, nor/del heterozygotes, del/del 
rare homozygotes 
We performed an additional analysis and classified BRCAJ and BRCA2 mutations in 
two different groups, based on the expected functional effect of each mutation, according 
to criteria established by CIMBA (Antoniou et aI., 2009). Class 1 mutations include those 
potentially causing the complete loss-of-function of the protein, while class 2 mutations 
include those, potentially responsible for the formation of stable mutant protein with a 
possible dominant negative effect. The group of mutation carriers of class 1 was analyzed 
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separately, whereas the group of mutation carries of class 2 was too small to justify a 
separate analysis. Here, we found an association of the del allele, under the dominant 
model, with an increased breast cancer risk with a fiR of 1.46 (95 % CI 1.08-1.99, P = 
0.015) for BRCAl and BRCA2 mutation carriers combined and 1.74 (95 % CI 1.24-2.46, P 
= 0.002) for only BRCAI mutation carriers (Table 4.12). Consistently with previous 
analyses, no association was found in BRCA2 mutation carriers 
Table 4.12. Genotype frequencies of rs3834129 by BRCA mutation and disease status, and 
corresponding hazard ratios estimated in carriers of BRCA loss-of-function (class I) mutations 
BRCA Genotype Unaffected Affected HR 95% CI group (%) (%) P-value 
nor/nor 143 (36.8) 156(29.4) 1.00 
BRCAJ and nor/del 165 (42.4) 265 (49.9) 1.56 1.12-2.15 0.008 
BRCA2 del/del 81 (20.8) 110(20.7) 1.29 0.87-1.93 0.208 
(N=920) del vs nor (per allele) 1.18 0.95-1.46 0.138 
Dominant (del) 1.46 1.08-1.99 0.015 
nor/nor 94 (38.4) 69 (26.6) 1.00 
BRCAJ nor/del 100 (40.8) 128 (49.4) 1.83 1.27-2.64 0.001 
(N = 504) del/del 51 (20.8) 62 (23.9) 1.60 1.03-2.48 0.035 
del vs nor (per allele) 1.33 1.05-1.69 0.019 
Dominant (del) 1.74 1.24-2.46 0.002 
nor/nor 49 (34.0) 87 (32.0) 1.00 
BRCA2 nor/del 65 (45.1) 137 (50.4) 1.24 0.73-2.10 0.419 
(N = 416) del/del 30 (20.8) 48 (17.6) 0.79 0.40-\.57 0.506 
del vs nor (per allele) 0.92 0.65-1.32 0.662 
Dominant (del) 1.09 0.66-1.80 0.738 
HR hazard ratio, CI confidence interval, nor/nor common homozygotes, nor/del heterozygotes, del/del 
rare homozygotes 
It was possible to reject the null hypothesis that the odds ratio observed in affected 
carriers of the del allele compared to non-carriers equals 1 with probability (power) of 
0.727 with a Type I error probability of 0.05. However, the analysis of BRCAI and BRCA2 
modifiers is potentially more complex of the classical case-control association study, in 
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which genotype frequencies are compared between cases and controls, because a high 
proportion of carriers become affected. More powerful analyses can be conducted by 
treating breast cancer as a survival (age at onset), rather than a simple binary, endpoint. To 
increase the power of the tested hypothesis, a weighted Cox regression model can be used, 
as reported in our study performed in collaboration with the CIMBA Consortium (Osorio 
et a1., 2009; Antoniou et aI., 2005). 
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DISCUSSION 
Chapter 5 - Discussion 
In the present study, the role of different candidate breast cancer susceptibility loci has 
been investigated. In particular, the two Fanconi Anemia genes PALB2 and SLX4 have 
been screened to assess their impact in breast cancer predisposition genes in the Italian 
population. In addition, I sought to elucidate the role of rs895819, located in the miR-27a 
gene, and rs3834129, located in the promoter region of the CASP8 gene, as low-risk allele 
and genetic risk modifier, respectively. 
The entire coding region and corresponding splice sites of the P ALB2 gene was 
screened for mutations in 575 familial BRCAX cases and a total of 34 different variants 
were detected. While eight were previously reported as common and considered as neutral 
polymorph isms, 26 were rare or unique mutations. Of these, eight were novel truncating 
mutations, including two, c.72delG (p.Arg26fs) and c.l027C>T (p.Gln343X), that were 
recurrent, and one, c.48G>A, was ascertained to alters the canonical mRNA splicing and to 
introduce a premature termination codon. None of above mutations were found in 784 
controls, recruited in Milan. 
Overall, we found 12 individuals carrying a PALB2 truly pathogenic mutation, for a 
frequency of 2.1 %. Even if this frequency appears to be higher with respect to that 
observed in the other two Italian studies, where mutation frequencies of 0.75% and 1.1 % 
were found (Papi et aI., 2009; Dalia et aI., 2010), this result is comparable to that observed 
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in other populations, where PALB2 mutations were detected with frequency from 0.2 to 
3.3%, and confirms the role of this gene in breast cancer susceptibility. 
Interestingly, the actual proportion of carriers of pathogenic PALB2 mutations in our 
group could be even higher. In fact, in silica analyses indicated that the c.23 79C> T 
(p.Gly793Gly) and the c.2418G>T (p.Pr0806Pro) affect the canonic mRNA splicing, 
causing the activation of a cryptic donor and acceptor splice site, respectively. In addition, 
the missense mutations c.2792T>G (p.Leu931Arg) and c.2816G>T (p.Leu939Trp) were 
predicted to be deleterious by all of the three software used in this analysis. Interestingly, 
the c.2792T>G is located in a highly conserved residue (in all species from II sapiens to 
D. rerio) in the WD40-repeat domain of the protein, that is responsible for the BRCA2 
binding. 
Additional analyses performed on the c.l027C>T (p.Gln343X) showed that this is a 
recurrent mutation, with an higher frequency in cases and controls recruited in the 
Bergamo area, with respect to that observed in cases and controls recruited in Milan. In 
particular, we identified 5/112 (4.5%) and 2/477 (0.4%) carriers of the c.1027C>T in cases 
and controls from Bergamo versus 3/907 (0.3%) and 0/960 (0.0%) in those recruited in 
cancer centers in Milan, which recruit patients from all of the country, with an increased 
frequency in cases of more than 10-fold. 
Interestingly, a similar frequency difference was also observed for a few BRCAJ and 
BRCA2 mutations carriers. In particular, two of these mutations, identified through routine 
BRCA gene testing, occur with a 10-fold higher frequency in the Bergamo area with 
respcct to that observed in cases recruited in Milan. These are the BRCAJ C64R, reported 
in 15/2,065 (0.7%) cases recruited in Milan and in 15/158 (9.5%) of those recruited in 
Bergamo, and the BRCA2 V1969fs, detected in 5/2,065 (0.2%) cases recruited in Milan 
and in 5/158 (3.2%) of those recruited in Bergamo (unpublished data; Table 5.1). 
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Table 5.1. Frequency of BRCAI C64R, BRCA2 VI969fs and PALB2 
c.1027C>T recurrent mutations in probands recruited in Milan and Bergamo 
Mutation 
BRCAI C64R 
BRCA2 VI969fs 
PALB2 c.1 027C>T 
Carriers/Probands Carriers/Probands 
from Milan 
15/2,065 (0.7%) 
512,065 (0.2%) 
3/575 (0.5%) 
from Bergamo 
15/158 (9.5%) 
5/158 (3.2%) 
5/112 (4.5%) 
Previous studies showed the presence of P ALB2 founder mutations in Finnish (2.7%; 
Erkko et aI., 2007), French-Canadian (0.7%; Ghadirian et aI., 2009), Polish (0.6%; 
Dansonka-Mieszkowska et al., 2010) and Australian (0.4%; Southey et aI., 2010) breast 
cancer cases and also in Finnish (0.2%; Erkko et aI., 2007) and Polish (0.08%; Dansonka-
Mieszkowska et aI., 20 I 0) unrelated controls. All these populations are geographically 
isolated andlor characterized by rapid expansion and low grade of immigration. However, 
compared to the previously mentioned populations, Italians are much more heterogeneous, 
characterized by ethnic mixture, a higher grade of internal immigration and lower 
probability of finding founder mutations. Nevertheless, some BRCA genes founder 
mutations were observed in diITerent regional areas. The first Italian founder mutation, the 
BRCA I 5083dcl19, was identified by Baudi and colleagues, with the high frequency of 
16.7% in individuals from Calabria (Baudi et al., 2001). Other BRCAI and BRCA2 founder 
mutations were also described in breast cancer cases from other Italian regions, including 
Sardinia, Sicily, Tuscany, Calabria and the Northeast of Italy (Pisano et al. 2000; Russo et 
al. 2007; Papi et al. 2009; Russo et al. 2009; Malacrida et aI., 2008). 
In conclusion, we identified the novel PALB2 c.l027C>T mutation and observed that 
this is recurrent in the area of Bergamo, being detecting with a 10-fold increased frequency 
with respect to that observed in breast cancer cases recruited in Milan. This result, 
combined with the identification of two other recurrent mutations in BRCAI and BRCA2 in 
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the same area, suggests that this region could be characterized by a lower grade of genetic 
heterogeneity. This hypothesis is reinforced by the fact that this area includes several deep 
and isolated valleys that could prevent genetic admixture and promote the circulation of a 
small number of mutations with higher frequencies. However, further analyses are 
necessary to confirm these results. 
Through the analysis of families screened for P ALB2 mutations, we observed an 
apparent excess of pancreatic cancer cases in families with pathogenic P ALB2 pathogenic 
mutations. In particular, we identified 39/575 families with both breast and pancreatic 
cancer cases and in three of them the index case carried a truncating mutation, with a 
frequency of 7.7% (3/39). However, no other truncating mutation was found in additional 
23 index cases from breast and pancreatic cancer families, for a final frequency of 4.8% 
(3/62). 
In early 2011, breast cancer cases with personal/family history of pancreatic cancer 
were screened for PALR2 mutations in two different studies, showing a cumulative 
mutation frequency of 1.2% (llofstatter et aI., 2011; Stadler et aI., 2011). Although our 
reported frequency appears to be increased with respect to that observed in these studies, 
this result is not significant, possibly due to the limited sample size. If a preferential co-
occurrence of breast and pancreatic cancer in PALB2 positive families exists, it could be 
detected only in larger analyses. 
To evaluate its contribution in breast cancer susceptibility, .the entire coding region 
and intronlcxon junctions of the SIX.J gene were screened in 526 Italian familial breast 
cancer cases. Even if a large amount of different variants were identified (n=81), none of 
them could be classified as truly pathogenic. In silico analyses predicted as deleterious two 
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of the identified variants. These are c.833G>A (p.Arg278Gln), with a possible effect on 
canonical splicing, and c.5155T>A (p.Serl719Tyr), with a predicted negative effect both 
on the splicing and on the protein structure. Since it appears unlikely that the c.5155T>A 
mutation may have a pathological effect both at splicing and protein level, the latter 
observation underlines the actual limitations of in silico tools of predicting the pathogenic 
role of genetic variants. 
These data indicate that SLX4 is unlikely to act as a breast cancer susceptibility gene in 
the Italian popUlation. In addition, we could estimate that truncating SLX4 mutations are 
very rare in our population. In fact, if such mutations were present in our sample group of 
526 individuals with a frequency of no less than 0.6% (corresponding to the 95% CI upper 
limit of the event probability in a sample of the examined size negative for truncating 
mutations), we would have a 95% probability to detect at least one such mutation. 
To date, only two SLX4 truncating mutations were reported in breast cancer cases from 
four different studies (Landwehr ct al., 2011; Fernandez-Rodriguez et al., 2012; de Garibay 
et al., 2012; Bakker et al., 2013) even if a very large amount of non-truncating variants 
were detected in each of them (Table 5.2). Therefore, considering our results, combined 
with those reported in these studies, a cumulative mutation frequency of 0.1 % was found in 
a total of 1,887 tested cases. These results are consistent with the hypothesis that SLX4 
pathogenic mutations are very rare and this gene plays a marginal role in breast cancer 
susceptibility. 
In the present study, the analysis of the rs895819 variant, located in the miR-27a, 
failed to support any association of this SNP with breast cancer risk in Italian familial 
breast cancer cases, as reported in the German population (Yang et al., 2009). A 
subsequent analysis, performed considering cases only, showed a marginal association of 
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the minor allele with increased risk of bilateral breast cancer (OR = 1.33, 95 % ClI.O 1-
1.74, P = 0.041). 
Table 5.2. Frequency of SLX4 truncating and non-truncating mutations 
Study 
Present study 
Landwehr et aI., 20 II 
Fernandez-Rodriguez et aI., 2012 
de Garibay et aI., 2012 
Bakker et al., 2013 
Number of 
tested cases 
526 
52 
94 
486 
729 
Truncating 
mutations 
(frequency) 
0(0%) 
0(0%) 
0(0%) 
1(0.2%) 
1(0.1%) 
Non-truncating 
mutations 
(frequency) 
81 (15.4%) 
27 (51.9%) 
49 (52.1%) 
56 (11.5%) 
102 (14%) 
To date, studies that have explored the association of the rs895819 with breast cancer 
risk, reported controversial results. As mentioned above, an association of the minor allele 
with a reduced risk has been reported in familial breast cancer cases from Germany (Yang 
ct al., 2009). Ilowever, a study involving a series of 252 Chinese breast cancer cases and 
248 unrelated controls failed to confirm this association (Zhang et al., 2012). 
Similar controversial data were also observed in other types of cancer. In 2010, 304 
Chinese gastric cancer cases and 304 controls were screened and an association of the SNP 
with an increased risk was detected (OR = 1.48, 95 % CI 1.06-2.05, P = 0.019; Sun et al., 
2010). Nevertheless, a subsequent analysis involving 311 Chinese gastric cancer cases and 
427 controls indicated an opposite result, showing an association of the minor allele of 
rs895819 with a reduced risk (OR = 0.771,95 % CI 0.604-0.985, P = 0.037; Zhou et al., 
2012). In 2012, Zhong and colleagues performed a meta-analysis considering six different 
studies, of which three involving Caucasian and three Asian individuals, for breast and 
gastric cancer. The overall analysis did not show any association of rs895819 with cancer 
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susceptibility whereas stratification by cancer type indicated only a marginal association 
with reduced risk of developing breast cancer (OR = 0.92, 95 % CI 0.74-1.14, P = 0.04; 
Zhong et aI., 2013). Very recently, in addition to breast and gastric cancer, an association 
of rs895819 with reduced risk has been reported in renal cell cancer (OR = 0.71, 95% CI 
0.56-0.90, P = 0.004; Shi et aI., 2012), whereas no associations were found with colorectal 
and lung cancer (Hezova et aI., 2012; Yoon et aI., 2012). Finally, an additional meta-
analysis was carried out in 2013, including results from seven studies involving Caucasian 
and Asian cases affected with breast, gastric, colorectal and renal cell cancer. Here, no 
association was found both in the overall analysis and after the stratification of samples by 
tumor type (Wang et aI., 2013). 
To date, several SNPs in microRNA genes were reported to be associated with breast 
cancer risk, even if these associations failed to be confirm in subsequent analyses. 
Interestingly, a very recent GWAS reported 41 novel SNPs associated with breast cancer, 
including two SNPs located in miRNA genes. This are the rs11780156, in miR-1208, and 
the rs17817449, in the miR-1972-2 (Michailidou et aI., 2013). 
In conclusion, these studies did not provide conclusive results on the impact of 
rs895819 both in breast and in other types of cancer. The apparent conflicting results could 
be due to an underpowered sample size of each single study and could be resolved only by 
the establishment of larger collaboration studies, involving a larger number of individuals. 
The analysis of the rs3834129 ins/del polymorphism, located in the promoter region of 
CASPS, suggested an association of the del allele with an increased breast cancer risk in 
BRCA 1 mutation carriers. 
Our study indicated that the SNP rs3834129 del allele can be also considered a genetic 
risk modifier of breast cancer in DRCA genes mutation carriers, in a similar way as 
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reported for other low-penetrance alleles (Antoniou et al., 2008; Antoniou et al., 2009, 
Antoniou et al., 2010; Antoniou et aI., 2011). However, the association of this SNP with 
breast cancer risk in BRCA 1 mutation carriers was in the opposite direction with respect to 
that described in the general population, where it has been reported that the rs895819 del 
allele reduces the risk of developing breast cancer (Sun et aI., 2007; Sergentanis and 
Economopoulos, 2009; Yin et aI., 2010). These contradictory results may be due to the 
different clinical and pathological characteristics of BRCAI-related tumors compared with 
breast cancer in the general population. Typically, the majority of BRCAI-related tumors 
are of the "triple-negative" type, being characterized by the absence immunohistochemical 
positivity for estrogen receptor (ER), progesterone receptor (PR) and a negativity for 
IIER2 expressing cells. In addition, they present high proliferation grade, higher frequency 
of TP 53 somatic mutations and arc generally associated with a poor prognosis. In contrast 
to BRCA i-related tumors, breast cancer in the general population, and also in BRCA2 
mutation carriers, are more frequently ER-positive and PR-positive, with lower frequency 
of TP53 mutations and low proliferation grade (reviewed in Mavaddat et aI., 2010 and in 
Lalloo and Evans, 2012). Consistently, it has been suggested that low-penetrance alleles in 
unsclected breast cancer are more frequently genetic modifiers for BRCA2 than for BRCAI 
mutation carriers. In fact, it has been reported that low-risk alleles associated with ER-
positive tumors in the general population tend to be associated with increased risk in 
BRCA2 mutation carriers, whereas those associated with ER-negative tumors appear 
preferentially associated with BRCA 1 mutation carriers (reviewed in Milne and Antoniou, 
2011). As an example, it has been reported that a polymorphism located in the CASP8 gene 
(p.D302I1; rs 1045485) and associated with decreased breast cancer risk only in BRCAI 
mutation carriers, appears to have a stronger protective effect in ER-negative (OR = 0.90, 
95 % CI 0.84-0.96, P = 0.001) than in ER-positive breast cancer cases of the general 
population (Brocks ct aI., 2011). 
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To our knowledge, this is the first report of an the association of the rs3834129 del 
allele, which would appear to be a protective factor in the general population, with 
increased breast cancer risk in BRCA I mutation carriers. 
CONCLUSIONS AND FUTURE DIRECTIONS 
The evidence of familial predisposition to breast cancer encouraged an extensive 
research of genes underlying this susceptibility. In this context, a large number of 
susceptibility loci have emerged, classified on the basis of the risk that they conferred. The 
present investigation provides a contribution to the general knowledge on breast cancer 
predisposition. Firstly, it confirms the role of PALB2 mutations in increasing breast cancer 
risk and led to the identification of a possible founder mutation in a specific area in the 
Northern Italy, the province of Bergamo. In addition, this analysis contributes to assess the 
marginal role of the Fanconi Anemia gene SLX4 in breast cancer susceptibility. Finally, it 
provides support to the role of rs3834129 as risk modifier in BRCAI mutations carriers 
increasing the possibility to improve risk assessment of breast cancer in these individuals. 
One of the major limitation of this study is represented by the relatively reduced size 
of the sample tested. This issue firstly emerges in the investigation of the association of 
PALR2 mutations with pancreatic cancer, due to the very small series of recruited families 
with both breast and pancreatic cancer cases. A similar limitation regards also the analysis 
of the role of SLX4 gene in breast cancer susceptibility. While we excluded a major role of 
mutations in this gene in breast cancer predisposition, truncating mutations have been 
subsequently found in breast cancer cases, even if rare, resulting in a difficult assessment 
of the SLX4 role. Considering the low frequency of these truncating mutations and the 
costs inherent to their detection by conventional re-sequencing, the role of this gene could 
88 
Chapler 5 - Discussion 
be established using next generation sequencing approaches. Finally, the limited sample 
size represents the main issue also for association studies. In fact, all of the candidate low-
penetrance alleles and genetic modifiers found to be associated with breast cancer risk in 
single studies, only the CASP8Ip.D302H (rs 1 045485) and the RAD51 C/c.135G>C 
(rs 180 1320) polymorphisms, respectively, were confirmed to be associated with breast 
cancer in larger analyses (Mavaddat et aI., 2010). 
In the last two decades, great advances have been made in understanding breast cancer 
genetic predisposition and several novel genes have been identified. Nevertheless, 
mutations in these genes are not sufficient to explain all familial breast cancer cases. To 
date, known high-, moderate- and low-penetrance alleles account for no more than 30-35% 
of breast cancer familial clustering, leaving most of them unexplained (reviewed In 
Mavaddat et aI., 20 I 0 and in Lalloo and Evans, 2012; Michailidou et aI., 2013). 
An interesting field that remains to be explored is to identify novel breast cancer 
predisposition alleles in the FA pathway. It is known that mutations in several FA genes, 
including FANCDlIBRCA2, FANCJIBRIPl, FANCNIPALB2 and FANCOlRAD51C, 
increase the risk of developing breast cancer (reviewed in Hollestelle et aI., 2010). These 
are downstream genes of the FA pathway, directly involved in the DNA repair mechanism 
by mediating homologous recombination. However, this pathway consists of a large 
number of genes with different functions, all potentially candidates as breast cancer 
predisposing factors. As an example, potential breast cancer susceptibility alleles have 
been recently reported in two genes forming the FA core complex, FANCA and FANCC 
(Litim et aI., 2013; Thompson et aI., 2012), supporting the notion that a fraction of the 
unexplained hereditary breast cancer cases could be due to mutations in other genes of the 
FA pathway. 
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Together with this candidate gene approach, technological improvements have 
provided agnostic strategies, such as whole exome andlor whole genome sequencing, that 
allow efficient mutation identification without any prior biological or molecular 
knowledge. It has been suggested that these analyses may represent a good approach to the 
detection of loci responsible for heterogenic diseases, such as hereditary breast cancer 
(Gracia-Aznarez at aI., 2013). 
Of all of identified mutations in cancer predisposing genes, only a fraction has a 
clearly pathogenic role. Thus, the characterization of variants of unclassified significance 
(VUSs) represents another essential issue for the understanding breast cancer 
susceptibility. To date, a large amount of VUSs have been identified in breast cancer 
genes, both in BRCA genes and in the other high- and moderate-penetrance genes. Most of 
them are extremely rare and their effect on breast cancer risk cannot be measured by 
association studies. The assessment of the role of these variants may be improved using a 
combined approach based on genetic and epidemiological data, the use of in silica tools for 
prediction of the effects of these mutations on canonical splicing andlor protein structure 
and functioning and, finally, the development of novel functional assays to test the 
biological effects of the variants (Radice et aI., 2011). In particular, multifactorial 
likelihood prediction models have been developed, in which the probability of a genetic 
variant to be pathogenic is estimated combining the prior probability based on in silica 
analyses with likelihood ratios derived from the analysis of different features including: a) 
co-segregation of the variant with the disease; b) co-occurrence of the variant with 
pathogenic mutations; c) personal family history in variant carriers; d) pathological 
characteristics of tumor in variant carriers (Lindor et aI., 2012). The usefulness of 
multifactorial models depend on the amount of data that are available in order to reach the 
odds ratios that are required for a realible classification of VUSs. This has prompted the 
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established of large international consortia such as the Evident-based Network for the 
Interpretation of Gennline Mutant Alleles (ENIGMA; Spurdle et aI., 2012). 
The advent of large international consortia and the GWASs has allowed identification 
of over 70 low-risk alleles for breast cancer. It has been speculated that, although these loci 
contribute only a small risk increase, they might act with a combined effect (reviewed in 
Varghese and Easton, 2010). Further large scale genotyping efforts may disclose a larger 
number of novel low-penetrance loci, substantially increasing individual risk prediction 
(Michailidou et aI., 2013). An identical strategy has to be pursued for the identification of 
additional genetic risk modifiers in BRCAI and BRCA2 mutation carriers, particularly 
because the contribution of these loci in high-risk families results in larger risk differences 
with respect to that observed in the general population (reviewed in Milne and Antoniou, 
2011 ). 
In conclusion, clearer understanding of breast cancer genetic susceptibility will be 
obtained using a combined strategy based on the identification of candidate loci in small 
selected populations by large scale sequencing, followed by the validation of these loci in 
large association studies, including several thousands of samples, and on the assessment of 
the clinical relevance of identified variants by integrated genetic and functional analyses. 
With the discovery of novel predisposition genes and genetic risk modifiers and their 
characterization, a more complete polygenic risk profile may be obtained for each affected 
or at-risk individual and in different populations. In addition, a personal risk assessment by 
profiling of known predisposition loci might lead to the development of more accurate 
surveillance programs and more adequate treatments, specifically designed for each 
patient. 
91 
References 
REFERENCES 
Adzhubei lA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, 
Kondrashov AS, Sunyaev SR. A method and server for predicting damaging missense 
mutations. Nat Methods 2010;4:248-249. 
Ahmed M, LaIloo F, Evans DG. Update on genetic predisposition to breast cancer. 
Expert Rev Anticancer Ther. 2009;9:1103-13. 
AIRTUM Working Group. Italian cancer figures, report 2011: Survival of cancer 
patients in Italy. Epidemiol Prevo 2011;35:1-200. 
Altshuler D et al. 1000 Genomes Project Consortium. A map of human genome 
variation from population-scale sequencing. Nature 2010;7319: 1 061-1 073. 
Antoniou AC, Goldgar DE, Andrieu N, Chang-Claude J, Brohet R, Rookus MA, 
Easton DF. A weighted cohort approach for analysing factors modifying disease risks in 
carriers of high-risk susceptibility genes. Genet Epidemiol. 2005;29:1-11. 
Antoniou AC, Sinilnikova OM, Simard J, Leone M, Dumont M, Neuhausen SL, 
Struewing JP, Stoppa-Lyonnet D, Barjhoux L, Hughes DJ, Coupier I, Belotti M, Lasset C, 
Bonadona V, Bignon YJ; Genetic Modifiers of Cancer Risk in BRCAI/2 Mutation Carriers 
Study (GEMO), Rebbeck TR, Wagner T, Lynch HT, Domchek SM, Nathanson KL, Garber 
JE, Weitzel J, Narod SA, Tomlinson G, Olopade 01, Godwin A, Isaacs C, lakubowska A, 
Lubinski 1, Gronwald 1, Gorski B, Byrski T, Huzarski T, Peock S, Cook M, Baynes C, 
Murray A, Rogers M, Daly PA, Dorkins H; Epidemiological Study ofBRCAl and BRCA2 
Mutation Carriers (EMBRACE), Schmutzler RK, Versmold B, Engel C, Meindl A, Arnold 
N, Niederacher D, Deissler H; German Consortium for Hereditary Breast and Ovarian 
Cancer (GCHBOC), Spurdle AB, Chen X, Waddell N, Cloonan N; Kathleen Cuningham 
Consortium for Research into Familial Breast Cancer (kConFab), Kirchhoff T, Offit K, 
Friedman E, Kaufmann B, Laitman Y, Galore G, Rennert G, Lejbkowicz F, Raskin L, 
Andrulis IL, Ilyushik E, Ozcelik H, Devilee P, Vreeswijk MP, Greene MH, Prindiville SA, 
Osorio A, Benitez J, Zikan M, Szabo CI, Kilpivaara 0, Nevanlinna H, Hamann U, 
Durocher F, Arason A, Couch FJ, Easton DF, Chenevix-Trench G; Consortium of 
Investigators of Modifiers of BRCA1I2 (CIMBA). RAD51 135G-->C modifies breast 
cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 
studies. Am J Hum Genet. 2007;81: 1186-200. 
Antoniou AC, Spurdle AB, Sinilnikova OM, Healey S, Pooley KA, Schmutzler RK, 
Versmold B, Engel C, Meindl A, Arnold N, Hofmann W, Sutter C, Niederacher D, 
Deissler H, Caldes T, Kampjarvi K, Nevanlinna H, Simard J, Beesley J, Chen X; Kathleen 
Cuningham Consortium for Research into Familial Breast Cancer, Neuhausen SL, Rebbeck 
TR, Wagner T, Lynch HT, Isaacs C, Weitzel J, Ganz PA, Daly MB, Tomlinson G, 
Olopade 01, Blum JL, Couch FJ, Peterlongo P, Manoukian S, Barile M, Radice P, Szabo 
CI, Pereira LH, Greene MH, Rennert G, Lejbkowicz F, Barnett-Griness 0, Andrulis IL, 
Ozcelik II; OCGN, Gerdes AM, Caligo MA, Laitman Y, Kaufman B, Milgrom R, 
92 
References 
Friedman E; Swedish BRCAI and BRCA2 study collaborators, Domchek SM, Nathanson 
KL, Osorio A, LIort G, Milne RL, Benitez J, Hamann U, Hogervorst FB, Manders P, 
Ligtenberg MJ, van den Ouweland AM; DNA-HEBON collaborators, Peock S, Cook M, 
Platte R, Evans DG, Eeles R, Pichert G, Chu C, Eccles D, Davidson R, Douglas F; 
EMBRACE, Godwin AK, Barjhoux L, Mazoyer S, Sobol H, Bourdon V, Eisinger F, 
Chompret A, Capoulade C, Bressac-de Paillerets B, Lenoir GM, Gauthier-Villars M, 
Houdayer C, Stoppa-Lyonnet D; GEMO, Chenevix-Trench G, Easton DF; CIMBA. 
Common breast cancer-predisposition alleles are associated with breast cancer risk in 
BRCAI and BRCA2 mutation carriers. Am J Hum Genet. 2008;82:937-48. 
Antoniou AC, Sinilnikova OM, McGuffog L, Healey S, Nevanlinna H, Heikkinen T, 
Simard J, Spurdle AB, Beesley J, Chen X; Kathleen Cuningham Foundation Consortium 
for Research into Familial Breast Cancer, Neuhausen SL, Ding YC, Couch FJ, Wang X, 
Fredericksen Z, Peterlongo P, Peissel B, Bonanni B, Viel A, Bernard L, Radice P, Szabo 
CI, Foretova L, Zikan M, Claes K, Greene MH, Mai PL, Rennert G, Lejbkowicz F, 
Andrulis IL, Ozcelik H, Glendon G; OCGN, Gerdes AM, Thomassen M, Sunde L, Caligo 
MA, Laitman Y, Kontorovich T, Cohen S, Kaufman B, Dagan E, Baruch RG, Friedman E, 
Harbst K, Barbany-Bustinza G, Rantala J, Ehrencrona H, Karlsson P, Domchek SM, 
Nathanson KL, Osorio A, Blanco I, Lasa A, Benitez J, Hamann U, Hogervorst FB, Rookus 
MA, CoHee JM, Devilee P, Ligtenberg MJ, van der Luijt RB, Aalfs CM, Waisfisz Q, 
Wijnen J, van Roozendaal CE; HEBON, Peock S, Cook M, Frost D, Oliver C, Platte R, 
Evans DG, Lalloo F, Eeles R, Izatt L, Davidson R, Chu C, Eccles D, Cole T, Hodgson S; 
EMBRACE, Godwin AK, Stoppa-Lyonnet D, Buecher B, Leone M, Bressac-de Paillerets 
B, Remenieras A, Caron 0, Lenoir GM, Sevenet N, Longy M, Ferrer SF, Prieur F; GEMO, 
Goldgar D, Miron A, John EM, Buys SS, Daly MB, Hopper JL, Terry MB, Yassin Y; 
Breast Cancer Family Registry, Singer C, Gschwantler-Kaulich D, Staudigl C, Hansen TO, 
Barkardottir RB, Kirchhoff T, Pal P, Kosarin K, Offit K, Piedmonte M, Rodriguez GC, 
Wakeley K, Boggess JF, Basil J, Schwartz PE, Blank SV, Toland AE, Montagna M, 
Casella C, Imyanitov EN, Allavena A, Schmutzler RK, Versmold B, Engel C, Meindl A, 
Ditsch N, Arnold N, Niederacher D, Deissler H, Fiebig B, Suttner C, Schonbuchner I, 
Gadzicki D, Caldes T, de la Hoya M, Pooley KA, Easton DF, Chenevix-Trench G; 
CIMBA. Common variants in LSPI, 2q35 and 8q24 and breast cancer risk for BRCAI and 
BRCA2 mutation carriers. Hum Mol Genet. 2009; 18:4442-56. 
Antoniou AC, Beesley J, McGuffog L, Sinilnikova OM, Healey S, Neuhausen SL, 
Ding YC, Rebbeck TR, Weitzel IN, Lynch HT, Isaacs C, Ganz PA, Tomlinson G, Olopade 
01, Couch FJ, Wang X, Lindor NM, Pankratz VS, Radice P, Manoukian S, Peissel B, 
Zaffaroni D, Barile M, Viel A, Allavena A, Dall'Olio V, Peterlongo P, Szabo CI, Zikan M, 
Claes K, Poppe B, Foretova L, Mai PL, Greene MH, Rennert G, Lejbkowicz F, Glendon 
G, Ozcelik H, Andrulis IL; Ontario Cancer Genetics Network, Thomassen M, Gerdes AM, 
Sunde L, Cruger D, Birk Jensen U, Caligo M, Friedman E, Kaufman B, Laitman Y, 
Milgrom R, Dubrovsky M, Cohen S, Borg A, Jemstrom H, Lindblom A, Rantala J, 
Stenmark-Askmalm M, Melin B; SWE-BRCA, Nathanson K, Domchek S, Jakubowska A, 
Lubinski J, Huzarski T, Osorio A, Lasa A, Duran M, Tejada MI, Godino J, Benitez J, 
Hamann U, Kriege M, Hoogerbrugge N, van der Luijt RB, van Asperen CJ, Devilee P, 
Meijers-Heijboer EJ, Blok MJ, Aalfs CM, Hogervorst F, Rookus M; HEBON, Cook M, 
Oliver C, Frost D, Conroy D, Evans DG, Lalloo F, Pichert G, Davidson R, Cole T, Cook J, 
Paterson J, Hodgson S, Morrison PJ, Porteous ME, Walker L, Kennedy MJ, Dorkins H, 
Peock S; EMBRACE, Godwin AK, Stoppa-Lyonnet D, de Pauw A, Mazoyer S, Bonadona 
V, Lasset C, Dreyfus H, Leroux D, Hardouin A, Berthet P, Faivre L; GEMO, Loustalot C, 
Noguchi T, Sobol H, Rouleau E, Nogues C, Fn!nay M, Venat-Bouvet L; GEMO, Hopper 
93 
References 
JL, Daly MB, Terry MB, John EM, Buys SS, Yassin Y, Miron A, Goldgar D; Breast 
Cancer Family Registry, Singer CF, Dressler AC, GschwantIer-Kaulich D, Pfeiler G, 
Hansen TV, J0nson L, Agnarsson BA, Kirchhoff T, Offit K, Devlin V, Dutra-Clarke A, 
Piedmonte M, Rodriguez GC, Wakeley K, Boggess JF, Basil J, Schwartz PE, Blank SV, 
Toland AE, Montagna M, Casella C, Imyanitov E, Tihomirova L, Blanco I, Lazaro C, 
Ramus SJ, Sucheston L, Karlan BY, Gross J, Schmutzler R, Wappenschmidt B, Engel C, 
Meindl A, Lochmann M, Arnold N, Heidemann S, Varon-Mateeva R, Niederacher D, 
Sutter C, Deissler II, Gadzicki D, Preisler-Adams S, Kast K, Schonbuchner I, Caldes T, de 
la Hoya M, Aittomaki K, Nevanlinna H, Simard J, Spurdle AB, Holland H, Chen X; 
kConFab, Platte R, Chenevix-Trench G, Easton DF; CIMBA. Common breast cancer 
susceptibility alleles and the risk of breast cancer for BRCA 1 and BRCA2 mutation 
carriers: implications for risk prediction. Cancer Res. 2010;70:9742-54. 
Antoniou AC, Chenevix-Trench G. Common genetic variants and cancer risk in 
Mendelian cancer syndromes. Curr Opin Genet Dev. 2010;20:299-307. doi: 
10.1 016/j.gde.2010.03.01 o. 
Antoniou AC, Kartsonaki C, Sinilnikova OM, Soucy P, McGuffog L, Healey S, Lee 
A, Peterlongo P, Manoukian S, Peissel B, Zaffaroni D, Cattaneo E, Barile M, Pensotti V, 
Pasini B, Dolcetti R, Giannini G, Putignano AL, Varesco L, Radice P, Mai PL, Greene 
MH, Andrulis IL, Glendon G, Ozcelik H, Thomassen M, Gerdes AM, Kruse T A, Birk 
Jensen U, Cruger DG, Caligo MA, Laitman Y, Milgrom R, Kaufman B, Paluch-Shimon S, 
Friedman E, Loman N, Harbst K, Lindblom A, Arver B, Ehrencrona H, Melin B; SWE-
BRCA, Nathanson KL, Domchek SM, Rebbeck T, Jakubowska A, Lubinski J, Gronwald J, 
Huzarski T, Byrski T, Cybulski C, Gorski B, Osorio A, Ramon y Cajal T, Fostira F, 
Andres R, Benitez J, Hamann U, Hogervorst FB, Rookus MA, Hooning MJ, Nelen MR, 
van der Luijt RD, van as TA, van Asperen CJ, Devilee P, Meijers-Heijboer HE, Gomez 
Garcia EB; HEBON, Peock S, Cook M, Frost D, Platte R, Leyland J, Evans DG, Lalloo F, 
Eeles R, Izatt L, Adlard J, Davidson R, Eccles D, Ong KR, Cook J, Douglas F, Paterson J, 
Kennedy MJ, Miedzybrodzka Z; EMBRACE, Godwin A, Stoppa-Lyonnet D, Buecher B, 
Belotti M, Tirapo C, Mazoyer S, Barjhoux L, Lasset C, Leroux D, Faivre L, Bronner M, 
Prieur F, Nogues C, Rouleau E, Pujol P, Coupier I, Frenay M; CEMO Study Collaborators, 
Hopper JL, Daly MB, Terry MB, John EM, Buys SS, Yassin Y, Miron A, Goldgar D; 
Breast Cancer Family Registry, Singer CF, Tea MK, Pfeiler G, Dressler AC, Hansen Tv, 
J0nson L, Ejlertsen B, Barkardottir RB, Kirchhoff T, Offit K, Piedmonte M, Rodriguez G, 
Small L, Boggess J, Blank S, Basil J, Azodi M, Toland AE, Montagna M, Tognazzo S, 
Agata S, Imyanitov E, Janavicius R, Lazaro C, Blanco I, Pharoah PD, Sucheston L, Karlan 
BY, Walsh CS, Olah E, Bozsik A, Teo SH, Seldon JL, Beattie MS, van Rensburg EJ, 
Sluiter MD, Diez 0, Schmutzler RK, Wappenschmidt B, Engel C, Meindl A, Ruehl I, 
Varon-Mateeva R, Kast K, Deissler H, Niederacher D, Arnold N, Gadzicki D, 
Schonbuchner I, Cal des T, de la Hoya M, Nevanlinna H, Aittomaki K, Dumont M, 
Chiquette J, Tischkowitz M, Chen X, Beesley J, Spurdle AB; kConFab investigators, 
Neuhausen SL, Chun Ding Y, Fredericksen Z, Wang X, Pankratz VS, Couch F, Simard J, 
Easton DF, Chenevix-Trench G; CIMBA. Common alleles at 6q25.l and Ipl1.2 are 
associated with breast cancer risk for BRCAI and BRCA2 mutation carriers. Hum Mol 
Genet. 2011 ;20:3304-21. 
Balia C, Sensi E, Lombardi G, Roncella M, Bevilacqua G, Cali go MA. PALB2: a 
novel inactivating mutation in a Italian breast cancer family. Fam Cancer 2010;4:531-536. 
94 
References 
Bakker JL, van Mil SE, Crossan G, Sabbaghian N, De Leeneer K, Poppe B, Adank M, 
Gille H, Verheul H, Meijers-Heijboer H, de Winter JP, Claes K, Tischkowitz M, Waisfisz 
Q. Analysis of the Novel Fanconi Anemia Gene SLX4/F ANCP in Familial Breast Cancer 
Cases. Hum Mutat. 2013;34:70-3. doi: lO.1002lhumu.22206. 
Baudi F, Quaresima B, Grandinetti C, Cuda G, Faniello C, Tassone P, Barbieri V, 
Bisegna R, Ricevuto E, Conforti S, Viel A, Marchetti P, Ficorella C, Radice P, Costanzo F, 
Venuta S. Evidence of a founder mutation of BRCA 1 in a highly homogeneous population 
from southern Italy with breast/ovarian cancer. Hum Mutat. 2001;18:163-4. 
Bergman A, Einbeigi Z, Olofsson U, Taib Z, Wallgren A, Karlsson P, Wahlstrom J, 
Martinsson T, Nordling M. The western Swedish BRCAI founder mutation 317lins5; a 
3.7 cM conserved haplotype of today is a reminiscence of a 1500-year-old mutation. Eur J 
Hum Genet. 2001;9:787-93. 
Bergman A, Flodin A, Engwall Y, Arkblad EL, Berg K, Einbeigi Z, Martinsson T, 
Wahlstrom J, Karlsson P, Nordling M. A high frequency of germline BRCA1I2 mutations 
in western Sweden detected with complementary screening techniques. Fam Cancer. 
2005;4:89-96. 
Blanco A, de la Hoya M, BalmaTia J, Ramon y Cajal T, Teule A, Miramar MD, 
Esteban E, Infante M, Benitez J, Torres A, Tejada MI, Brunet J, Grana B, Balbin M, Perez-
Segura P, Osorio A, Velasco EA, Chirivella I, Calvo MT, Feliubadalo L, Lasa A, Diez 0, 
Carracedo A, Caldes T, Vega A. Detection of a large rearrangement in P ALB2 in Spanish 
breast cancer families with male breast cancer. Breast Cancer Res Treat. 2012;132:307-15. 
doi: 10.1007 Is 10549-011-1842-2. 
Bogdanova N, Sokolenko AP, Iyevleva AG, Abysheva SN, Blaut M, Bremer M, 
Christiansen II, Rave-Frank M, Dork T, Imyanitov EN. PALB2 mutations in German and 
Russian patients with bilateral breast cancer. Breast Cancer Res Treat. 2011; 126:545-50. 
Bradbury AR, Olopade 01. Genetic susceptibility to breast cancer. Rev Endocr Metab 
Disord. 2007;8:255-67. 
Breast Cancer Association Consortium. Commonly studied single-nucleotide 
polymorphisms and breast cancer: results from the Breast Cancer Association Consortium. 
J Natl Cancer Inst. 2006;98:1382-96. 
Brendel V, Xing L, Zhu W. Gene structure prediction from consensus spliced 
alignment of multiple ESTs matching the same genomic locus. Bioinformatics 
2004;20:1157-1169. 
Broeks A, Schmidt MK, Sherman ME, Couch FJ, Hopper JL, Dite GS, Apicella C, 
Smith LD, Hammet F, Southey MC, Van 't Veer LJ, de Groot R, Smit VT, Fasching PA, 
Beckmann MW, Jud S, Ekici AB, Hartmann A, Hein A, Schulz-WendtIand R, Burwinkel 
B, Marme F, Schneeweiss A, Sinn HP, Sohn C, Tchatchou S, Bojesen SE, Nordestgaard 
BG, Flyger II, 0rsted DD, Kaur-Knudsen D, Milne RL, Perez 11, Zamora P, Rodriguez 
PM, Benitez J, Brauch H, Justenhoven C, Ko YD; Genica Network, Hamann U, Fischer 
liP, Briining T, Pesch B, Chang-Claude J, Wang-Gohrke S, Bremer M, Karstens JH, 
HiIlemanns P, Dork T, Nevanlinna HA, Heikkinen T, Heikkila P, Blomqvist C, Aittomaki 
K, Aaltonen K, Lindblom A, Margolin S, Mannermaa A, Kosma VM, Kauppinen JM, 
95 
References 
Kataja V, Auvinen P, Eskelinen M, Soini Y, Chenevix-Trench G, Spurdle AB, Beesley J, 
Chen X, Holland H; kConFab; AOCS, Lambrechts D, Claes B, Vandorpe T, Neven P, 
Wildiers H, Flesch-Janys D, Hein R, Loning T, Kosel M, Fredericksen ZS, Wang X, Giles 
GO, Baglietto L, Severi 0, McLean C, Haiman CA, Henderson BE, Le Marchand L, 
Kolonel LN, Alnres GO, Kristensen V, B0rresen-Dale AL, Hunter DJ, Hankinson SE, 
Andrulis IL, Mulligan AM, O'Malley FP, Devilee P, Huijts PE, Tollenaar RA, Van 
Asperen CJ, Seynaeve CS, Chanock SJ, Lissowska J, Brinton L, Peplonska B, Figueroa J, 
Yang XR, Hooning MJ, Hollestelle A, Oldenburg RA, Jager A, Kriege M, Ozturk B, van 
Leenders GJ, Hall P, Czene K, Humphreys K, Liu J, Cox A, Connley D, Cramp HE, Cross 
SS, Balasubramanian SP, Reed MW, Dunning AM, Easton DF, Humphreys MK, Caldas C, 
Blows F, Driver K, Provenzano E, Lubinski J, Jakubowska A, Huzarski T, Byrski T, 
Cybulski C, Gorski B, Gronwald J, Brennan P, Sangrajrang S, Gaborieau V, Shen CY, 
Hsiung CN, Yu JC, Chen ST, Hsu GC, Hou MF, Huang CS, Anton-Culver H, Ziogas A, 
Pharoah PD, Garcia-Closas M. Low penetrance breast cancer susceptibility loci are 
associated with specific breast tumor subtypes: findings from the Breast Cancer 
Association Consortium. Hum Mol Genet. 2011;20:3289-303. doi: lO.l093lhmglddr228. 
Brunak S, Engelbrecht J, Knudsen S. Prediction of human mRNA donor and acceptor 
sites from the DNA sequence. J Mol Bioi 1991;220:49-65. 
Calabrese R, Capriotti E, Fariselli P, Martelli PL, Casadio R. Functional annotations 
improve the predictive score of human disease-related mutations in proteins. Hum Mutat 
2009;30: 1237-1244. 
Cali go MA, Ghimenti C, Cipollini G, Ricci S, Brunetti I, Marchetti V, Olsen R, 
Neuhausen S, Shattuck-Eidens D, Conte PF, Skolnick MH, Bevilacqua G. BRCAI 
germline mutational spectrum in Italian families from Tuscany: a high frequency of novel 
mutations. Oncogene. 1996; 13: 1483-8. 
Caligo MA, Agata S, Aceto G, Crucianelli R, Manoukian S, Peissel B, Scaini MC, 
Sensi E, Veschi S, Cama A, Radice P, Viel A, D'Andrea E, Montagna M. The CHEK2 
c.ll00delC mutation plays an irrelevant role in breast cancer predisposition in Italy. Hum 
MUlat.2004;24:100-1. 
Casadci S, Norquist BM, Waish T, Stray SM, Mandell JB, Lee MK, 
Stamatoyannopoulos JA, King MC. Contribution to Familial Breast Cancer of Inherited 
Mutations in the BRCA2-interacting Protein PALB2. Cancer Res. 2011 ;71 :2222-9. 
Cao A Y, Huang J, Hu Z, Li WF, Ma ZL, Tang LL, Zhang B, Su FX, Zhou J, Di OH, 
Shen KW, Wu J, Lu JS, et al. The prevalence of P ALB2 germ line mutations in 
BRCAIIBRCA2 negative Chinese women with early onset breast cancer or affected 
relatives. Breast Cancer Res Treat. 2009;114:457-62. 
Catucci I, Yang R, Verderio P, Pizzamiglio S, Heesen L, Hemminki K, Sutter C, 
Wappenschmidt B, Dick M, Arnold N, Bugert P, Niederacher D, Meindl A, Schmutzler 
RK, Bartram CC, Ficarazzi F, Tizzoni L, Zaffaroni D, Manoukian S, Barile M, Pierotti 
MA, Radice P, Burwinkel B, Peterlongo P. Evaluation of SNPs in miR-146a, miR196a2 
and miR-499 as low-penetrance alleles in German and Italian familial breast cancer cases. 
Hum Mutat. 2010;31:EI052-7. 
96 
References 
Catucci I, Milgrom R, Kushnir A, Laitman Y, Paluch-Shimon S, Volorio S, Ficarazzi 
F, Bernard L, Radice P, Friedman E, Peterlongo P. Germline mutations in BRIPI and 
PALB2 in Jewish high cancer risk families. Fam Cancer 2012;11:483-91. doi: 
10.1007 Is 1 0689-0 12-9540-8. 
Clague J, Lippman SM, Yang H, Hildebrandt MA, Ye Y, Lee JJ, Wu X. Genetic 
variation in MicroRNA genes and risk of oral premalignant lesions. Mol Carcinog. 
2010;49: 183-9. 
Chenevix-Trench G, Milne RL, Antoniou AC, Couch FJ, Easton DF, Goldgar DE; 
CIMBA. An international initiative to identify genetic modifiers of cancer risk in BRCAI 
and BRCA2 mutation carriers: the Consortium of Investigators of Modifiers of BRCAI 
and BRCA2 (CIMBA). Breast Cancer Res. 2007;9:104. 
Couch FJ, Rasmussen LJ, Hofstra R, Monteiro AN, Greenblatt MS, de Wind N; IARC 
Unclassified Genetic Variants Working Group. Assessment of functional effects of 
unclassified genetic variants. Hum Mula!. 2008;29: 1314-26. 
Couch FJ, Wang X, McGuffog L, Lee A, Olswold C, Kuchenbaecker KB, Soucy P, 
Fredericksen Z, Barrowdale D, Dennis J, Gaudet MM, Dicks E, Kosel M, Healey S, 
Sinilnikova OM, Lee A, Bacot F, Vincent D, Hogervorst FB, Peock S, Stoppa-Lyonnet D, 
Jakubowska A, Investigators K, Radice P, Schmutzler RK; SWE-BRCA, Domchek SM, 
Piedmonte M, Singer CF, Friedman E, Thomassen M; Ontario Cancer Genetics Network, 
Hansen TV, Neuhausen SL, Szabo CI, Blanco I, Greene MH, Karlan BY, Garber J, Phelan 
CM, Weitzel IN, Montagna M, Olah E, Andrulis IL, Godwin AK, Yannoukakos D, 
Goldgar DE, Caldes T, Nevanlinna H, Osorio A, Terry MB, Daly MB, van Rensburg EJ, 
Hamann U, Ramus SJ, Ewart Toland A, Caligo MA, Olopade 01, Tung N, Claes K, Beattie 
MS, Southey MC, Imyanitov EN, Tischkowitz M, Janavicius R, John EM, Kwong A, Diez 
0, Balmaiia J, Barkardottir RB, Arun BK, Rennert G, Teo SH, Ganz PA, Campbell I, van 
der Hout AI I, van Deurzen CH, Seynaeve C, Gomez Garcia EB, van Leeuwen FE, 
Meijers-Heijboer HE, Gille JJ, Ausems MG, Blok MJ, Ligtenberg MJ, Rookus MA, 
Devilee P, Verhoef S, van Os TA, Wijnen JT; HEBON; EMBRACE, Frost D, Ellis S, 
Fineberg E, Platte R, Evans DG, Izatt L, Eeles RA, Adlard J, Eccles DM, Cook J, Brewer 
C, Douglas F, Hodgson S, Morrison PJ, Side LE, Donaldson A, Houghton C, Rogers MT, 
Dorkins II, Eason J, Gregory H, McCann E, Murray A, Calender A, Hardouin A, Berthet 
P, Delnatte C, Nogues C, Lasset C, Houdayer C, Leroux D, Rouleau E, Prieur F, Damiola 
F, Sobol H, Coupier I, Venat-Bouvet L, Castera L, Gauthier-Villars M, Leone M, Pujol P, 
Mazoyer S, Bignon YJ; GEMO Study Collaborators, Zlowocka-Perlowska E, Gronwald J, 
Lubinski J, Durda K, Jaworska K, Huzarski T, Spurdle AB, Viel A, Peissel B, Bonanni B, 
Melloni G, Ottini L, Papi L, Varesco L, Tibiletti MG, Peterlongo P, Volorio S, Manoukian 
S, Pensotti V, Arnold N, Engel C, Deissler H, Gadzicki D, Gehrig A, Kast K, Rhiem K, 
Meindl A, Niederacher D, Ditsch N, Plendl H, Preisler-Adams S, Engert S, Sutter C, 
Varon-Mateeva R, Wappenschmidt B, Weber BH, Arver B, Stenmark-Askmalm M, 
Loman N, Rosenquist R, Einbeigi Z, Nathanson KL, Rebbeck TR, Blank SV, Cohn DE, 
Rodriguez GC, Small L, Friedlander M, Bae-Jump VL, Fink-Retter A, Rappaport C, 
Gschwantler-Kaulich D, Pfeiler G, Tea MK, Lindor NM, Kaufman B, Shimon Paluch S, 
Laitman Y, Skytte AB, Gerdes AM, Pedersen IS, Moeller ST, Kruse T A, Jensen UB, Vijai 
J, Sarrel K, Robson M, Kauff N, Mulligan AM, Glendon G, Ozcelik H, Ejlertsen B, 
Nielsen FC, Jonson L, Andersen MK, Ding YC, Steele L, Foretova L, Teule A, Lazaro C, 
Brunet J, Pujana MA, Mai PL, Loud JT, Walsh C, Lester J, Orsulic S, Narod SA, Herzog J, 
Sand SR, Tognazzo S, Agata S, Vaszko T, Weaver J, Stavropoulou AV, Buys SS, Romero 
97 
References 
A, de la Hoya M, Aittomaki K, Muranen TA, Duran M, Chung WK, Lasa A, Dorfling CM, 
Miron A; BCFR, Benitez J, Senter L, Huo D, Chan SB, Sokolenko AP, Chiquette J, 
Tihomirova L, Friebel TM, Agnarsson BA, Lu KH, Lejbkowicz F, James PA, Hall P, 
Dunning AM, Tessier D, Cunningham J, Slager SL, Wang C, Hart S, Stevens K, Simard J, 
Pastinen T, Pankratz VS, Offit K, Easton DF, Chenevix-Trench G, Antoniou AC; CIMBA. 
Genome-Wide Association Study in BRCAI Mutation Carriers Identifies Novel Loci 
Associated with Breast and Ovarian Cancer Risk. PLoS Genet. 2013;9:el003212. doi: 
10.1371/joumal.pgen.l003212. 
Cox A, Dunning AM, Garcia-Closas M, Balasubramanian S, Reed MW, Pooley KA, 
Scollen S, Baynes C, Ponder BA, Chanock S, Lissowska J, Brinton L, Peplonska B, 
Southey MC, Hopper JL, McCredie MR, Giles GG, Fletcher 0, Johnson N, dos Santos 
Silva I, Gibson L, Bojesen SE, Nordestgaard BG, Axelsson CK, Torres D, Hamann U, 
Justenhoven C, Brauch H, Chang-Claude J, Kropp S, Risch A, Wang-Gohrke S, 
SchUrmann P, Bogdanova N, Dark T, Fagerholm R, Aaltonen K, Blomqvist C, Nevanlinna 
H, Seal S, Renwick A, Stratton MR, Rahman N, Sangrajrang S, Hughes D, Odefrey F, 
Brennan P, Spurdle AB, Chenevix-Trench G; Kathleen Cunningham Foundation 
Consortium for Research into Familial Breast Cancer, Beesley J, Mannermaa A, 
Hartikainen J, Kataja V, Kosma VM, Couch FJ, Olson JE, Goode EL, Broeks A, Schmidt 
MK, Hogervorst FB, Van't Veer LJ, Kang D, Yoo KY, Noh DY, Ahn SH, Wedren S, Hall 
P, Low YL, Liu J, Milne RL, Ribas G, Gonzalez-Neira A, Benitez J, Sigurdson AJ, 
Stredrick DL, Alexander BH, Struewing JP, Pharoah PD, Easton DF; Breast Cancer 
Association Consortium. A common coding variant in CASP8 is associated with breast 
cancer risk. Nat Genet. 2007;39:352-8. 
Cybulski C, Wokolorczyk D, Gliniewicz B, Sikorski A, Gorski B, Jakubowska A, 
Huzarski T, Byrski T, Debniak T, Gronwald J, Lubinski J, Narod SA. A six-nucleotide 
deletion in the CASP8 promoter is not associated with a susceptibility to breast and 
prostate cancers in the Polish population. Breast Cancer Res Treat. 2008;112:367-8. 
Cybulski KE, Howlett NG. FANCP/SLX4: a Swiss army knife of DNA interstrand 
crosslink repair. Cell Cycle. 2011;10:1757-63. 
Dansonka-Mieszkowska A, Kluska A, Moes J, Dabrowska M, Nowakowska D, 
Niwinska A, Derlatka P, Cendrowski K, Kupryjanczyk J. A novel germline PALB2 
deletion in Polish breast and ovarian cancer patients. BMC Med Genet. 2010; 11 :20. 
de Garibay GR, Diaz A, Gavifia B, Romero A, Garre P, Vega A, Blanco A, Tosar A, 
Diez 0, Perez-Segura P, Diaz-Rubio E, Caldes T, de la Hoya M. Low prevalence of SLX4 
loss-of-function mutations in non-BRCA1I2 breast and/or ovarian cancer families. Eur J 
Hum Genet. 2012. doi: 1O.1038/ejhg.2012.268. 
De Leon Matsuda ML, Liede A, K wan E, Mapua CA, Cutiongco EM, Tan A, Borg A, 
Narod SA. BRCA 1 and BRCA2 mutations among breast cancer patients from the 
Philippines. In! J Cancer. 2002;98:596-603. 
De Vecchi G, Verderio P, Pizzamiglio S, Manoukian S, Barile M, Fortuzzi S, 
Ravagnani F, Pierotti MA, Radice P, Peterlongo P. Evidences for association of the 
CASP8 -652 6N del promoter polymorphism with age at diagnosis in familial breast cancer 
cases. Breast Cancer Res Treat. 2009;113:607-8. 
98 
References 
Engel C, Versmold B, Wappenschmidt B, Simard J, Easton DF, Peock S, Cook M, 
Oliver C, Frost D, Mayes R, Evans DG, Eeles R, Paterson J, Brewer C; Epidemiological 
Study of Familial Breast Cancer (EMBRACE), McGuffog L, Antoniou AC, Stoppa-
Lyonnet D, Sinilnikova OM, Barjhoux L, Frenay M, Michel C, Leroux D, Dreyfus II, 
Toulas C, GladieffL, Uhrhammer N, Bignon YJ, Meindl A, Arnold N, Varon-Mateeva R, 
Niederacher D, Preisler-Adams S, Kast K, Deissler H, Sutter C, Gadzicki D, Chenevix-
Trench G, Spurdle AB, Chen X, Beesley J; Kathleen Cuningham Foundation Consortium 
for Research into Familial Breast Cancer (kConFab), Olsson H, Kristoffersson U, 
Ehrencrona H, Liljegren A~ Swedish Breast Cancer Study, Sweden (SWE-DRCA), van der 
Luijt RB, van Os T A, van Leeuwen FE; Hereditary Breast and Ovarian cancer group 
Netherlands (HEBON), Domchek SM, Rebbeck TR, Nathanson KL, Osorio A, Ramon y 
Cajal T, Konstantopoulou I, Benitez J, Friedman E, Kaufman B, Laitman Y, Mai PL, 
Greene MH, Nevanlinna H, Aittomaki K, Szabo CI, Caldes T, Couch FJ, Andrulis IL, 
Godwin AK, Hamann U, Schmutzler RK; Consortium of Investigators of Modifiers of 
BRCA1I2 (CIMDA). Association of the variants CASP8 D302H and CASPIO V410I with 
breast and ovarian cancer risk in BRCAI and DRCA2 mutation carriers. Cancer Epidemiol 
Biomarkers Prevo 2010; 19:2859-68. 
Erkko II, Xia B, Nikkila J, Schleutker J, Syrjakoski K, Mannermaa A, Kallioniemi A, 
Pylkas K, Karppinen SM, Rapakko K, Miron A, Sheng Q, Li G, Mattila H, Bell DW, 
Haber DA, Grip M, Reiman M, Jukkola-Vuorinen A, Mustonen A, Kere J, Aaltonen LA, 
Kosma VM, Kataja V, Soini Y, Drapkin RI, Livingston DM, Winqvist R. A recurrent 
mutation in PALB2 in Finnish cancer families. Nature. 2007;446:316-319. 
Fackenthal JD, Olopade 01. Breast cancer risk associated with BRCAI and BRCA2 in 
diverse populations. Nat Rev Cancer. 2007;7:937-48. 
Fekairi S, Scaglione S, Chahwan C, Taylor ER, Tissier A, Coulon S, Dong MQ, Ruse 
C, Yates JR 3rd, Russell P, Fuchs RP, McGowan CH, Gaillard PH. Human SLX4 is a 
Holliday junction resolvase subunit that binds multiple DNA repair/recombination 
endonucleases. Cell. 2009; 138:78-89. 
Ferla R, CalC> V, Cascio S, Rinaldi G, Badalamenti G, Carreca I, Surmacz E, Colucci 
G, Bazan V, Russo A. Founder mutations in BRCAI and BRCA2 genes. Ann Oncol. 
2007;18 SuppI6:vi93-8. 
Fernandez-Rodriguez J, Quiles F, Blanco I, Teule A, Feliubadalo L, Valle JD, Salinas 
M, Izquierdo A, Darder E, Schindler D, Capella G, Brunet J, Lazaro C, Pujana MA. 
Analysis of SLX4/FANCP in non-BRCA1I2-mutated breast cancer families. BMC Cancer. 
2012;12:84. doi: 10.1186/1471-2407-12-84. 
Foulkes WD. Inherited susceptibility to common cancers. N Engl J Med. 
2008; 13;359:2143-53. 
Frank B, Hemminki K, Wappenschmidt B, Meindl A, Klaes R, Schmutzler RK, 
Bugert P, Untch M, Bartram CR, Burwinkel B. Association of the CASPIO V410I variant 
with reduced familial breast cancer risk and interaction with the CASP8 D302H variant. 
Carcinogenesis. 2006;27:606-9. 
Frank D, Rigas SH, Bermejo JL, Wiestler M, Wagner K, Hemminki K, Reed MW, 
Sutter C, Wappenschmidt D, Balasubramanian SP, Meindl A, Kiechle M, Bugert P, 
99 
References 
Schmutzler RK, Bartram CR, Justenhoven C, Ko YD, Bruning T, Brauch H, Hamann U, 
Pharoah PP, Dunning AM, Pooley KA, Easton DF, Cox A, Burwinkel B. The CASP8 -652 
6N del promoter polymorphism and breast cancer risk: a multicenter study. Breast Cancer 
Res Treat. 2008; 111: 139-44. 
Garcia MJ, Fernandez V, Osorio A, Barroso A, LIort G, Lazaro C, Blanco I, Caldes T, 
de la Hoya M, Ram6n Y Cajal T, Alonso C, et a1. Analysis of F ANCB and 
FANCN/PALB2 fanconi anemia genes in BRCA1I2-negative Spanish breast cancer 
families. Breast Cancer Res Treat. 2009;113:545-51. 
Gaudet MM, Kuchenbaecker KB, Vijai J, Klein RJ, Kirchhoff T, McGuffog L, 
Barrowdale D, Dunning AM, Lee A, Dennis J, Healey S, Dicks E, Soucy P, Sinilnikova 
OM, Pankratz VS, Wang X, Eldridge RC, Tessier DC, Vincent D, Bacot F, Hogervorst FB, 
Peock S, Stoppa-Lyonnet 0; KConFab Investigators, Peterlongo P, Schmutzler RK, 
Nathanson KL, Piedmonte M, Singer CF, Thomassen M; Ontario Cancer Genetics 
Network, Hansen TV, Neuhausen SL, Blanco I, Greene MH, Garber J, Weitzel IN, 
Andrulis IL, Goldgar DE, D'Andrea E, Cal des T, Nevanlinna H, Osorio A, van Rensburg 
EJ, Arason A, Rennert G, van den Ouweland AM, van der Hout AH, Kets CM, Aalfs CM, 
Wijnen JT, Ausems MG; HEDON; EMBRACE, Frost D, Ellis S, Fineberg E, Platte R, 
Evans DG, Jacobs C, Adlard J, Tischkowitz M, Porteous ME, Damiola F; GEMO Study 
Collaborators, Golmard L, Barjhoux L, Longy M, Belotti M, Ferrer SF, Mazoyer S, 
Spurdle AB, Manoukian S, Barile M, Genuardi M, Arnold N, Meindl A, Sutter C, 
Wappenschmidt D, Domchek SM, Pfeiler G, Friedman E, Jensen UB, Robson M, Shah S, 
Lazaro C, Mai PL, Benitez J, Southey MC, Schmidt MK, Fasching PA, Peto J, Humphreys 
MK, Wang Q, Michailidou K, Sawyer EJ, Burwinkel B, Guenel P, Bojesen SE, Milne RL, 
Brenner H, Lochmann M; GENICA Network, Aittomaki K, Dork T, Margolin S, 
Mannermaa A, Lambrechts 0, Chang-Claude J, Radice P, Giles GG, Haiman CA, 
Winqvist R, Devillee P, Garcia-Closas M, Schoof N, Hooning MJ, Cox A, Pharoah PD, 
Jakubowska A, Orr N, Gonzalez-Neira A, Pita G, Alonso MR, Hall P, Couch FJ, Simard J, 
Altshuler D, Easton OF, Chenevix-Trench G, Antoniou AC, Offit K. Identification of a 
BRCA2-Specific Modifier Locus at 6p24 Related to Breast Cancer Risk. PLoS Genet. 
2013;9:el 003173. doi: lO.l3711journa1.pgen.1003173. 
Gao LB, Bai P, Pan XM, Jia J, Li LJ, Liang WB, Tang M, Zhang LS, Wei YG, Zhang 
L. The association between two polymorphisms in pre-miRNAs and breast cancer risk: a 
meta-analysis. Breast Cancer Res Treat. 2011;125:571-4. 
Ghadirian P, Robidoux A, Zhang P, Royer R, Akbari M, Zhang S, Fafard E, Costa M, 
Martin G, Potvin C, Patocskai E, Larouche N, Younan R, Nassif E, Giroux S, Narod SA, 
Rousseau F, Foulkes WD. The contribution of founder mutations to early-onset breast 
cancer in French-Canadian women. Clin Genet. 2009;76:421-6. 
Gracia-Aznarez FJ, Fernandez V, Pita G, Peterlongo P, Dominguez 0, de la Hoya M, 
Duran M, Osorio A, Moreno L, Gonzalez-Neira A, Rosa-Rosa JM, Sinilnikova 0, 
Mazoyer S, Hopper J, Lazaro C, Southey M, Odefrey F, Manoukian S, Catucci I, Caldes T, 
Lynch HT, Hilbers FS, van Asperen CJ, Vasen HF, Goldgar D, Radice P, Devilee P, 
Benitez J. Whole exome sequencing suggests much ofnon-BRCAIIBRCA2 familial breast 
cancer is due to moderate and low penetrance susceptibility alleles. PLoS One. 
2013;8:e55681. doi: 1O.13711journal.pone.0055681. 
100 
References 
Haiman CA, Garcia RR, Kolonel LN, Henderson BE, Wu AH, Le Marchand L. A 
promoter polymorphism in the CASP8 gene is not associated with cancer risk. Nat Genet. 
2008;40:259-60. 
Hall JM, Lee MK, Newman B, Morrow JE, Anderson LA, Huey B, King MC. Linkage 
of early-onset familial breast cancer to chromosome 17q21. Science. 1990;250: 1684-9. 
Hebsgaard SM, Korning PG, Tolstrup N, Engelbrecht J, Rouze P, Brunak S. Splice 
site prediction in Arabidopsis thaliana pre-mRNA by combining local and global sequence 
information. Nucleic Acids Res 1996;24:3439-3452. 
Hellebrand H, Sutter C, Honisch E, Gross E, Wappenschmidt B, Schem C, DeiJ3ier II, 
Ditsch N, Gress V, Kiechle M, Bartram CR, Schmutzler RK, Niederacher D, Arnold N, 
Meindl A. Germline mutations in the PALB2 gene are population specific and occur with 
low frequencies in familial breast cancer. Hum Mulat. 2011. doi: 10.1002lhumu.21478. 
Hezova R, Kovarikova A, Bienertova-Vasku J, Sachlova M, Redova M, Vasku A, 
Svoboda M, Radova L, Kiss I, Vyzula R, Slaby O. Evaluation of SNPs in miR-196-a2, 
miR-27a and miR-146a as risk factors of colorectal cancer. World J Gastroenterol. 
2012;18:2827-31. doi: 10.3748/wjg.vI8.i22.2827. 
Hilbers FS, Wijnen JT, Hoogerbrugge N, Oosterwijk JC, Collee MJ, Peterlongo P, 
Radice P, Manoukian S, Feroce I, Capra F, Couch FJ, Wang X, Guidugli L, Offit K, Shah 
S, Campbell IG, Thompson ER, James PA, Trainer AH, Gracia J, Benitez J, van Asperen 
CJ, Devilee P. Rare variants in XRCC2 as breast cancer susceptibility alleles. J Med Genet. 
2012;49:618-20. doi: 1O.1136/jmedgenet-2012-101191. 
Ho PK, Hawkins CJ. Mammalian initiator apoptotic caspases. FEES J. 
2005;272:5436-53. 
Hoffman AE, Zheng T, Yi C, Leaderer D, Weidhaas J, Slack F, Zhang Y, Paranjape T, 
Zhu Y. microRNA miR-196a-2 and breast cancer: a genetic and epigenetic association 
study and functional analysis. Cancer Res. 2009;69:5970-7. 
Hofstatter EW, Domchek SM, Miron A, Garber J, Wang M, Componeschi K, 
Boghossian L, Miron PL, Nathanson KL, Tung N. PALB2 mutations in familial breast and 
pancreatic cancer. Fam Cancer. 2011; 1 0:225-31. 
Hollestelle A, Wasielewski M, Martens JW, Schutte M. Discovering moderate-risk 
breast cancer susceptibility genes. Curr Opin Genet Dev. 2010;20:268-76. 
Hosmer DW, Lemeshow S (1989) Applied logistic regression. John Wiley & Sons, 
New York. 
Howlett NG, Taniguchi T, Olson S, Cox B, Waisfisz Q, De Die-Smulders C, Persky 
N, Grompe M, Joenje H, Pals G, Ikeda H, Fox EA, D'Andrea AD. Biallelic inactivation of 
BRCA2 in Fanconi anemia. Science. 2002;297:606-9. 
Hu Z, Liang J, Wang Z, Tian T, Zhou X, Chen J, Miao R, Wang Y, Wang X, Shen H. 
Common genetic variants in pre-microRNAs were associated with increased risk of breast 
cancer in Chinese women. Hum Mutat. 2009;30:79-84. 
101 
References 
Ikeda N, Miyoshi Y, Yoneda K, Shiba E, Sekihara Y, Kinoshita M, Noguchi S. 
Frequency of BRCAI and BRCA2 gennline mutations in Japanese breast cancer families. 
Int J Cancer. 2001 ;91 :83-8. 
Jones S, Hruban RH, Kamiyama M, et al. Exomic sequencing identifies PALB2 as a 
pancreatic cancer susceptibility gene. Science 2009;324:217. 
Kadouri L, Kote-Jarai Z, Hubert A, Durocher F, Abeliovich D, Glaser B, Hamburger 
T, Eeles RA, Peretz T. A single-nucleotide polymorphism in the RAD51 gene modifies 
breast cancer risk in BRCA2 carriers, but not in BRCA 1 carriers or noncarriers. Br J 
Cancer. 2004;90:2002-5. 
Khoo US, Chan KY, Cheung AN, Xue WC, Shen DH, Fung KY, Ngan BY, Choy 
KW, Pang CP, Poon CS, Poon AY, Ozcelik H. Recurrent BRCAI and BRCA2 germ line 
mutations in ovarian cancer: a founder mutation of BRCA 1 identified in the Chinese 
population. Hum Mutat. 2002;19:307-8. 
Kim Y, Lach FP, Desetty R, Hanenberg H, Auerbach AD, Smogorzewska A. 
Mutations of the SLX4 gene in Fanconi anemia. Nat Genet. 2011;43:142-6. 
Kitao H, Takata M. Fanconi anemia: a disorder defective in the DNA damage 
response. Int J Hematol. 2011 ;93:417-24. 
Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous 
variants on protein function using the SIFT algorithm. Nat Pro toe 2009;7: 1 073-1 081. 
Lalloo F, Evans DG. Familial breast cancer. Clin Genet. 2012;82:105-14. doi: 
10.11111j.1399-0004.2012.01859.x. 
Landwehr R, Bogdanova NV, Antonenkova N, Meyer A, Bremer M, Park-Simon TW, 
Hillemanns P, Karstens JH, Schindler D, Dork T. Mutation analysis of the SLX4/FANCP 
gene in hereditary breast cancer. Breast Cancer Res Treat. 2011; 130: 1021-8. doi: 
1O.1007/s10549-011-1681-1. 
Le Quesne J, Caldas C. Micro-RNAs and breast cancer. Mol Oncol. 2010;4:230-41. 
Lee AS, Ho GH, Oh PC, Balram C, Ooi LL, Lim DT, Wong CY, Hong GS. Founder 
mutation in the BRCAI gene in Malay breast cancer patients from Singapore. Hum Murat. 
2003;22:178. 
Levy-Lahad E, Lahad A, Eisenberg S, Dagan E, Papema T, Kasinetz L, Catane R, 
Kaufman B, Beller U, Renbaum P, Gershoni-Baruch R. A single nucleotide polymorphism 
in the RAD51 gene modifies cancer risk in BRCA2 but not BRCAI carriers. Proc Natl 
A cad Sci USA. 2001 ;98:3232-6. 
Li W, Duan R, Kooy F, Sherman SL, Zhou W, Jin P. Germline mutation of 
microRNA-125a is associated with breast cancer. J Med Genet. 2009;46:358-60. 
Lian H, Wang L, Zhang J. Increased risk of breast cancer associated with CC genotype 
ofHas-miR-146a Rs2910164 polymorphism in Europeans. PLoS One. 2012;7:e31615. 
102 
References 
Lindor NM, Guidugli L, Wang X, Vallee MP, Monteiro AN, Tavtigian S, Goldgar DE, 
Couch FJ. A review of a multifactorial probability-based model for classification of 
BRCAI and BRCA2 variants of uncertain significance (VUS). Hum Mutat. 2012;33:8-21. 
doi: 10.1002lhumu.21627. 
Litim N, Labrie Y, Desjardins S, Ouellette G, Plourde K, Belleau P; INHERIT 
BRCAs, Durocher F. Polymorphic variations in the FANCA gene in high-risk non-
BRCA 112 breast cancer individuals from the French Canadian population. Mol Oneal. 
2013;7:85-100. doi: 1O.l016/j.molonc.2012.08.002. 
MacPherson G, Healey CS, Teare MD, Balasubramanian SP, Reed MW, Pharoah PD, 
Ponder BA, Meuth M, Bhattacharyya NP, Cox A. Association of a common variant of the 
CASP8 gene with reduced risk of breast cancer. J Natl Cancer Inst. 2004;96:1866-9. 
Mavaddat N, Antoniou AC, Easton DF, Garcia-Closas M. Genetic susceptibility to 
breast cancer. Mol Oneal. 2010;4:174-91. 
Malacrida S, Agata S, Callegaro M, Casella C, Barana D, Scaini MC, Manoukian S, 
OIiani C, Radice P, Barile M, Menin C, D'Andrea E, Montagna M. BRCAI p.Val1688deI 
is a deleterious mutation that recurs in breast and ovarian cancer families from Northeast 
Italy. J Clin Oneal. 2008;26:26-31. doi: 1O.l200/JCO.2007.l3.2118. 
Meindl A, Hellebrand H, Wiek C, Erven V, Wappenschmidt B, Niederacher D, Freund 
M, Lichtner P, Hartmann L, Schaal H, Ramser J, Honisch E, Kubisch C, Wichmann HE, 
Kast K, Deissler H, Engel C, Miiller-Myhsok B, Neveling K, Kiechle M, Mathew CG, 
Schindler D, Schmutzler RK, Hanenberg H. Germline mutations in breast and ovarian 
cancer pedigrees establish RAD51 C as a human cancer susceptibility gene. Nat Genet. 
2010;42:410-4. 
Michailidou K, Hall P, Gonzalez-Neira A, Ghoussaini M, Dennis J, Milne RL, 
Schmidt MK, Chang-Claude J, Bojesen SE, Bolla MK, Wang Q, Dicks E, Lee A, Turnbull 
C, Rahman N; Breast and Ovarian Cancer Susceptibility Collaboration, Fletcher 0, Peto J, 
Gibson L, Dos Santos Silva I, Nevanlinna H, Muranen T A, Aittomaki K, Blomqvist C, 
Czene K, Irwanto A, Liu J, Waisfisz Q, Meijers-Heijboer H, Adank M; Hereditary Breast 
and Ovarian Cancer Research Group Netherlands (HEBON), van der Luijt RB, Hein R, 
Dahmen N, Beckman L, Meindl A, Schmutzler RK, Miiller-Myhsok B, Lichtner P, Hopper 
JL, Southey MC, Makalic E, Schmidt OF, Uitterlinden AG, Hofman A, Hunter DJ, 
Chanock SJ, Vincent D, Bacot F, Tessier DC, Canisius S, Wessels LF, Haiman CA, Shah 
M, Luben R, Brown J, Luccarini C, Schoof N, Humphreys K, Li J, Nordestgaard BG, 
Nielsen SF, Flyger H, Couch FJ, Wang X, Vachon C, Stevens KN, Lambrechts D, Moisse 
M, Paridaens R, Christiaens MR, Rudolph A, Nickels S, Flesch-Janys D, Johnson N, 
Aitken Z, Aaltonen K, Heikkinen T, Broeks A, Veer LJ, van der Schoot CE, Guenel P, 
Truong T, Laurent-Puig P, Menegaux F, Marme F, Schneeweiss A, Sohn C, Burwinkel B, 
Zamora MP, Perez JI, Pita G, Alonso MR, Cox A, Brock IW, Cross SS, Reed MW, Sawyer 
EJ, Tomlinson I, Kerin MJ, Miller N, Henderson BE, Schumacher F, Le Marchand L, 
Andrulis IL, Knight JA, Glendon G, Mulligan AM; kConFab Investigators; stralian 
Ovarian Cancer Study Group, Lindblom A, Margolin S, Hooning MJ, Hollestelle A, van 
den Ouweland AM, Jager A, Bui QM, Stone J, Dite GS, Apicella C, Tsimiklis H, Giles 
GG, Severi G, Baglietto L, Fasching PA, Haeberle L, Ekici AB, Beckmann MW, Brenner 
H, MUller H, Arndt V, Stegmaier C, Swerdlow A, Ashworth A, Orr N, Jones M, Figueroa 
J, Lissowska J, Brinton L, Goldberg MS, Labreche F, Dumont M, Winqvist R, Pylkas K, 
103 
References 
Jukkola-Vuorinen A, Grip M, Brauch H, Hamann U, Bruning T; GENICA (Gene 
Environment Interaction and Breast Cancer in Germany) Network, Radice P, Peterlongo P, 
Manoukian S, Bonanni B, Devilee P, Tollenaar RA, Seynaeve C, van Asperen CJ, 
Jakubowska A, Lubinski J, Jaworska K, Durda K, Mannermaa A, Kataja V, Kosma VM, 
Hartikainen JM, Bogdanova NV, Antonenkova NN, Dark T, Kristensen VN, Anton-Culver 
H, Slager S, Toland AE, Edge S, Fostira F, Kang D, Yoo KY, Noh DY, Matsuo K, Ito II, 
Iwata H, Sueta A, Wu AH, Tseng CC, Van Den Berg D, Stram DO, Shu XO, Lu W, Gao 
YT, Cai H, Teo SH, Yip CH, Phuah SY, Comes BK, Hartman M, Miao H, Lim WY, Sng 
JH, Muir K, Lophatananon A, Stewart-Brown S, Siriwanarangsan P, Shen CY, Hsiung CN, 
Wu PE, Ding SL, Sangrajrang S, Gaborieau V, Brennan P, McKay J, Blot WJ, Signorello 
LB, Cai Q, Zheng W, Deming-Halverson S, Shrubsole M, Long J, Simard J, Garcia-Closas 
M, Pharoah PO, Chenevix-Trench G, Dunning AM, Benitez J, Easton DF. Large-scale 
genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet. 
2013;45:353-61. doi: 10.1038/ng.2563. 
Miki Y, Swensen J, Shattuck-Eidens 0, Futreal PA, Harshman K, Tavtigian S, Liu Q, 
Cochran C, Bennett LM, Ding W, et al. A strong candidate for the breast and ovarian 
cancer susceptibility gene BRCA I. Science. 1994;266:66-71. 
Milne RL, Antoniou AC. Genetic modifiers of cancer risk for BRCAI and BRCA2 
mutation carriers. Ann Oncol. 20 II ;22 Suppl l:i 11-7. 
Moller P, Hagen AI, Apold J, Maehle L, Clark N, Fiane B, Lovslett K, Hovig E, Vabo 
A. Genetic epidemiology of BRCA mutations--family history detects less than 50% of the 
mutation carriers. Eur J Cancer. 2007;43: 1713-7. 
Muller D, Bonaiti-Pellie C, Abecassis J, Stoppa-Lyonnet D, Fricker JP. BRCAI 
testing in breast andlor ovarian cancer families from northeastern France identifies two 
common mutations with a founder effect. Fam Cancer. 2004;3:15-20. 
Mucaki EJ, Shirley BC, Rogan PK. Prediction of mutant mRNA splice isoforms by 
information theory-based exon definition. Hum Mutat. 2013;34:557-65. doi: 
10.1002lhumu.22277. 
Munoz 1M, Hain K, Dcclais AC, Gardiner M, Toh GW, Sanchez-Pulido L, 
Heuckmann JM, Toth R, Macartney T, Eppink B, Kanaar R, Ponting CP, Lilley DM, 
Rouse J. Coordination of structure-specific nucleases by human SLX4IBTBDI2 is required 
for DNA repair. Mol Cell. 2009;35: 116-27. 
Oliver A W, Swift S, Lord CJ, Ashworth A, Pearl LH. Structural basis for recruitment 
of BRCA2 by P ALB2. EMBO Rep. 2009; I 0:990-6. 
Olopade 01, Fackenthal JD, Dunston G, Tainsky MA, Collins F, Whitfield-Broome C. 
Breast cancer genetics in African Americans. Cancer. 2003;97:236-45. 
Oros KK, Leblanc G, Arcand SL, Shen Z, Perret C, Mes-Masson AM, Foulkes WD, 
Ghadirian P, Provencher D, Tonin PN. Haplotype analysis suggest common founders in 
carriers of the recurrent BRCA2 mutation, 3398delAAAAG, in French Canadian 
hereditary breast andlovarian cancer families. BMC Med Genet. 2006;7:23. 
104 
References 
Osorio A, Milne RL, Pita G, Peterlongo P, Heikkinen T, Simard J, Chenevix-Trench 
G, Spurdle AB, Beesley J, Chen X, Healey S; KConFab, Neuhausen SL, Ding YC, Couch 
FJ, Wang X, Lindor N, Manoukian S, Barile M, Viel A, Tizzoni L, Szabo CI, Foretova L, 
Zikan M, Claes K, Greene MH, Mai P, Rennert G, Lejbkowicz F, Barnett-Griness 0, 
Andrulis IL, Ozcelik H, Weerasooriya N; OCGN, Gerdes AM, Thomassen M, Cruger DG, 
Cali go MA, Friedman E, Kaufman B, Laitman Y, Cohen S, Kontorovich T, Gershoni-
Baruch R, Dagan E, Jernstrom H, Askmalm MS, Arver B, MaImer B; SWE-BRCA, 
Domchek SM, Nathanson KL, Brunet J, Ramon Y Cajal T, Yannoukakos D, Hamann V; 
HEBON, Hogervorst FB, Verhoef S, Gomez Garcia EB, Wijnen JT, van den Ouweland A; 
EMBRACE, Easton DF, Peock S, Cook M, Oliver CT, Frost D, Luccarini C, Evans DG, 
Lalloo F, Eeles R, Pi chert G, Cook J, Hodgson S, Morrison Pl, Douglas F, Godwin AK; 
GEMO, Sinilnikova OM, Barjhoux L, Stoppa-Lyonnet D, Moncoutier V, Giraud S, Cassini 
C, Olivier-Faivre L, RevilIion F, Peyrat JP, Muller D, Fricker JP, Lynch HT, John EM, 
Buys S, Daly M, Hopper JL, Terry MB, Miron A, Yassin Y, Goldgar D; Breast Cancer 
Family Registry, Singer CF, Gschwantler-Kaulich D, Pfeiler G, Spiess AC, Hansen TV, 
Johannsson OT, Kirchhoff T, Offit K, Kosarin K, Piedmonte M, Rodriguez GC, Wakeley 
K, Boggess JF, Basil J, Schwartz PE, Blank SV, Toland AE, Montagna M, Casella C, 
Imyanitov EN, Allavena A, Schmutzler RK, Versmold B, Engel C, Meindl A, Ditsch N, 
Arnold N, Niederacher D, Deissler H, Fiebig B, Varon-Mateeva R, Schaefer D, Froster 
VG, Caldes T, de la Hoya M, McGuffog L, Antoniou AC, Nevanlinna H, Radice P, 
Benitez J; CMBA. Evaluation of a candidate breast cancer associated SNP in ERCC4 as a 
risk modifier in BRCAI and BRCA2 mutation carriers. Results from the Consortium of 
Investigators of Modifiers of BRCA lIBRCA2 (CIMBA). Br J Cancer. 2009; 1 01:2048-54. 
doi: 1O.1038/sj.bjc.6605416. 
Papi L, Putignano AL, Congregati C, Zanna I, Sera F, Morrone D, Falchetti M, Turco 
MR, Ottini L, Palli D, Genuardi M. Founder mutations account for the majority of 
BRCA I-attributable hereditary breast/ovarian cancer cases in a population from Tuscany, 
Central Italy. Breast Cancer Res Treat. 2009;117:497-504. 
Park DJ, Lesueur F, Nguyen-Dumont T, Pertesi M, Odefrey F, Hammet F, Neuhausen 
SL, John EM, Andrulis IL, Terry MB, Daly M, Buys S, Le Calvez-Kelm F, Lonie A, Pope 
BJ, Tsimiklis H, Voegele C, Hilbers FM, Hoogerbrugge N, Barroso A, Osorio A; Breast 
Cancer Family Registry; Kathleen Cuningham Foundation Consortium for Research into 
Familial Breast Cancer, Giles GG, Devilee P, Benitez J, Hopper JL, Tavtigian SV, Goldgar 
DE, Southey MC. Rare mutations in XRCC2 increase the risk of breast cancer. Am J Hum 
Genet. 2012;90:734-9. 
Peng S, Kuang Z, Sheng C, Zhang Y, Xu H, Cheng Q. Association of microRNA-
196a-2 gene polymorphism with gastric cancer risk in a Chinese population. Dig Dis Sci. 
2010;55:2288-93. 
Pertea M, Lin X, Salzberg SL. GeneSplicer: a new computational method for splice 
site prediction. Nucleic Acids Res 2001 ;29: 1185-1190. 
Peterlongo P, Caleca L, Cattaneo E, Ravagnani F, Bianchi T, Galastri L, Bernard L, 
Ficarazzi F, Dall'olio V, Marme F, Langheinz A, Sohn C, Burwinkel B, Giles GG, 
Baglietto L, Severi G, Odefrey FA, Southey MC, Osorio A, Fernandez F, Alonso MR, 
Benitez J, Barile M, Peissel B, Manoukian S, Radice P. The rs12975333 variant in the 
miR-125a and breast cancer risk in Germany, Italy, Australia and Spain. J Med Genet. 
2011 ;48:703-4. 
105 
References 
Pisano M, Cossu A, Persico I, Palmieri G, Angius A, Casu G, Palomba G, Sarobba 
MG, Rocca PC, Dedola MF, DImeo N, Pasca A, Budroni M, Marras V, Pisano A, Farris A, 
Massarelli G, Pirastu M, Tanda F. Identification of a founder BRCA2 mutation in Sardinia. 
Br J Cancer. 2000;82:553-9. 
Qiu LX, Wang Y, Xia ZG, Xi B, Mao C, Wang JL, Wang BY, Lv FF, Wu XII, lIu 
LQ. miR-196a2 C allele is a low-penetrant risk factor for cancer development. Cytokine. 
2011 ;56:589-92. 
Radice P, De Summa S, Caleca L, Tommasi S. Unclassified variants in BRCA genes: 
guidelines for interpretation. Ann Oncol. 2011 ;22 Suppl 1 :i18-23. doi: 
10.1093/annonc/mdq661. 
Rahman N, Seal S, Thompson D, Kelly P, Renwick A, Elliott A, Reid S, Spanova K, 
Barfoot R, Chagtai T, Jayatilake H, McGuffog L, Hanks S, Evans DG, Eccles D; Breast 
Cancer Susceptibility Collaboration (UK), Easton DF, Stratton MR. PALB2, which 
encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet. 
2007;39: 165-7. 
Rashid MU, Zaidi A, Torres D, Sultan F, Benner A, Naqvi B, Shakoori AR, Seidel-
Renkert A, Farooq H, Narod S, Amin A, Hamann U. Prevalence of BRCAI and BRCA2 
mutations in Pakistani breast and ovarian cancer patients. Int J Cancer. 2006; 119:2832-9. 
Rebbeck TR, Kantoff PW, Krithivas K, Neuhausen S, Blackwood MA, Godwin AK, 
Daly MB, Narod SA, Garber JE, Lynch HT, Weber BL, Brown M. Modification of 
BRCAI-associated breast cancer risk by the polymorphic androgen-receptor CAG repeat. 
Am J Hum Genet. 1999;64:1371-7. 
Rebbeck TR, Wang Y, Kantoff PW, Krithivas K, Neuhausen SL, Godwin AK, Daly 
MB, Narod SA, Brunet JS, Vesprini D, Garber JE, Lynch HT, Weber BL, Brown M. 
Modification of BRCA 1- and BRCA2-associated breast cancer risk by AlB 1 genotype and 
reproductive history. Cancer Res. 2001;61:5420-4. 
Reese MG, Eeckman FH, Kulp D, Haussler D. Improved splice site detection in 
Genie. J Com put Bioi 1997;4:311-323. 
Reeves MD, Yawitch TM, van der Merwe NC, van den Berg HJ, Dreyer G, van 
Rensburg EJ. BRCAI mutations in South African breast and/or ovarian cancer families: 
evidence of a novel founder mutation in Afrikaner families. Int J Cancer. 2004;110:677-
82. 
Reid S, Schindler D, Hanenberg H, Barker K, Hanks S, Kalb R, Neveling K, Kelly P, 
Seal S, Freund M, Wurrn M, Batish SD, Lach FP, Yetgin S, Neitzel H, Ariffin H, 
Tischkowitz M, Mathew CG, Auerbach AD, Rahman N. Biallelic mutations in PALB2 
cause Fanconi anemia subtype FA-N and predispose to childhood cancer. Nat Genet. 
2007;39: 162-4. 
Renwick A, Thompson D, Seal S, Kelly P, Chagtai T, Ahmed M, North B, Jayatilake 
H, Barfoot R, Spanova K, McGuffog L, Evans DG, Eccles D; Breast Cancer Susceptibility 
Collaboration (UK), Easton DF, Stratton MR, Rahman N. ATM mutations that cause 
ataxia-telangiectasia are breast cancer susceptibility alleles. Nat Genet. 2006;38:873-5. 
106 
References 
Roa BB, Boyd AA, Volcik K, Richards CS. Ashkenazi Jewish population frequencies 
for common mutations in BRCAI and BRCA2. Nat Genet. 1996;14:185-7. 
Rogozin IB and Milanesi L Analysis of donor splice signals in different organisms. J. 
Mol. Eval., 1997, VAS, 50-59. 
Roy R, Chun J, Powell SN. BRCAI and BRCA2: different roles in a common 
pathway of genome protection. Nat Rev Cancer. 2011;12:68-78. doi: 1O.1038/nrc3181. 
Ryan BM, Robles AI, Harris Cc. Genetic variation in microRNA networks: the 
implications for cancer research. Nat Rev Cancer. 2010;10:389-402. 
Russo A, Calo V, Augello C, Bruno L, Agnese V, Schiro V, Barbera F, Cascio S, 
Foddai E, Badalamenti G, Intrivici C, Cajozzo M, Gulotta G, Surmacz E, Colucci G, 
Gebbia N, Bazan V. 4843delC of the BRCAI gene is a possible founder mutation in 
Southern Italy (Sicily). Ann Oneal. 2007; 18 Suppl 6:vi99-102. 
Russo A, Calo V, Bruno L, Schiro V, Agnese V, Cascio S, Foddai E, Fanale D, Rizzo 
S, Di Gaudio F, Gulotta E, Surmacz E, Di Fede G, Bazan V. Is BRCAI-5083de119, 
identified in breast cancer patients of Sicilian origin, a Calabrian founder mutation? Breast 
Cancer Res Treat. 2009;113:67-70. doi: 10.1007/s10549-008-9906-7. 
Sarantaus L, lIuusko P, Eerola H, Launonen V, Vehmanen P, Rapakko K, Gillanders 
E, Syrjakoski K, Kainu T, Vahteristo P, Krahe R, Paakkonen K, Hartikainen J, Blomqvist 
C, Lopponen T, Holli K, Ryynanen M, BUtzow R, Borg A, Wastes on Arver B, Holmberg 
E, Mannermaa A, Kere J, Kallioniemi OP, Winqvist R, Nevanlinna H. Multiple founder 
effects and geographical clustering of BRCAI and BRCA2 families in Finland. Eur J Hum 
Genet. 2000;8:757-63. 
Sauty de Chalon A, Teo Z, Park DJ, Odefrey FA; kConFab, Hopper JL, Southey MC. 
Are P ALB2 mutations associated with increased risk of male breast cancer? Breast Cancer 
Res Treat. 2010; 121 :253-5. doi: 10.1007 Is 1 0549-009-0673-x. 
Seal S, Thompson D, Renwick A, Elliott A, Kelly P, Barfoot R, Chagtai T, Jayatilake 
1-1, Ahmed M, Spanova K, North B, McGuffog L, Evans DG, Eccles D; Breast Cancer 
Susceptibility Collaboration (UK), Easton DF, Stratton MR, Rahman N. Truncating 
mutations in the Fanconi anemia J gene BRIPI are low-penetrance breast cancer 
susceptibility alleles. Nat Genet. 2006;38: 1239-41. 
Sekine M, Nagata H, Tsuji S, Hirai Y, Fujimoto S, Hatae M, Kobayashi I, Fujii T, 
Nagata I, Ushijima K, Obata K, Suzuki M, Yoshinaga M, Umesaki N, Satoh S, Enomoto 
T, Motoyama S, Tanaka K; Japanese Familial Ovarian Cancer Study Group. Mutational 
analysis of BRCA 1 and BRCA2 and clinicopathologic analysis of ovarian cancer in 82 
ovarian cancer families: two common founder mutations of BRCAI in Japanese 
popUlation. Clin Cancer Res. 2001;7:3144-50. 
Sergentanis TN, Economopoulos KP. Association of two CASP8 polymorphisms with 
breast cancer risk: a meta-analysis. Breast Cancer Res Treat. 2010;120:229-34. 
107 
References 
Shen J, Ambrosone CB, DiCioccio RA, Odunsi K, Lele SB, Zhao H. A functional 
polymorphism in the miR-146a gene and age of familial breast/ovarian cancer diagnosis. 
Carcinogenesis. 2008;29: 1963-6. 
Sherry ST, Ward MH, Kholodov M, Baker J, Phan L, Smigielski EM, Sirotkin K. 
dbSNP: the NCBI database of genetic variation. Nucleic Acids Res 2001;1 :308-311. 
Shi D, Li P, Ma L, Zhong D, Chu H, Yan F, Lv Q, Qin C, Wang W, Wang M, Tong N, 
Zhang Z, Yin C. A genetic variant in pre-miR-27a is associated with a reduced renal cell 
cancer risk in a Chinese population. PLoS One. 2012;7:e46566. doi: 
10.13711journal.pone.0046566. 
Slater EP, Langer P, Niemczyk E, Strauch K, Butler J, Habbe N, Neoptolemos JP, 
Greenhalf W, Bartsch DK. PALB2 mutations in European familial pancreatic cancer 
families. Clin Genet. 2010;78:490-4. doi: 1O.11111j.1399-0004.201O.01425.x. 
Southey MC, Teo ZL, Dowty JG, Odefrey FA, Park DJ, Tischkowitz M, Sabbaghian 
N, Apicella C, Byrnes GB, Winship I, Baglietto L, Giles GG, Goldgar DE, Foulkes WD, 
Hopper JL; kConFab for the Beast Cancer Family Registry. A P ALB2 mutation associated 
with high risk of breast cancer. Breast Cancer Res. 201O;12:RI09. 
Spurdle AB, Healey S, Devereau A, Hogervorst FB, Monteiro AN, Nathanson KL, 
Radice P, Stoppa-Lyonnet D, Tavtigian S, Wappenschmidt B, Couch FJ, Goldgar DE; 
ENIGMA. Hum Mutat. 2012;33:2-7. doi: 1O.1002/humu.21628. 
Stadler ZK, Salo-Mullen E, Sabbaghian N, Simon JA, Zhang L, Olson SH, Kurtz R, 
Offit K, Foulkes WD, Robson ME, Tischkowitz M. Germline PALB2 mutation analysis in 
breast-pancreas cancer families. J Med Genet. 2011;48:523-5. 
Stoepker C, Hain K, Schuster B, Hilhorst-Hofstee Y, Rooimans MA, Steltenpool J, 
Oostra AB, Eirich K, Korthof ET, Nieuwint A W, Jaspers NG, Bettecken T, Joenje H, 
Schindler D, Rouse J, de Winter JP. SLX4, a coordinator of structure-specific 
endonucleases, is mutated in a new Fanconi anemia subtype. Nat Genet. 2011;43:138-41. 
Stratton MR, Rahman N. The emerging landscape of breast cancer susceptibility. Nat 
Genet. 2008;40: 17-22. 
Struewing JP, Abeliovich D, Peretz T, Avishai N, Kaback MM, Collins FS, Brody LC. 
The carrier frequency of the BRCAI 185delAG mutation is approximately 1 percent in 
Ashkenazi Jewish individuals. Nat Genet. 1995;11:198-200. Erratum in: Nat Genet 
1996;12:110. 
Svendsen JM, Smogorzewska A, Sowa ME, O'Connell BC, Gygi SP, Elledge SJ, 
Harper JW. Mammalian BTBD12/SLX4 assembles a Holliday junction resolvase and is 
required for DNA repair. Cell. 2009;138:63-77. 
Su X, Huang J. The Fanconi anemia pathway and DNA interstrand cross-link repair. 
Protein Cell. 2011 ;2:704-11. 
Sun Q, Gu II, Zeng Y, Xia Y, Wang Y, Jing Y, Yang L, Wang B. Hsa-mir-27a genetic 
variant contributes to gastric cancer susceptibility through affecting miR-27a and target 
gene expression. Cancer Sci. 2010;101:2241-7. doi: 1O.11111j.1349-7006.201O.01667.x. 
108 
References 
Sun T, Gao Y, Tan W, Ma S, Shi Y, Yao J, Guo Y, Yang M, Zhang X, Zhang Q, Zeng 
C, Lin D. A six-nucleotide insertion-deletion polymorphism in the CASP8 promoter is 
associated with susceptibility to multiple cancers. Nat Genet. 2007;39:605-13. 
Teo ZL, Park DJ, Provenzano E, Chatfield CA, Odefrey FA, Nguyen-Dumont T, 
Confab K, Dowty JG, Hopper JL, Winship I, Goldgar DE, Southey MC. Prevalence of 
PALB2 mutations in Australasian multiple-case breast cancer families. Breast Cancer Res. 
2013-a;15:RI7. 
Teo ZL, Sawyer SO, James PA, Mitchell G, Trainer AH, Lindeman GJ, Shackleton K, 
Cicciarelli L, Southey MC. The incidence of PALB2 c.3113G&gt;A in women with a 
strong family history of breast and ovarian cancer attending familial cancer centres in 
Australia. Fam Cancer. 2013-b. 
Thompson ER, Doyle MA, Ryland GL, Rowley SM, Choong DY, Tothill RW, Thome 
H; kConFab, Barnes DR, Li J, Ellul J, Philip GK, Antill YC, James PA, Trainer AH, 
Mitchell G, Campbell IG. Exome sequencing identifies rare deleterious mutations in DNA 
repair genes FANCC and BLM as potential breast cancer susceptibility alleles. PLoS 
Genet. 2012;8:e 1002894. doi: 10.1371 Ijournal. pgen.1 002894. 
Thorlacius S, Olafsdottir G, Tryggvadottir L, Neuhausen S, Jonasson JG, Tavtigian 
SV, Tulinius II, Ogmundsdottir HM, Eyfjord JE. A single BRCA2 mutation in male and 
female breast cancer families from Iceland with varied cancer phenotypes. Nat Genet. 
1996; 13: 117-9. 
Tian T, Shu Y, Chen J, lIu Z, Xu L, Jin G, Liang J, Liu P, Zhou X, Miao R, Ma H, 
Chen Y, Shen I I. A functional genetic variant in microRNA-196a2 is associated with 
increased susceptibility of lung cancer in Chinese. Cancer Epidemiol Biomarkers Prevo 
2009;18:1183-7. 
Tian T, Xu Y, Dai J, Wu J, Shen H, Hu Z. Functional polymorphisms in two pre-
microRNAs and cancer risk: a meta-analysis. Int J Mol Epidemiol Genet. 2010;1 :358-66. 
Tischkowitz M, Xia B, Sabbaghian N, Reis-Filho JS, Hamel N, Li G, van Beers EH, 
Li L, Khalil T, Quenneville LA, Omeroglu A, Poll A, Lepage P, Wong N, Nederlof PM, 
Ashworth A, Tonin PN, Narod SA, Livingston DM, Foulkes WO. Analysis of 
PALD2lFANCN-associated breast cancer families. Proc Natl Acad Sci. 2007;104:6788-93. 
Tischkowitz MO, Sabbaghian N, Hamel N, et a1. Analysis of the gene coding for the 
BRCA2-interacting protein PALB2 in familial and sporadic pancreatic cancer. 
Gastroenterology 2009;137:1183-1186. 
Tischkowitz M, Xia B. PALB2/FANCN: recombining cancer and Fanconi anemia. 
Cancer Res. 20 I 0;70:7353-9. 
Tischkowitz M, Capanu M, Sabbaghian N, Li L, Liang X, Vallee MP, Tavtigian SV, 
Concannon P, Foulkes WO, Bernstein L; WECARE Study Collaborative Group, Bernstein 
JL, Begg Cn. Rare germline mutations in P ALB2 and breast cancer risk: a population-
based study. Hum Mutat. 2012;33 :674-80. doi: 10.1 002lhumu.22022. 
109 
References 
Tonin PN, Mes-Masson AM, Narod SA, Ghadirian P, Provencher D. Founder BRCAI 
and BRCA2 mutations in French Canadian ovarian cancer cases unselected for family 
history. Clin Genet. 1999;55:318-24. 
Tonin PN, Perret C, Lambert JA, Paradis AJ, Kantemiroff T, Benoit MH, Martin G, 
Foulkes WD, Ghadirian P. Founder BRCAI and BRCA2 mutations in early-onset French 
Canadian breast cancer cases unselected for family history. Int J Cancer. 2001 ;95: 189-93. 
Torres D, Rashid MU, Gil F, Umana A, Ramelli G, Robledo JF, Tawil M, Torregrosa 
L, Briceno I, Hamann U. High proportion of BRCA1I2 founder mutations in Hispanic 
breast/ovarian cancer families from Colombia. Breast Cancer Res Treat. 2007; 1 03:225-32. 
Turnbull C, Rahman N. Genetic predisposition to breast cancer: past, present, and 
future. Annu Rev Genomics Hum Genet. 2008;9:321-45. 
Varghese JS, Easton DF. Genome-wide association studies in common cancers--what 
have we learnt? Curr Opin Genet Dev. 2010;20:201-9. 
Yang R, Schlehe B, IIemminki K, Sutter C, Bugert P, Wappenschmidt B, Volkmann J, 
Varon R, Weber BII, Niederacher D, Arnold N, Meindl A, Bartram CR, Schmutzler RK, 
Burwinkel B. A genetic variant in the pre-miR-27a oncogene is associated with a reduced 
familial breast cancer risk. Breast Cancer Res Treat 2009; 121 :693-702. 
Yin M, Van J, Wei S, Wei Q. CASP8 polymorphisms contribute to cancer 
susceptibility: evidence from a meta-analysis of 23 publications with 55 individual studies. 
Carcinogenesis. 2010;31 :850-7. 
Wang J, Wang Q, Liu II, Shao N, Tan B, Zhang G, Wang K, Jia Y, Ma W, Wang N, 
Cheng Y. The association of miR-146a rs2910164 and miR-196a2 rs11614913 
polymorphisms with cancer risk: a meta-analysis of 32 studies. Mutagenesis. 2012;27:779-
88. doi: 10.1 093/mutage/ges052. 
Wang WW, Spurdle AB, Kolachana P, Bove B, Modan B, Ebbers SM, Suthers G, 
Tucker MA, Kaufman DJ, Doody MM, Tarone RE, Daly M, Levavi H, Pierce H, Chetrit 
A, Yechezkel Gil, Chenevix-Trench G, Offit K, Godwin AK, Struewing JP. A single 
nucleotide polymorphism in the 5' untranslated region of RAD51 and risk of cancer among 
BRCA1I2 mutation carriers. Cancer Epidemiol Biomarkers Prevo 2001;10:955-60. 
Wang Z, Lai J, Wang Y, Nie W, Guan X. The Hsa-miR-27a rs895819 (A&gt;G) 
polymorphism and cancer susceptibility. Gene. 2013;521:87-90. doi: 
10.10 16/j .gene.20 13.02.042. 
Weitzel IN, Lagos V, Blazer KR, Nelson R, Ricker C, Herzog J, McGuire C, 
Neuhausen S. Prevalence of BRCA mutations and founder effect in high-risk Hispanic 
families. Cancer Epidemiol Biomarkers Prevo 2005; 14: 1666-71. 
Wooster R, Neuhausen SL, Mangion J, Quirk Y, Ford D, Collins N, Nguyen K, Seal 
S, Tran T, Averill D, et al. Localization of a breast cancer susceptibility gene, BRCA2, to 
chromosome 13qI2-13. Science. 1994;265:2088-90. 
110 
References 
Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, Collins N, Gregory S, 
Gumbs C, Micklem G. Identification of the breast cancer susceptibility gene BRCA2. 
Nature. 1995;378:789-92. Erratum in: Nature 1996;379:749. 
Xu W, Xu J, Liu S, Chen B, Wang X, Li Y, Qian Y, Zhao W, Wu J. Effects of 
common polymorphisms rs11614913 in miR-196a2 and rs2910164 in miR-146a on cancer 
susceptibility: a meta-analysis. PLoS One. 2011 ;6:e20471. 
Yang H, Dinney CP, Ye Y, Zhu Y, Grossman HB, Wu X. Evaluation of genetic 
variants in microRNA-related genes and risk of bladder cancer. Cancer Res. 
2008;68:2530-7. 
Ye Y, Wang KK, Gu J, Yang H, Lin J, Ajani JA, Wu X. Genetic variations in 
microRNA-related genes are novel susceptibility loci for esophageal cancer risk. Cancer 
Prev Res. 2008;1 :460-9. 
Yeo G, Burge GB. Maximum entropy modeling of short sequence motifs with 
applications to RNA splicing signals. J Compul Bioi 2004;11 :377-394. 
Yoon KA, Yoon 11, Park S, Jang HJ, Zo n, Lee HS, Lee JS. The prognostic impact of 
micro RNA sequence polymorphisms on the recurrence of patients with completely 
resected non-small cell lung cancer. J Thorac Cardiovasc Surg. 2012;144:794-807. doi: 
10.10 16/j.jtcvs.20 12.06.030. 
Zeegers MP, van Poppel F, Vlietinck R, Spruijt L, Ostrer H. Founder mutations among 
the Dutch. Eur J Hum Genet. 2004;12:591-600. 
Zhang F, Fan Q, Ren K, Andreassen PRo PALB2 functionally connects the breast 
cancer susceptibility proteins BRCA 1 and BRCA2. Mol Cancer Res. 2009;7: 111 0-8. 
Zhang M, Jin M, Yu Y, Zhang S, Wu Y, Liu II, Liu II, Chen B, Li Q, Ma X, Chen K. 
Associations of miRNA polymorphisms and female physiological characteristics with 
breast cancer risk in Chinese population Eur J Cancer Care (Engl). 2012;21 :274-80. doi: 
10.11111j.1365-2354.2011.01308.x. 
Zheng Y, Zhang J, Niu Q, Huo D, Olopade 01. Novel germline PALB2 truncating 
mutations in African American breast cancer patients. Cancer. 2012;118:1362-70. doi: 
10.1002/cncr.26388. 
Zhong S, Chen Z, Xu J, Li W, Zhao J. Pre-mir-27a rs895819 polymorphism and 
cancer risk: a meta-analysis. Mol Bioi Rep. 2013;40:3181-6. doi: 1O.1007/s11033-012-
2392-3. 
Zhou Y, Du WD, Chen G, Ruan J, Xu S, Zhou FS, Zuo XB, Lv ZJ, Zhang XJ. 
Association analysis of genetic variants in microRNA networks and gastric cancer risk in a 
Chinese Han population. J Cancer Res Clin Oneal. 2012;138:939-45. doi: 1O.1007/s00432-
012-1164-8. 
III 
LIST OF FIGURES 
Figure 1.1 Breast cancer genetic susceptibility loci 
Figure 1.2 A schematic model of the Fanconi Anemia (FA) pathway 
Figure 1.3 MicroRNA maturation processes 
Figure 1.4 Breast cancer age-specific cumulative risk for BRCA2 
mutation carriers 
Figure 1.5 Comparison of predicted age-specific cumulative breast 
cancer risks in the general population and in BRCA2 mutation 
carrIers 
Figure 1.6 Structure of the CASP8 promoter region 
Figure 3.1 The entire process of recruitment and selection of individuals 
affected with breast cancer or at-risk of breast cancer included 
in the present studies 
Figure 4.1 Bioinformatics analysis of the PALB2 c.48G>A splicing 
mutation 
List ofjigures 
8 
19 
27 
34 
34 
36 
41 
57 
Figure 4.2 Characterization of the mRNA transcripts caused by the 58 
P ALB2 c.48G> A mutation 
Figure 4.3 Electropherograms of the sequences where a PALR2 60 
pathogenic mutation was found. 
Figure 4.4 Pedigrees of the 12 families in which the index case carried a 63 
P ALB2 truncating mutation 
Figure 4.5 Pedigrees of the five families recruited at the Ospedali Riuniti 68 
of Bergamo, in which the index case carried the c.1027C>T 
P ALB2 mutation 
Figure 4.6 Venn diagram represents the distribution of PALB2 truncating 68 
mutations in breast and breast/pancreatic cancer families 
recruited in this study 
112 
Table 1.1 
Table 1.2 
Table 1.3 
Table 1.4 
Table 1.5 
Table 3.1 
Table 3.2 
Table 3.3 
Table 3.4 
Table 3.5 
Table 3.6 
Table 4.1 
Table 4.2 
Table 4.3 
Table 4.4 
Table 4.5 
LIST OF TABLES 
BRCAI and BRCA2 founder mutations identified in European 
countries 
BRCA 1 and BRCA2 founder mutations identified In non-
European countries 
Low-penetrance breast cancer susceptibility loci identified in 
the initial GWASs 
SNPs associated with breast cancer risk modification in 
BRCA 1 mutation carriers 
SNPs associated with breast cancer risk modification In 
BRCA2 mutation carriers 
CASP8 primer sequences and PCR conditions 
P ALB2 primer sequences and PCR conditions 
SLX4 primer sequences and PCR conditions 
TaqMan assay information of the PALB2 c.72delG mutation 
TaqMan assay information of the PALB2 c.1D27C>T mutation 
PALB2 PCR primer and conditions for c.48G>A variant 
characterization 
Frequencies of common PALB2 polymorphisms In 575 
BRCAX cases and 784 controls 
PALB2 truncating mutations found in 575 BRCAX cases 
Frequencies of rare or unique non-truncating P ALB2 variants 
in cases and controls 
Characteristics of families with PALB2 truncating mutations 
Number of carriers of 1027C>T mutation in BRCAX and 
113 
List of tables 
12 
13 
26 
32 
33 
44 
45 
46 
47 
47 
51 
53 
54 
56 
59 
61 
List of tables 
controls recruited in Milan and Bergamo 
Table 4.6 Frequencies of SLX4 variants in BRCAX cases 71 
Table 4.7 In silico analyses of SLX4 variants in BRCAX cases 73 
Table 4.8 Genotype frequencies ofmiR-27a in 1,025 breast cancer cases 75 
and 1,593 controls 
Table 4.9 Analyses of genotype frequencies of miR-27a in 144 bilateral 75 
and 881 unilateral breast cancer cases 
Table 4.10 List of centers participating to CONSIT TEAM with numbers 76 
of BRCAI and BRCA2 mutation carriers contributed 
Table 4.11 Genotypes frequencies of rs3834129 by BRCA mutation and 77 
disease status, and corresponding hazard ratio estimated in the 
overall group of BRCA mutation carriers 
Table 4.12 Genotype frequencies of rs3834129 by BRCA mutation and 78 
disease status, and corresponding hazard ratio estimated in 
carriers of BRCA loss-of-function (class 1) mutations 
Table 5.1 Frequency of BRCAI C64R, BRCA2 V1969fs and PALE2 82 
c.1 0 17C> T recurrent mutations in probands recruited in Milan 
and Bergamo 
Table 5.2 Frequency of SLX4 truncating and non-truncating mutations 85 
114 
Materials publishedfrom this thesis 
MATERIALS PUBLISHED FROM THIS THESIS 
Published from CHAPTER 4 - RESULTS, paragraph 4.1.3 "PALB2 mutation analysis 
in breast and pancreatic cancer families": 
Peterlongo P, Catucci I, Pasquini G, Verderio P, Peissel B, Barile M, Varesco L, Riboni M, 
Fortuzzi S, Manoukian S, Radice P. PALB2 germline mutations in familial breast cancer 
cases with personal and family history of pancreatic cancer. Breast Cancer Res Treat. 
2011;126:825-8. doi: 1O.1007/sI0549-01O-1305-1. 
Published from CHAPTER 4 - RESULTS, paragraph 4.2 "Sequencing analysis of 
SLX41FANCP gene": 
Catucci I, Colombo M, Verderio P, Bernard L, Ficarazzi F, Mariette F, Barile M, Peissel 
B, Cattaneo E, Manoukian S, Radice P, Peterlongo P. Sequencing analysis of 
SLX41FANCP gene in Italian familial breast cancer cases. PLoS One. 2012;7:e31038. doi: 
10. 13711journal.pone.0031038. 
Published from CIIAPTER 4 - RESULTS, paragraph 4.3 "Investigation of miR-27a 
rs895819 polymorphism as candidate low-penetrance allele": 
Catucci I, Verderio P, Pizzamiglio S, Bernard L, Dall'olio V, Sardella D, Ravagnani F, 
Galastri L, Barile M, Peissel B, Zaffaroni D, Manoukian S, Radice P, Peterlongo P. The 
SNP rs895819 in miR-27a is not associated with familial breast cancer risk in Italians. 
Breast Cancer Res Treat. 2012;133:805-7. doi: 10.1007/sI0549-012-2011-y. 
115 
Materials publishedfrom this thesis 
Published from CHAPTER 4 - RESULTS, paragraph 4.4 "Analysis of the CASP8 
rs3834129 insldel polymorphism as genetic modifier": 
Catucci I, Verderio P, Pizzamiglio S, Manoukian S, Peissel B, Zaffaroni D, Roversi G, 
Ripamonti CB, Pasini B, Barile M, Viel A, Giannini G, Papi L, Varesco L, Martayan A, 
Riboni M, Volorio S, Radice P, Peterlongo P. The CASP8 rs3834129 polymorphism and 
breast cancer risk in BRCAI mutation carriers. Breast Cancer Res Treat. 2011;125:855-60. 
doi: 1O.1007/s1 0549-010-1 068-8. 
116 
